

DIABETES®

The Journal of the American Diabetes Association

EDITOR, DAVID M. KIPNIS, M.D., *St. Louis*

ASSOCIATE EDITORS: PAUL E. LACY, M.D., *St. Louis* • FRANZ M. MATSCHINSKY, M.D., *St. Louis*

ADVISORY EDITORS: CHARLES H. BEST, M.D., *Toronto* • FRANK N. ALLAN, M.D., *Boston*

ABSTRACTS EDITOR, JOHN A. GALLOWAY, M.D., *Indianapolis* • MANAGING EDITOR, EDWARD W. SANDERSON, *New York*

EDITORIAL BOARD

TERM EXPIRING DECEMBER 1973

JOHN W. ENSINCK, M.D., *Seattle*

STEFAN S. FAJANS, M.D., *Ann Arbor*

GEROLD M. GRODSKY, PH.D., *San Francisco*

IRVING H. LEOPOLD, M.D., *New York*

ROGER H. UNGER, M.D., *Dallas*

PETER H. WRIGHT, M.D., *Indianapolis*

TERM EXPIRING DECEMBER 1974

MARGARET J. ALBRINK, M.D., *Morgantown, W. Va.*

RUBIN BRESSLER, M.D., *Tucson*

RONALD K. KALKHOFF, M.D., *Milwaukee*

CHRISTIAN R. KLIMT, M.D., DR. P.H., *Baltimore*

ARNOLD LAZAROW, M.D., PH.D., *Minneapolis*

ALEXANDER MARBLE, M.D., *Boston*

ARTHUR H. RUBENSTEIN, M.D., *Chicago*

TERM EXPIRING DECEMBER 1975

DAVID R. CHALLONER, M.D., *Indianapolis*

ALLAN L. DRASH, M.D., *Pittsburgh*

BRYCE L. MUNGER, M.D., *Hershey, Pa.*

HIROMICHI T. NARAHARA, M.D., *Albany*

DANIEL PORTE, JR., M.D., *Seattle*

LILLIAN RECANT, M.D., *Washington, D.C.*

DONALD F. STEINER, M.D., *Chicago*

ABSTRACTORS

TERM EXPIRING DECEMBER 1973

HUEY G. MCDANIEL, M.D., *Birmingham*

SUMER PEK, M.D., *Ann Arbor*

PAUL S. ROSENFELD, M.D., *Milwaukee*

PAUL H. SCHREIBMAN, M.D., *New York*

CHARLES R. SHUMAN, M.D., *Philadelphia*

TERM EXPIRING DECEMBER 1974

JOHN D. BAGDADE, M.D., *Seattle*

GUENTHER BODEN, M.D., *Philadelphia*

PAUL S. ENTMACHER, M.D., *New York*

JEROME M. FELDMAN, M.D., *Durham*

DINESH KUMAR, M.D., *Los Angeles*

THOMAS G. SKILLMAN, M.D., *Columbus, Ohio*

TERM EXPIRING DECEMBER 1975

R. PHILIP EATON, M.D., *Albuquerque*

N. KATSILAMBROS, M.D., *Athens, Greece*

ROGER L. LERNER, M.D., *New York*

THOMAS J. MERIMEE, M.D., *Boston*

JAMES E. VANCE, M.D., *Indianapolis*

DIABETES is published by the American Diabetes Association, Inc., to provide an official Journal for the Association and to furnish the medical profession with information concerning diabetes and related fields of medicine.

Contributions are invited from practicing physicians, clinical and laboratory investigators, and others who have data of importance to offer in these fields. Manuscripts, if suitable, will be accepted providing that the text has not been printed elsewhere.

Matter appearing in DIABETES is copyrighted by the American Diabetes Association, Inc. Permission to reproduce all or parts of papers appearing in it may be granted under appropriate conditions and if proper credit is given. Such requests should be addressed in writing to the Secretary of the Association, accompanied by a letter of permission from the senior author.

All signed articles and editorials are the responsibility of the author(s) and

not that of the American Diabetes Association. The Editors will be pleased to consider for publication papers presented at the Annual Meeting of the Association. *Manuscript Specifications:* The length of manuscripts (not including special articles or letters) should be limited to 5,000 words, exclusive of illustrations, etc. Exceptions to this limitation will be made at the discretion of the Editors.

Communications for the "Brief Notes and Comments" department should not exceed 1,000 words except in unusual circumstances. Figures and tables in these brief communications should be limited to one of each, and references should not exceed twenty in number.

Manuscripts should be typewritten, with double spacing, and if possible, submitted in triplicate together with three copies of figures and photomicrographs.

References should be presented in the style of the following examples: For Periodicals—Banting, F. G., and Best, C. H.: The internal secretion of the pancreas.

J. Lab. Clin. Med. 7:251-66, Feb. 1922. For Books—Allen, Frederick M.: *Studies Concerning Glycosuria and Diabetes.* Cambridge, Harvard University Press, 1913, p. 461.

An abstract or summary of the content of the paper in not more than 250 words should usually appear at the beginning. This should be self-contained and understandable without reference to the text.

Photographs, drawings, and figures should be suitable for reproduction. Photographs should be unmounted, untrimmed glossy prints. The names of authors should appear on the back. The tops of photographs and figures should be indicated.

Galley proofs are sent to the principal author of each paper, with a price list and order blank for reprints.

All manuscripts and editorial correspondence should be addressed to the Editorial Office, DIABETES, American Diabetes Association, Inc., 18 East 48th Street, New York, New York 10017.

Subscription and Advertising Information

DIABETES: *The Journal of the American Diabetes Association* is published every month by the Association at 18 East 48th Street, New York, New York 10017. © American Diabetes Association, Inc., 1973. All rights reserved under International and Pan-American Copyright Convention.

Professional Members receive the Journal as part of their membership privileges. The annual subscription rates for nonmembers are as follows: \$23.00 for one year; \$40.00 for two years; \$57.00 for three years. Individual copies \$2.00. For sub-

scriptions outside the United States and U. S. Possessions, add \$2.00 per year for postage.

Subscriptions for medical students and physicians within five years after completion of medical school and bioscientists who are predoctoral or not more than two years postdoctoral: \$11.50 per year plus \$2.00 for foreign postage where applicable. Subscriptions in this category may be entered or renewed for only one-year terms.

Correspondence concerning subscriptions should be addressed to the Subscription Department,

DIABETES. Checks, money orders and drafts for subscriptions should be made payable to the American Diabetes Association, Inc., and sent to the aforementioned address.

All inquiries about advertising and other business matters should be addressed to the Executive Director of the American Diabetes Association. The publishers reserve in their full discretion the right to accept or reject any proposed advertisement and the right to cancel any advertising contract.

SUBJECT INDEX 1972

This index covers all reading matter in Volume 21 of DIABETES. Entries marked with an asterisk (*) indicate material that appeared in the Abstracts only. The Author Index begins on page 44.

A

- ABDOMEN
 insulin administration to, 204
 tumors
 and lipid mobilization and food uptake, *774
- ABETALIPOPROTEINEMIA, *60
- ACETATE I-C-14
 utilization for fat synthesis
 rat strain differences in, *770
- ACETIC THIOKINASE
 and lipogenesis, *982
- ACETOACETATE
 brain utilization of, *247
 metabolism, *343
 palmitate oxidation to
 and ketosis, 258, 259, 261
- N-ACETYL-GLUCOSAMINE
 and insulin release, 540, 543
- ACHLORHYDRIA, 646
- ACID ETHANOL
 and serum nonsuppressible insulin-like activity, 271, 272-278
- ACID MUCOPOLYSACCHARIDES
 skin assays, 735, 738-742
- ACIDOSIS
 ammonium chloride induced
 and glucose tolerance and insulin sensitivity in rats, 794-796
- ACIDOSIS, LACTIC
 and phenformin, *1198
- ACIDOSIS, METABOLIC
 and carbohydrate tolerance, 1109-1114
- ACIDS
 alpha-ketomonocarboxylic, *359
 alpha-amino-isobutyric
 and pancreas beta cell transport, *181
 blood lactic and pyruvic
 and diabetic coma, *350
 isovaleric and alpha-methylbutyric
 and hypoglycin A., *316
 lactic
 and Tolinase and phenformin therapy, *351
 nicotinic
 and lipolysis, 427
- ACROMEGALY
 and blood proinsulin-like components, 664
 and insulin secretion
 and serotonin antagonists, *352
 and secretin
 and insulin release, *1118
- ACTH. *See* Adrenocorticotrophic hormone
- ACTINOMYCIN D
 and hexokinase, *185
 and rat adipocyte fatty acid synthetase activity, *914
- ADENOSINE 3', 5'-MONOPHOSPHATE. *See also* Cyclic adenosine 3',5'-monophosphate; Dibutyryl adenosine 3',5'-monophosphate
 and isolated fat cells, 1027-1034
 and potassium flux and glucose output, *254
 rat liver and adipose tissue
 and glucagon, *54
 and synaptic activity
 and dopamine-sensitive adenylyl cyclase, *773
- ADENYL CYCLASE, 440
 dopamine-sensitive
 and nervous system, *773
 epinephrine-responsive
 and insulin, *1117-1118
 glucagon-responsive
 macromolecular inhibitor of, *180
 and glucagon and tolbutamide
 and islet cell adenoma, *912
 inhibition study, 289-293
- and insulin release, *328-329
 in islets of Langerhans
 in obese and lean mice, *179
 localization in islets of Langerhans, *328
 response to glucagon, ACTH and epinephrine, *772
- ADIPOSE TISSUE
 adenosine 3',5'-monophosphate
 and glucagon, *54
 cellularity
 and growth hormone treatment in ateliotic dwarfs, *366
 epinephrine-stimulated lipolysis
 in siblings of diabetics, *361
 fat cell size
 and obesity, *54
 fat cell size and number
 assay, *247
 and metabolism in middle-aged men
 and women, *180
 fatty acid synthetase
 and glucose and insulin, *914
 and insulin, 427
 free fatty acids release, *59-60
 glucose metabolism
 and response to bovine insulin, 1151-1161
 and ventromedial hypothalamic nuclei destruction, *1204-1205
 and insulin sensitivity
 and obesity, 6-11
 isolated cells
 and adenosine 3',5'-monophosphate
 and dibutyryl adenosine 3',5'-monophosphate, 1027-1034
 and lipotrophic diabetes, 827-830
 lipolysis and cellularity
 and weight reduction in obese adolescents and adults, 754-760
 lipolysis and glycerol kinase
 and body weight, *911-912
 lipoprotein lipase, *344
 metabolism
 and glycerol kinase regulation by insulin, *122

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64	Supplement 1, 321-384	August, 843-922
February, 65-128	Supplement 2, 385-714	September, 923-986
March, 129-192	June, 715-778	October, 987-1050
April, 193-256	July, 779-842	November, 1051-1130
May, 257-320		December, 1131-1210

SUBJECT INDEX 1972

- monoglyceride hydrolase
and obese hyperglycemic mice, *186
noncollagen protein and cell number,
*1201
- phosphofructokinase
and cyclic AMP and dibutyryl cyclic
AMP, *363
- proinsulin activity, 485
- rat
glucose transport in, *1042
and insulin, *60
- resection
and diabetes and hyperinsulinism,
13-15
and sepharose-bound insulin, *335-336
- ADRENAL GLANDS**
and catecholamine release
and phenothiazine-induced hypergly-
cemia, *184
and glucagon secretion, *375
insufficiency
and hypoglycemia, *248
and insulin response to hemorrhagic
shock, *364
isolated cells
corticosterone production studies,
*983
and myocardial infarction, *119
tumors
and diabetes, *838
- ADRENALECTOMY**
and glucagon effect on adenosine 3'5'-
monophosphate levels, *54
and insulin response to hemorrhagic
shock, *364
and liver mitochondria structure, 259
and splanchnic nerve stimulation, *770
- ADRENALINE**
and adeny cyclase activity, *179
and amino acid metabolism, *56
and blood glucose and free fatty acid
responses to catecholamines,
*912
- ADRENOCORTICOTROPHIC
HORMONE**
action
and cyclic AMP, *251
adenyl cyclase response to, *772
and diabetic ketosis, 946-954
and growth hormone assays, *775-776
and insulin
and adipose tissue lipolysis, 427
in isolated adrenal cells, *983
and lipolysis
and mercury, *771
- and protein synthesis
and cyclic AMP, *119
unresponsiveness, *981
- AFRICAN PYGMIES**
metabolism studies in, *1045-1046
- AGE**
and blood glucose levels
and exercise, 89-99
and carbohydrate metabolism, *183-184
and insulin, glucagon and growth
hormone, *357
and carbohydrate tolerance, *347
and diabetes
and microangiopathy, *837
in Pima Indians, *180
in rural population in India, 1192
and diabetic mortality, *1044
and education of juvenile diabetics,
969
and fat cell size and number, *247
and glucose tolerance tests in children,
19
and motor nerve conduction velocity
in rats, 296-297
and muscle capillary basement mem-
brane changes
and diabetes, 881-896, 899-905
and proinsulin response to oral glu-
cose, *356
and retinal blood flow, *354
and retinopathy, *187
and serum glucose
in *Mystromys albicaudatus*, 718, 719,
720
and serum triglycerides response to
dietary fructose, *835
- ALANINE**
and glucagon secretion, *183
and gluconeogenesis
in diabetics and normal patients,
*341-342
and ethanol, *1202
-induced hyperglucagonemia
and alpha-adrenergic blockade,
*1043
and insulin activity, *1122-1123
and liver metabolism, 51
metabolism, *57
and glucose, *56
synthesis by muscle
and exercise, *770-771
uptake by pancreatic beta cells, *772
- L-ALANINE**
and pancreas a-amino isobutyric acid
transport, *181
- L-ALANINE-C-14**
metabolism
and tissue injury, *315
- ALBUMINURIA**
and bacteriuria, *118
- ALCOHOL**
and glucose tolerance, *247-248
and hypoglycemia
and basal insulin secretion, 65-69
-induced glucose intolerance, *184
and ketoacidosis, *56-57
sensitivity
ethnic differences in, *254
- ALCOHOLISM**
and fatty liver
and fatty acid metabolism, *835
and liver metabolism
and blood clearance rates, *983
- ALDOSE REDUCTASE**
and galactosemic cataracts, 295, 299-
300
in human placenta, *330
- ALDOSE REDUCTASE INHIBITORS**
and insulin release, *327
- ALKALINE PHOSPHATASE**
and diabetic pregnancy, 34-35
- ALLERGY**
to insulin
and purified pork insulin, 638-643
- ALLOXAN**
action
and diphenylhydantoin, 80-83
and beta cell membrane changes, *326
and glucose, *123
and insulin secretion, *326
and pancreatic beta cells, 77-78
- ALLOXAN DIABETES**
in arteriosclerotic and nonarterioscler-
otic rats, *1123
in female rats
and fetal pancreas transplants, 193-
201
and glucagon secretion, *183
glucose protection against, *123
and glycosaminoglycans metabolism,
1162-1166
and hypertriglyceridemia
and diet, *353-354
and jejunal mucosa enzymes, *188
and ketosis
and kidney function, *121
and lipid synthesis, *189

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64	Supplement 1, 321-384	August, 843-922
February, 65-128	Supplement 2, 385-714	September, 923-986
March, 129-192	June, 715-778	October, 987-1050
April, 193-256	July, 779-842	November, 1051-1130
May, 257-320		December, 1131-1210

SUBJECT INDEX 1972

- and lipoprotein lipase release, 149-155
 and liver mitochondria α -oxoglutarate carboxylation, *981
 and liver protein synthesis, *339
 and liver ribosomes, 84-88
 and pH of inflammatory exudates, *1201
 and pressor response to angiotensin and norepinephrine
 and insulin treatment, *354-355
- ALPHA-ADRENERGIC BLOCKADE**
 and alanine-induced hyperglucagonemia, *1043
 and insulin release, *181, 783-784, *1045
- ALPHA ADRENERGIC RECEPTORS**
 and diazoxide-induced insulin secretion, *1045
 and L-dopa
 and growth hormone secretion, *911
 and hypoinsulinemia, *348
- ALPHA-KETOMONOCARBOXYLIC ACIDS**
 and insulin secretion, *359
- AMERICAN DIABETES ASSOCIATION**
 Address of the President, 918-919
 annual awards
 Lilly, 920-921, 985, 1049, 1127-1128
 Annual Banquet, 917
 annual meetings
 Central Council, 919
 Thirty-second, 61-62, 124, 190, 255, 317-318, 840, 915-916, 1049
 Thirty-third, 1128, 1208
 Committee on Employment and Insurance
 statement on employment of diabetics, 834-835
 Committee on the Use of Therapeutic Agents, 832
Diabetes index, 255
Diabetes Week, 778, 841, 921, 986, 1049
 and FDA labeling of oral hypoglycemic drugs, 833
- FORECAST**
 "Cholesterol and Other Blood Fats in Diabetes," 1208
 "Diabetes in the Desert: The Pima Indians of Arizona," 841
 "Health Foods: Are They Healthful for Diabetics?" 778
- "U100 Insulin: A New Era in Diabetes Therapy," 1128
 International Diabetes Federation Eighth Congress, 1050, 1128, 1208
 necrology, 63, 128, 192, 256, 320, 778, 842, 922, 986, 1050, 1130, 1210
 new members, 191-192, 256, 921-922, 1208-1209
 news of Affiliate Associations, 128, 192, 319-320, 778, 986, 1129, 1209
 news notes, 62-63, 128, 192, 256, 320, 778, 842, 922, 986, 1050, 1130, 1210
- obituaries
 Beardwood, Joseph T., Jr., 839
 Marks, Henry E., 178
 personals, 63, 256, 320, 922, 1050, 1130, 1210
 postgraduate courses, 62, 125-127, 190-191, 777, 840, 919-920, 984, 1048, 1124-1127, 1207, 1208, 1210
 Research and Development Awards, 127, 841, 920, 985, 1048-1049
 research grants program, 62, 1050
 research symposiums, 191, 255, 318-319, 777, 840, 919, 984, 1128-1129
- AMES REFLECTANCE METER, *1120**
- AMINES**
 and insulin secretion, *248
 uptake by brain, *315
- AMINO ACIDS**
 and alloxan toxicity, *123
 in fasted and fed rats
 and exercise, *119
 and glucagon metabolism, 848-855
 and glucagon secretion, *183
 and insulin, 447-451, *909
 and insulin release, *56, 613, 617-618
 insulin response to
 and 2-deoxy-D-glucose and mannoheptulose, 1-5
 and insulin secretion, 539, 570-571
 liver transport
 and proteins, *316
 metabolic and hormonal responses to in malnourished infants, *182
 metabolism
 and exercise, *770-771
 and glucose, *56
 in perfused rat liver, *57
- and starvation during pregnancy, *1118-1119
 plasma and tissues
 and starvation, *179
 sequences of insulin, 457-459, 485
 sequences of proinsulins and intermediates, 461-466
 uptake
 by brain, *315
 by pancreatic beta cells, *772
- 6-AMINONICOTINAMIDE**
 as diabetogenic agent in rats, 143-148
 and insulin release
 and glucose C-14 metabolism, *1198
- AMINOPHYLLINE**
 and 6-aminonicotinamide, *1198
 and glucagon and insulin secretion, 289-293
 and insulin release, 689-690
 and insulin-resistant hyperglycemia, *775
 and insulin response to glucose, *770
- AMITRIPTYLINE**
 and lipolysis and cyclic AMP in isolated fat cells, *1045
- AMMONIA**
 intoxication
 and mitochondrial swelling, *835-836
 production
 and ketone bodies, *251
 in muscle, *1203
 and renal gluconeogenesis, *57
- AMMONIUM CHLORIDE**
 -induced acidosis
 and glucose tolerance and insulin sensitivity, 794-796
 and insulin secretion, *248
- AMNIOTIC FLUID**
 substrates
 and maternal caloric deprivation, *1202
- AMPHETAMINES**
 and insulin release, *252
- AMPHOTERICIN B**
 and rhinocerebral phycomycosis, *185
- ANDROGENS**
 and diabetic impotency, 23-28

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64
 February, 65-128
 March, 129-192
 April, 193-256
 May, 257-320

Supplement 1, 321-384
 Supplement 2, 385-714
 June, 715-778
 July, 779-842

August, 843-922
 September, 923-986
 October, 987-1050
 November, 1051-1130
 December, 1131-1210

SUBJECT INDEX 1972

- ANEMIA**
 hemolytic
 and pancreatic acinar atrophy and fibrosis, *773-774
 hypochromic microcytic
 and acetoacetate, *311
 and hypothyroidism
 and diabetes, *769
- ANGINA PECTORIS**
 and clofibrate therapy, *838, *910
- ANGIOGRAPHY**
 fluorescein
 and prediabetes diagnosis, *354
- ANGIOPATHY, DIABETIC**
 and hemochromatosis
 and cirrhosis, *123
 in juvenile diabetics, *913
- ANGIOTENSIN**
 pressor response to
 and insulin treatment in alloxan diabetic rats, *354-355
- ANOXIA**
 and lactic acid levels
 and phenformin and Tolinase therapy, *351
- ANTIBODIES**
 to insulin, 649-656, 657-659, 660, 677 assays, *769
 and diabetes, *57, *775
 in dogs adapted to bovine-porcine insulin, *182
 and insulin secretion, *914
 and insulinitis, 764-765
 polyethylene glycol screening test for, *379
 and serum-bound insulin neutralization, 930-934
 without previous immunization, 814-825
 to C-peptide, 1013-1025
 proinsulin
 in insulin-resistant patient, *368
 to smooth muscle tissue
 binding to fibroblasts, *314
 to thyroid antigen, *253
- ANTICOAGULANT DRUGS**
 hereditary resistance to
 and vitamin K, *183
- ANTIMITOTIC AGENTS**
 and insulin release, 987-997
- ANTIMYCIN A**
 and insulin release, *56
- APES, See *Macaca nigra***
- ARGAMINE**
 and lipolysis, 427
- ARGININE**
 and blood glucose levels, 308-310
 derivatives
 and metabolism, *1122-1123
 and glucose
 and serum insulin and growth hormone, *316
 and glucose-induced insulin secretion, *1045
 and growth hormone secretion
 and sex, *774-775
 -induced glucagon and insulin secretion
 and aminophylline, 289-293
 -induced glucagon release
 and diabetes, *324
 -induced insulin release
 and cyclic AMP system in man, *312
 infusion
 and Huntington's chorea, *1121
 and insulin release, 1-2, *56, 570, 617
 insulin response to
 in *acomys cahirinus*, 1063
 and diethylstilbestrol and growth hormone, *378
 maternal and fetal, *251
 metabolism
 and glucose, *56
 and plasma glucagon, 218-223
 plasma growth hormone response to
 and diabetes, *312
 provocative tests
 plasma growth hormone unresponsiveness to, *981
 uptake by pancreatic beta cells, *772
- ARGININE-U-C-14**
 incorporation into blood glucose, 308-310
- ARTERIES**
 calcification
 and glucose tolerance, *252
- ARTERIOGRAPHY**
 and insulinoma diagnosis, *1206
 and islet cell adenomas, *185
- ARTERIOSCLEROSIS**
 and diabetes mortality, 634
 and hyperglycemia
 and tolbutamide therapy, *122-123
 in rats
 and alloxan diabetes, *1123
- ARTERITIS**
 and insulin response to glucose, *837
- L-ASPARAGINASE**
 and leukemia
 and transient diabetes, *1119
- ASPARTATE**
 metabolism, *57
- ASPIRIN**
 and hypoglycemia, 959
- ATHEROSCLEROSIS**
 and familial hypercholesterolemia, *1121
 and insulin, *186, 684
 and insulin response, *836
 and macroangiopathy, 679-680
 and plasma insulin, blood sugar, and serum lipid abnormalities, *253
- ATROPINE**
 and serum insulin response to glucose
 and konnyaku ingestion, *60
- AUTOANALYZER, 308-310, 644**
 and glucose tolerance tests in *Macaca nigra*, 1078-1088
- AUTO-IMMUNE DISEASE, *914**
 and insulinitis in late-onset diabetes, 764-766
- AUTOTUTOR MARK II, 967-971**

B

- BABOONS**
 and alpha-adrenergic blockade
 and insulin release, *181
 and diabetes
 and kidney glomerulosclerosis, *338
 and hemorrhagic shock
 insulin release during, *982
- BACTERIA**
 and jet insulin injection studies, 41
- BACTERIURIA**
 and diabetes, *118
- BANTING, FREDERICK G., 385-395**
- BANTING MEMORIAL LECTURE, 1131-1150**
- BASEMENT MEMBRANE**
 and diabetic glomerulosclerosis, 163-173
 and fluid secretion, *315
 thickening
 and aging and diabetes, 881-896, 899-905

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64	Supplement 1, 321-384	August, 843-922
February, 65-128	Supplement 2, 385-714	September, 923-986
March, 129-192	June, 715-778	October, 987-1050
April, 193-256	July, 779-842	November, 1051-1130
May, 257-320		December, 1131-1210

SUBJECT INDEX 1972

- and glucose tolerance, *321
 and insulin and gamma globulin complexes, 872-879
 and juvenile diabetes, *913
 and pseudodiabetes of myopathy, *118
 width, *254
- BEARDWOOD, JOSEPH T., JR., 839
- BETA ADRENERGIC BLOCKING AGENTS
 and glucagon secretion, *332-333
 and insulin secretion, 783-784
 and pancreatic glucagon and insulin secretion, *332
 and tolbutamide response and diazoxide, *311
- BETA ADRENERGIC RECEPTORS
 and carbohydrate metabolism, *1203
- BICARBONATE
 and diabetic ketoacidosis, *323, *1203
 and lactic acidosis, *1198
- BIGUANIDES
 and sugar transport, *119
 and unstable diabetes, *123
- BILE
 lipids
 and pregnancy, *912
- BLADDER
 dysfunction
 and diabetes, *364
 function
 and prediabetes, *359
 neurogenic
 and diabetic impotency, 24, 26-27
- BLOOD
 acetoacetate, 3-hydroxybutyrate and glucose
 diurnal variations in, *1205
 and acetoacetate injections in rats, *311
 and brain metabolism, *774
 cholesterol
 and diet, *1043
 cholesterol, triglycerides and immunoreactive insulin
 in normals and prediabetics, *383
 circulation
 and diabetes, *981
- citrated
 and exchange transfusion, *185
- coagulation
 and diabetes, 108-112
- constituents
 and diet, *1202
- erythrocytes
 glycolytic enzymes, in insulinoma, *773
- ethanol and tolbutamide clearance
 and alcoholism, *983
- flow
 and brain perfusion technic, *1123
 and diabetes and prediabetes, *769
 and glucose tolerance during bed-rest and exercise, 103-104
 pancreatic, and exogenous insulin, *1204
 and prostaglandins, *369
 retinal, *354
- ketone bodies
 rapid estimation of, *1117
- lactate and ketone bodies
 and diabetic ketoacidosis, *186-187
- lactic and pyruvic acids
 and diabetic coma, *350
- lipids
 in monkeys, 1084-1086
- lipoproteins
 in combined hyperlipoproteinemia, *376
- lymphocytes
 response to phytohemagglutinin and *Candida albicans* antigen, 906-907
- lymphocytes and fibroblasts
 insulin binding to, 426-427
- C-peptide, 661-670
- platelet aggregation
 and diabetes, 108-112; *355
 and glucagon, *311-312
- platelets
 and diabetic retinopathy, *120-121
 and fatty acid metabolism, *312
- proinsulin, 661-670
- prothrombin time
 and vitamin K, *183
- samples
 and responses to amino acids in malnourished infants, *182
 in study of diabetes in *Mystromys albicaudatus*, 716
 and sulfonyleurea study, 217-223
- transfusions
 and glucose, *1120
- viscosity
 and juvenile diabetics, *254
- BLOOD GLUCOSE. *See also* Blood sugar
 and alloxan
 and diphenylhydantoin and glutathione, 80-83
 and 6-aminonicotinamide, 144-148
 and arginine, 308-310
 assays
 and surgery for islet cell adenomas, *185
 and body weight, *362-363
 capillary and venous, 1103-1105, 1107
 control
 and vascular diseases, 976-978
 determination
 and reflectance meter/enzyme test strip system, *1119
 and diabetic instability, *836
 and diet
 in obese hyperglycemic mice, *119
 diurnal
 and unstable diabetes, *1203
 and exercise
 and diabetes, 89-99
 and obesity, *909
 in female diabetic rats
 and fetal pancreatic transplants, 199-200
 and glucose dosage, 1103-1104
 and insulin
 in diabetics and nondiabetics, *1047
 and insulin administration to gastrointestinal tract, 203-207
 and insulinoma, *250
 and ketoacidosis, *181
 and lipotrophic diabetes, 827-830
 and metformin, *771
 monitoring, 705-706
 plasma immunoreactive insulin during, *324-325
 and oral insulin, 644-647
 and plasma growth hormone
 and diabetic retinopathy, *322
 production and oxidation
 and insulin-dependent diabetes, *375
 and propranolol, *122
 response to catecholamines
 and noradrenaline and adrenaline, *912
 response to glucagon, glucose and tolbutamide
 and liver cirrhosis and insulinemia, *121-122

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64
 February, 65-128
 March, 129-192
 April, 193-256
 May, 257-320

Supplement 1, 321-384
 Supplement 2, 385-714
 June, 715-778
 July, 779-842

August, 843-922
 September, 923-986
 October, 987-1050
 November, 1051-1130
 December, 1131-1210

SUBJECT INDEX 1972

BLOOD PRESSURE. *See also* Hypertension and kidney transplantation and diabetes, *322

BLOOD SUGAR
and atherosclerosis, *253
control, 834
and nerve tissue sorbitol and fructose, 1173-1178
determination
and Ames reflectance meter, *1120
and diabetic pregnancy outcome, *1201-1202
in diabetes survey, 1193-1196
formation
and lactate, *189
and glucagon infusion
in congestive heart failure patients, 940-944
and glycosuria
and insulin, *186
and insulin stability, 812
and nialamide, *363-364
in normals and prediabetics, *383
and pancreas extract injection in depancreatized dogs
and discovery of insulin, 386-395
and phenobarbitone, *1123
and sulfonyleureas, *1120
and kidney failure, *1120-1121
and uterine relaxants, *1045

BLOOD VESSELS. *See* Capillaries; Vascular disease; Vascular system

BODY
composition
and growth hormone administration to hypopituitary dwarfs, *982-983
and obesity and insulin secretion, *118
fat
and adipose tissue fat cell size and number, *180
forearm metabolism
and tolbutamide, *1206
growth
and adrenocorticotrophic hormone unresponsiveness, *981
and Cushing's syndrome, *1122
and metabolic response to growth hormone, *119-120
hands
and diabetic neuropathy, *314

height
and abetalipoproteinemia, *60
height and weight
in diabetes survey, 1193
and muscle capillary basement membrane changes, 883, 899-905
limbs
and gangrene surgery, *187
lower extremity ischemia
and femorotibial bypass, *322-323
organs
and insulin and proinsulin degradation, 1091-1100
weight
and adipose tissue glycerol kinase and lipolysis, *911-912
and diabetes, *362-363
and hypothalamic damage, *1206
and insulin sensitivity, 6-11
and spontaneous diabetes in monkeys, 1081
weight reduction
cardiovascular effects of, *980
and fat utilization and calorie restriction, *835
and insulin secretion, *1118

BONE
calcium, phosphorus, and magnesium and intestinal microflora, *775
neonatal development
and maternal protein restriction, *1047

BOOK REVIEWS
Calories and Carbohydrates, by Barbara Kraus, 908
Current Topics on Glucagon, edited by M. Austoni, C. Scandellari, G. Federspil, and A. Trisotto, 311
Diabetic at Work and Play, The: A Modern Manual for Diabetics with the Latest Information on Oral Drugs, Diabetic Camps, Research and Many Other New Topics, by Buris R. Boshell, 908
Gourmet Recipes for Diabetics: The International Diabetic Diet Book, by Dorothy Tompkins Revell, 908
How to Live with Diabetes, by Henry Dolger, and Bernard Seeman, 1041

BRAIN
amino acid, amines and hexose uptake, *315
calcium
and feeding response in satiated rats, *1046
and extracellular markers for blood and cerebrospinal fluid transport, *774
and galactose toxicity, *315
glucose metabolism
in newborn rat, *775
hexokinase
localization on synaptosomal mitochondria, *1205
metabolism
and galactose toxicity, 202-208
and hepatic response to insulin-induced hypoglycemia, 802-803
and neonatal hypoglycemia, *910
perfused rat
glucose and D-3-hydroxybutyrate uptake, *1206
perfusion technic, *1123
utilization of ketone bodies and ketoacidosis, *247

BRIJ 98
and oral insulin, 643-647, 648

BRUNNER'S GLAND
enterokinase secretion
and glucagon, *771

BUPHENIN
and hyperglycemia, *1045

BUTYLAMINE
and insulin secretion, *248

C

CAFFEINE
and cholesterol and triglyceride changes during glucose tolerance tests
in prediabetics, *365
and insulin secretion, 540, 543, 571

CALCIUM
absorption
and diabetes, *983
binding mechanisms
and hormones, *1121-1122
and feeding response in satiated rats, *1046

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64

February, 65-128

March, 129-192

April, 193-256

May, 257-320

Supplement 1, 321-384

Supplement 2, 385-714

June, 715-778

July, 779-842

August, 843-922

September, 923-986

October, 987-1050

November, 1051-1130

December, 1131-1210

SUBJECT INDEX 1972

- flux
 and glucose ingestion in children, *376
 and insulin action, 696,697-698
 and insulin release, 544-545, 570, *837
 and insulin storage, 591-592
 intestinal absorption, *775
 in isolated adrenal cells, *982
 and lipoprotein lipase, *188
 and pancreatic beta cell amino acid uptake, *772
 and serum cholesterol and triglycerides and hyperlipidemia patients, *980
 uptake
 and cytochalasin B, 602, 605
- CALCIUM-45**
 efflux from perfused islets, *326-327
- CALORIES**
 intake
 and plasma insulin levels, 613, 617-618
 and weight loss in obese hyperglycemic mice, *835
 and pregnancy
 and amino acid metabolism, *1118-1119
 and maternal and amniotic fluid substrate level, *1202
- CANDIDA ALBICANS ANTIGEN**
 peripheral blood lymphocytes response to
 and diabetes, 906-907
- CAPILLARIES**
 basement membrane thickening
 and age and diabetes, *837
 and pseudodiabetes of myopathy, *118
 muscle
 basement membrane changes, *254, 881-896, 899-905
 permeability and blood flow
 and diabetes and prediabetes, *769
 and polyol pathway activity, *330
- CARBOHYDRATES**
 antinatriuretic effects of, *772
 dietary
 and childhood ketotic hypoglycemia, *56
 and glucagon and insulin secretion, *912-913
 and hypertriglyceridemia, *55
 and liver glucose-6-phosphate dehydrogenase, 49, 53
 and plasma tryptophan, *909
 and regulation of pancreatic enzymes, *186
 homeostasis
 and insulin, glucagon and growth hormone, *357
 and insulin release, 559-561
 metabolism
 and adrenergic agents, *1203
 and age, *183-184
 and alcohol, *247-248
 and catecholamines and methylprednisolone, *772
 and diabetic microangiopathy, 872
 and glucagon, 939-944
 and glucose tolerance and insulin response to glucose, *1119
 in infants of diabetic mothers, *1046
 and menstrual cycle, *1204
 and metformin, *914
 in newborn infants of diabetic mothers, *912
 and psoriasis, *250
 and streptozotocin, *59
- CARBOHYDRATE INTOLERANCE**
 and acromegaly, *352
 and chemical diabetes screening in childhood, 46-47
 severity of
 and proinsulin response to oral glucose, *356
- CARBOHYDRATE TOLERANCE**
 and acute uremia and metabolic acidosis, 1109-1114
 and aging, *347
 and progesterin, *313
 protein-bound
 and diabetes, 863-870
 and serotonin, *1200
- CARBON DIOXIDE**
 production
 and obesity, 6-11
- CARCINOMA**
 and glucose metabolism
 and insulin secretion, *1200
- islet cell
 circulating insulin in, *909-910
 and streptozotocin therapy, *1204
 and pancreatoduodenectomy, *188
- CARDIOVASCULAR DISEASE**
 and disodium ethylenediaminetetraacetate and hypoglycemia, 960
 etiology, 679-680
 and oral hypoglycemic drug labeling, 832
 and patient selection for UGDP, 1035-1036
 and pheochromocytoma
 and insulin-dependent diabetes, *838
- CARDIOVASCULAR SYSTEM**
 in chickens
 and nonavian insulin, *59
 and weight reduction, *980
- CARNITINE**
 and liver palmitate metabolism, 259
- CASE REPORTS**
 abetalipoproteinemia, *60
 adipose tissue resection, 13-15
 adrenocorticotrophic hormone unresponsiveness and excessive growth, *981
 alcoholic ketoacidosis, *56
 ateliotic dwarfism and growth hormone treatment, *366
 concurrent bullous and atrophic skin lesions, *251
 congenital neuroblastoma and islet hyperplasia, *1122
 Cushing's syndrome and growth retardation, *1122
 diabetes
 and defective pituitary reserve capacity, *981
 and hypokalemic nephropathy, *1042
 and mumps in siblings, *182
 in neonate, *249
 and renal transplantation, *322
 and rhinocerebral phycomycosis, *185
 secondary to L-asparaginase therapy in acute leukemia, *1119
 diabetic coma
 and fibrinolysis and peritoneal dialysis, *913
 diabetic glomerulosclerosis without diabetes, *769

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64
 February, 65-128
 March, 129-192
 April, 193-256
 May, 257-320

Supplement 1, 321-384
 Supplement 2, 385-714
 June, 715-778
 July, 779-842

August, 843-922
 September, 923-986
 October, 987-1050
 November, 1051-1130
 December, 1131-1210

SUBJECT INDEX 1972

- diabetic microangiopathy in identical twins, *321-322
 drug-induced hypoglycemia, 956-962
 femorotibial bypass, *322-323
 generalized lipodystrophy with abnormal growth hormone homeostasis, *771
 hyperglycemia and hypoglycemia attacks
 and anti-insulin antibodies production without previous immunization, 814-825
 hyperparathyroidism
 and plasma insulin, *773
 hypoglycemia during pregnancy following pancreatoduodenectomy, *188
 hypophysectomy during diabetic pregnancy, 972-974
 idiopathic hypoglycemia and epinephrine excretion, *1200
 infant hypoglycemia
 and cataracts, *182
 infant ketoacidosis
 new syndrome in, *181
 insulinitis and late-onset diabetes, 762-763
 islet hypertrophy and beta-cell hyperplasia in juvenile diabetic, 114-116
 ketoacidosis and hemorrhaging, 108-110
 lipotrophic diabetes without ketosis, 827-830
 lipotrophy, *381-382
 lipoproteinemia, 745
 maternal blood sugar levels and fetal mortality and morbidity, *1201-1202
 pancreas transplantation, *355
 pheochromocytoma with insulin-dependent diabetes, *838
 temperate sprue, *773
- CATARACTS**
 and galactosemia, 202, 295-300
 and infant hypoglycemia, *182
 and polyol accumulation, *352
 in tuco-tuco, *1206
- CATECHOLAMINES**
 action
 and cyclic AMP, *251
 blood glucose and free fatty acid responses to
 and noradrenaline and adrenaline, *912
- and carbohydrate metabolism, *772
 and exercise-induced glucagon secretion, *334
 and insulin secretion, *119, *316
 and methysergide, 783-784
 release
 and glucagon, 944
 and phenothiazine-induced hyperglycemia, *184
 -secreting tumors
 and glucose intolerance, *838
- CATS**
 adrenalectomized
 and splanchnic nerve stimulation, *770
- CAUDAL DYSPLASIA**
 and diabetic pregnancy, *1042
- CEREBROSPINAL FLUID**
 and brain metabolism, *774
 and diabetic ketosis, *181
- CHICKS**
 galactose toxicity in, *315
 and nonavian insulin
 and cardiovascular response, *59
 and oral glucose loading
 and plasma insulin and glucose, *1046
 ornithine utilization in, *771
- CHILDREN. See also Diabetes, juvenile; Infants**
 and chemical diabetes, 45-47
 and Cushing's syndrome
 and growth retardation, *1122
 diabetes control evaluation in, *361-362
 and diabetic ketoacidosis
 and coma, *60
 of diabetic parents
 retinal blood flow in, *354
 and effects of neonatal hypoglycemia, *910
 and glucose ingestion
 and calcium, magnesium and phosphorus flux, *376
 and glucose tolerance tests
 and diphenylhydantoin therapy, *355-356
 and growth hormone levels during sleep, *776
 and hypoglycemia, *248
 and epinephrine excretion, *1200
 and intravenous hyperalimentation, *837
- and ketotic hypoglycemia, *56
 obese
 and five-hour oral glucose tolerance test, *1042-1043
 and oral glucose tolerance tests, 16-20
 and salicylate-induced hypoglycemia, 959
 of short stature
 and metabolic response to growth hormone, *119-120
- CHINESE**
 and diabetes prevalence, *353
- CHINESE HAMSTER**
 prediabetic
 diabetes prevention in, *337-338
 pancreas structure in newborns, 1051-1059
- CHLORMADINONE ACETATE**
 and insulin release, *313
- CHLORPROMAZINE**
 -induced hypoglycemia, *184, 961
- CHLORPROPAMIDE**
 antidiuretic action of, *189
 and plasma glucagon, 216-223
- CHOLECYSTOKININ**
 release, *252
- CHOLESTEROL**
 and clofibrate, *838, *910
 levels
 and alloxan diabetes, 1163-1166
 and pediatric familial type II hyperlipoproteinemia, *1043
 metabolism
 and clofibrate, *1200-1201
 and insulin, *186
 and temperature, *314
 and metformin, *771
- CHOLESTEROL-C-14**
 production
 and liver tissue injury, *315
- CHOLINERGIC AGENTS**
 and pancreatic glucagon and insulin secretion, *332
- CHORIONIC GONADOTROPIN**
 and diabetic pregnancy, 33-34
- CHORIONIC SOMATOMAMMOTROPIN**
 and insulin and glucagon release, 1072-1075

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64	Supplement 1, 321-384	August, 843-922
February, 65-128	Supplement 2, 385-714	September, 923-986
March, 129-192	June, 715-778	October, 987-1050
April, 193-256	July, 779-842	November, 1051-1130
May, 257-320		December, 1131-1210

SUBJECT INDEX 1972

CHROMATOGRAPHY

- column
 - and isolation of insulin-tryptophan complex, *1045
 - and mucopolysaccharides assays, 735
 - and glycoprotein study, 865-866
 - and insulin antibodies study, 822-823
 - and serum nonsuppressible insulin-like activity study, 271-278
- thin layer
 - and sodium acetate incorporation into rat aorta lipids, *186

CHROMIUM

- dietary
 - and diabetes in monkeys, 1079
 - in glucose tolerance factor, *1043
- and glucose utilization
 - and marasmus, *313
- hepatic
 - and diabetes, *1046

CINANSERIN

- and insulin secretion, 784-786

CITRATE

- and amino acid metabolism, *56
- pancreatic
 - and insulin release, 999-1001

CITRIC ACID CYCLE

- and diabetic ketosis, 257
- and liver ketogenesis, 50-52

CLOFIBRATE

- and cholesterol metabolism
 - and hyperlipidemia, *1200-1201
- and fatty acid metabolism, *835
- and ischaemic heart disease, *838, *910
- and tumor-bearing mice, *837

COLCHICINE

- and insulin release, 991, 996-997

COLLAGEN

- in connective tissue study of diabetic rats, 736, 739

COMA, DIABETIC

- and blood ketone body estimation method, *1117
- and blood lactic and pyruvic acids, *350
- and diabetic ketoacidosis, *60
- and drug-induced hypoglycemia, 955-962
- and fibrinolysis and peritoneal dialysis, *913

- and insulin, 632-633
- and mortality, 633-634
- symposium on, *246

COMA, HYPYPOGLYCEMIC

- diagnosis, 961
- treatment, 961-962

CONCANAVALIN A

- binding to isolated white fat cells, *336-337
- and insulin, 1144

CONGENITAL DEFECTS

- dwarfism, *366, 633, 872-873, *982-983, *1046
- neuroblastoma and islet hyperplasia, *1122
- rubella
 - and diabetes incidence, *248-249

CORONARY DISEASE. *See* Arteriosclerosis; Cardiovascular disease; Heart disease; Myocardial infarction

CORTICOTROPHIN

- and lipolysis
- and iodinated insulin, *55

CORTISONE ACETATE

- and fasting triglyceride and cholesterol in offspring of diabetic couples, *1044-1045

COXSACKIE B₁ VIRUS

- and diabetes, 766-767

CTENOMYS TALARUM. *See* Tuco-Tuco

CUSHING'S SYNDROME

- and growth retardation, *1122
- in infancy, *120

CYCLAMATES

- and blood constituents and hepatic lipids, *1202

CYCLIC ADENOSINE 3',5'-MONOPHOSPHATE

- and adipose tissue metabolism
 - and insulin, 414-424
- and adrenalectomy, *340
- and amino acid metabolism, *56
- binding mechanisms, *1122
- formation
 - in islet cell adenoma, *912
- formation and degradation
 - in islet cell tumor, *185

- and glucagon
 - and pancreatectomy, 453
- and glucose, 571
- and glucose-induced insulin release, *1042
- and glucose release
 - and glucagon, *332
- and glucose repression in rat liver, *187
- and glycogen synthase, 429, 433-436
- and growth hormone secretion, *313
- and hormone action, *251
- and insulin
 - and lipolysis, 403
 - and liver metabolism, 439-445
- and insulin action, 454-455, 696-697, *772
- and insulin release, 1, 224-225, *312, *329, 545
 - and prediabetes, 689-690
- in islet cell adenomas
 - and glucose, glucagon, tolbutamide and theophylline, *346-347
- in isolated adrenal cells, *983
- in isolated fat cells, 1027-1034
 - and amitriptyline, *1045
- and kidney gluconeogenesis, *910
- and lipolysis
 - and mercury, *771
 - and tolbutamide, *836
- and liver protein synthesis, 453
- and phosphofructokinase, *363
- and plasma insulin, *180
- and plasma insulin response to tolbutamide, *311
- and protein synthesis
 - and hormones, *119
- in white fat cells
 - and tolbutamide, *835

CYCLIC ADENOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE, 441, *838

- and insulin, 415-416
- localization in islets of Langerhans, *328

CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE

- and glycogen synthase, 435
- phosphodiesterase activity against, *838

CYCLIC NUCLEOTIDES

- receptor sites in fat cells, *336

DIABETES: VOLUME 21 (1972), PAGE NUMBERS BY ISSUE

- January, 1-64
- February, 65-128
- March, 129-192
- April, 193-256
- May, 257-320

- Supplement 1, 321-384
- Supplement 2, 385-714
- June, 715-778
- July, 779-842

- August, 843-922
- September, 923-986
- October, 987-1050
- November, 1051-1130
- December, 1131-1210

SUBJECT INDEX 1972

CYCLOHEXAMIDE
and gluconeogenesis
and glucocorticoid, *349
and hexokinase, *185
and insulin secretion, *55
and rat adipocyte fatty acid synthetase activity, *914

CYCLOHEXYLAMINE
and insulin secretion, *248

CYCLOPHOSPHAMIDE
and immune response to insulin, *58

CYPROHEPTADINE
and acromegaly, *352
and insulin release, 784-786
and pancreatic beta-cell alterations, 71-78

CYTOCHALASIN B
and insulin release, *327, 598, 600-602, 603

D

DECADRON
and shock, *1201

2-DEOXYGLUCOSE
and insulin release, 565
in fetal rat pancreas, *121
and insulin response to amino acids, 1-5

DEUTERIUM OXIDE
and insulin release, 991-993, 996-997

DEXTRAN
-insulin complex
and insulin action studies, *1122

DEXTROTIX
and blood glucose determination, *119

DIABETES MELLITUS
and acute pancreatitis, *911
and adipose tissue lipolysis, *361
and adipose tissue resection, 13-15
adult-onset
and oral hypoglycemic agents and vascular complications, *57
and 6-aminonicotinamide, 143-148
and arterial calcification
and glucose tolerance, *252
in baboons, *338
and bacteriuria, *118

and beta-cell sensitivity to glucose, 224-233
and bladder dysfunction, *364
and blood glucose levels
and walking, 89-99
and blood lymphocytes response to phytohemagglutinin and *Candida albicans* antigen, 906-907
and body weight constancy, *362-363
and calcium absorption, *983
chemical
in children, 45-47
and hyperglycemia and hyperinsulinemia, *1121
and circulating C-peptide immunoreactivity, 1013-1025
and connective tissue changes, 733-743
control
and diabetic retinopathy, *382
diagnosis
and glucose tolerance during pregnancy, *186
and scintiphotoscanning, *351
and UGDP patient selection criteria, 1036
duration
and platelet aggregation, *120-121
and retinopathy, *187, *321-322
and employment, 834-835
etiology
and insulin action, 698-700
and viruses, 713-714
and fructose, *314
and gangrene surgery study, *187
and glibenclamide therapy, *55, *913
and glomerular lesions
and proteinuria, *1120
and glucagon, *60, *332
and glucagon secretion, *183
and gluconeogenesis
and alanine, *341-342
and glucose tolerance
and microangiopathy, *321
and glycoprotein fucose elevation, 863-870
and graded insulin infusions
and plasma glucose, serum growth hormone and cortisol responses to, *379
growth-hormone induced
and Huntington's chorea, *374-375
in guinea pigs, *338
and hemochromatosis
and angiopathy, *123
hospital care for, *1120

and Huntington's chorea, *1121
and hyperphagia and polydipsia
and adrenalectomy and hypophysectomy, *358-359
and hypertriglyceridemia
and postheparin lipolytic activity, *342
and hypophysectomy during pregnancy, 972-974
and hypothyroidism, *769
and impotence
and androgenic function, 23-28
incidence
and congenital rubella, *248-249
and infection
and plasma glucagon, *324
and insulin
and antigenicity, 649-656, 657-659, 660
and insulin antibodies, *57, *775
insulin-dependent
and acute hypoglycemic insulin action, *182
and blood glucose production and oxidation, *375
and pheochromocytoma, *838
and insulin disappearance rates, *1047
and insulin and glucagon patterns, *359-360
and insulin resistance
and proinsulin antibodies, *368
and insulin secretion, 608-613
and alcohol hypoglycemia, 65-69
and methysergide maleate, *315-316
and xylitol and glucose, *187-188
insulin-treated, 632-636
and plasma insulin, glucose and free fatty acids, *325
and intestinal absorption, *252-253
and intestinal growth and hexose transport in rats, *59
juvenile
and blood viscosity, *254
control evaluation, *361-362
and fructose, *349-350
and glomerular basement membrane thickening, *913
and growth hormone, *312
and growth hormone metabolism, 175-177
and islet hypertrophy and beta-cell hyperplasia, 114-116
and plasma lipid levels and diet, *366
and programmed education, 967-971

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320

Supplement 1, 321-384
Supplement 2, 385-714
June, 715-778
July, 779-842

August, 843-922
September, 923-986
October, 987-1050
November, 1051-1130
December, 1131-1210

SUBJECT INDEX 1972

- and pseudo-dwarfism and Mauriac syndrome, 633
 "remission," *1205
 and self-management, *1204
 and sensory perception thresholds, *1199
 and ketone body metabolism, *246
 and kidney disease
 in Pima Indians, *365-366
 late-onset
 and insulinitis, 762-767
 -like syndrome
 and encephalomyocarditis virus infection, *247
 and lipemia
 and insulin concentrations, *376-377
 and liver cholesterol turnover, *314
 and liver chromium content, *1046
 and liver free fatty acid metabolism, 280-288
 and liver gluconeogenesis
 and glucocorticoids, *339-340
 and liver 3-hydroxybutyrate dehydrogenase, *184-185
 and liver metabolism, 257-268
 and lower extremity ischemia
 and femorotibial bypass, *322-323
 management, 683, 684
 computer-delivered protocol for, *367
 and diabetic neuropathy, 679
 and diet, 681-682
 and insulin, 678, 713
 and macroangiopathy and atherosclerosis, 679-680
 and microangiopathy, 680-681
 and new insulins, 637-647
 maternal
 and carbohydrate metabolism in newborn infants, *912
 and diabetic fetopathy, 687
 and infant erythroblastosis fetalis, *1199-2000
 and infant hypocalcemia, *914
 and infant hypoglycemia, *1202-1203
 and neonatal carbohydrate metabolism, *1046
 maturity-onset
 and diet, 1116-1117
 and serotonin antagonists, *352
 and metabolic insulin clearance, 1003-1011
 and metformin, *771
 and microangiopathy
 and age, *837
 mortality studies, *1044
 and mumps, *182
 and muscle capillary basement membrane changes, 881-896, 899-905
 and muscle capillary permeability and blood flow, *769
 in *Mystromys albicaudatus*, 715-721
 in neonate, *249
 and neuropathy of hands, *314
 new research on, *314
 and obesity, *246
 and insulin resistance, *370
 and insulin secretion, *1118
 and low calorie diet with phentermine resin, *361
 and phenformin, *362
 onset
 and heredity and diet, *770
 and oral hypoglycemic drug labeling, 833
 and pancreatic alpha cell function
 and insulin, 301-307
 and pancreatic beta cell function, 511
 and pancreas transplantation, *355
 and peripheral circulation
 infrared thermography studies, *981
 and phenformin
 and lactic acidosis, *1198
 and pituitary gland reserve capacity, *981
 and placental glycogen metabolism, 1185-1190
 and plasma amino acids, *340-341
 and plasma glucagon levels, *324
 and plasma immunoreactive insulin during continuous blood glucose monitoring, *324-325
 and platelet aggregation, *355
 and prediabetes transition to, 691-693
 prevalence
 among Florida Seminoles, *776
 and heredity and obesity, *250
 prevention, 693
 and diet, *337-338
 and rat liver nuclear proteins, *377
 and renal transplantation, *322
 research
 and beta-cell dysfunction, 703-704
 and blood glucose analysis, 705-706
 and glucose-insulin relationships, 704, 707-710
 and rhinocerebral phycomycosis, *185
 screening
 errors in, *254
 and serum N-acetyl-beta-glucosaminidase, 1168-1171
 and serum phospholipids, *123
 and serum protein changes
 and microangiopathy, *371
 and skin lesions, *251
 spontaneous
 in *Macaca nigra*, 1077-1088
 and submaxillary gland extirpation, 722-731
 and sulfonylureas
 and kidney insufficiency, *1120-1121
 surveys
 among Chinese, *353
 and Pima Indians, *180
 of rural population of India, 1192-1195
 therapy
 and U100 insulin, 832
 and thyrotoxicosis, *370-371
 transient
 and L-asparaginase therapy in acute leukemia, *1119
 treatment
 and hemochromatosis, *1199
 and jet insulin injection, 39-44
 and sulfonylureas, *120
 and UGDP, 1036-1037
 in tuco-tuco, *1205
 unstable
 and biguanides, *123
 and diurnal growth hormone and glucose abnormalities, *1203
 and insulinogenic reserve, *836
 and vascular disease, *314
 and blood coagulation study, 108-112
 in combined hyperlipoproteinemia, *376
 and venous changes, *909
 DIALYSIS
 and diabetes, *322
 peritoneal
 and diabetic coma, *913
 DIAMINE OXIDASE
 and diabetic pregnancy, 35
 20, 25-DIAZACHOLESTEROL, *837
 DIAZOXIDE
 and amino acid metabolism, *56
 and beta cell tumors, 535

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64
 February, 65-128
 March, 129-192
 April, 193-256
 May, 257-320

Supplement 1, 321-384
 Supplement 2, 385-714
 June, 715-778
 July, 779-842

August, 843-922
 September, 923-986
 October, 987-1050
 November, 1051-1130
 December, 1131-1210

SUBJECT INDEX 1972

- and hyperresponsiveness to tolbutamide, *360
 and insulin secretion, *327, 856-861, *1045
 and pancreatic beta cell uptake of amino acids, *772
 and tolbutamide response, *311
- DIBUTEROL**
 and amino acid metabolism, *56
- DIBUTYRYL CYCLIC 3',5'-ADENOSINE MONOPHOSPHATE**
 and fat cell metabolism, *343
 and insulin
 and adipose tissue lipolysis, 427
 and insulin release
 in *acomys cahirinus*, 1065, 1067
 and isolated fat cells, 1027-1034
 and lipolysis
 and insulin, 415-424
 and phosphofruktokinase, *363
 and protein synthesis, *119
- DIET**
 and adipose tissue glucose metabolism and insulin response, 1152
 and alimentary lipemia, *58
 and blood constituents and hepatic lipids, *1202
 and blood glucose control
 and tolbutamide and phenformin, 976-978
 and blood glucose and serum insulin in obese hyperglycemic mice, *119
 carbohydrate
 and glucose metabolism, *179
 and pancreatic alpha cell function, 301-307
 and cerebral development in rat fetus, *189
 and diabetes control, *361-362
 and diabetes management, 681-682
 and diabetes onset, *770
 and diabetes prevention, *337-338
 and diabetes survey of rural population in India, 1192
 and diabetes treatment, 1116-1117
 diabetic
 and xylitol, *350-351
 and differential feeder for parabiotic rats, *983
 "elemental" liquids
 and hemolytic anemia and pancreatic acinar atrophy and fibrosis, *773-774
- and exocrine pancreas development in neonatal rat, *186
 food intake
 and stomach tumors in obese mice, *774
 galactose
 and motor nerve conduction studies in rats, 295-300
 and glucagon and insulin secretion, *912-913
 and glucose tolerance tests, 1197
 and growth hormone release during sleep, *913
 high fat
 and obese-hyperglycemic and non-obese mice, *182
 high fructose
 and juvenile diabetes, *349-350
 high protein
 and liver gluconeogenesis from fructose and glycerol, *358
 and hyperlipemia
 in gerbils, *60
 and hypertriglyceridemia of streptozotocin diabetes, *353-354
 -induced hypercholesterolemia, *1044
 -induced jejunal lipodystrophy, *248
 isocaloric
 in lipoproteinemia study, 744
 and konnyaku ingestion
 and serum insulin response to glucose, *60
 and lactose intolerance, 871
 low calorie
 and anorectic agents, obese diabetics and, *361
 low casein and methionine
 and rat fatty liver metabolism, *183
 low cholesterol, high polyunsaturated fat
 and insulin sensitivity, *361-362
 and nutrient regulation of insulin secretion, 606-615, 617-618
 and obesity
 and hyperinsulinemia, *249
 and pancreatic enzymes, *186
 in weaned rats, *59
 and pediatric familial type II hyperlipoproteinemia, *1043
 and plasma glucagon, *331-332
 and plasma lipid levels, *366
 and proliferative diabetic retinopathy, *382
- protein-restricted
 and neonatal growth hormone production and bone development, *1047
 safflower oil
 and insulin secretion, 923-928
 sucrose
 serum triglyceride response to, *835
 and ventromedial hypothalamic nuclei destruction
 and glucose metabolism, *1204-1205
 vitamin K deficient
 and resistance to oral anticoagulants, *183
- DIETHYLSTILBESTROL**
 and insulin response to arginine and tolbutamide, *378
- DIHYDROXYACETONE**
 and liver gluconeogenesis, *330-331
- DI-ISOPROPYLAMMONIUM DI-CHLORACETATE**, *358
- DILANTIN**. See Diphenylhydantoin
- DIMETHYLBIGUANIDE**. See Metformin
- DIPA**. See Di-isopropylammonium dichloracetate
- DIPHENYLHYDANTOIN**
 and alloxan diabetogenic action, 80-83
 and insulin secretion, *327, 856-861, *982
 long-term therapy
 and glucose and insulin responses to glucose tolerance tests, *355-356
- DISODIUM ETHYLENEDIAMINE-TETRA-ACETATE**
 and insulin
 and hypoglycemia, 960
- DIURESIS**
 and secretin, *769
- DNA**
 fetal, *315
 kidney
 in progeny of protein-deficient rats, *1041
 in mouse diaphragm, *184
 pancreatic
 and diet in neonatal rats, *186

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64	Supplement 1, 321-384	August, 843-922
February, 65-128	Supplement 2, 385-714	September, 923-986
March, 129-192	June, 715-778	October, 987-1050
April, 193-256	July, 779-842	November, 1051-1130
May, 257-320		December, 1131-1210

SUBJECT INDEX 1972

DOGS
 and acute uremia and metabolic acidosis
 and carbohydrate tolerance, 1109-1114
 adrenalectomized
 and splanchnic nerve stimulation, *770
 and ammonium chloride acidosis
 and glucose tolerance, 794, 796
 and antidiuretic action of chlorpropamide, *189
 arginine and tolbutamide infusion
 and diethylstilbestrol and growth hormone, *378
 Brunner's gland secretion
 and glucagon, *771
 and carbohydrate metabolism
 and catecholamines and methylprednisolone, *772
 depancreatized
 and discovery of insulin, 385-394
 glucose turnover rates during running, *382-383
 and exercise
 and plasma glucagon, *1198-1199
 and glucagon secretion
 and growth hormone, *313
 glucagon studies in, *360-361
 and glucose feeding
 and insulin secretion, *911
 and glucose kinetics studies, *188
 hypophysectomized
 and tolbutamide and glybenclamide injections, *378-379
 and insulin antibodies, *182
 insulin distribution and binding in hindlimb of, *775
 and insulin-induced hypoglycemia, 802-803
 and insulin release
 and amino acids, *56
 and insulin secretion
 and oral glucose feedings, *909
 and thyroxine and hypophysectomy, *253
 and intestinal glucagon-like immunoreactivity
 and insulin secretion and glucose levels, *58
 liver free fatty acids metabolism
 and anti-insulin serum, 280-288
 mongrel and beagle
 and serum insulin response, *356

and pancreas blood flow and insulin output
 and prostaglandins, *369
 partially depancreatized
 and glucose tolerance and insulin response, *339
 and pepsin secretion study, *250
 reticuloendothelial system
 and vascular clearance and lipid metabolism, *312
 and secretin
 and diuresis, *769
 and sodium linoleate infusion
 and plasma free fatty acids, glucose, insulin and ketones, 1179-1184
 submaxillary gland extirpation
 and glucose and insulin tolerance, 722-731
 and tolbutamide response
 and diazoxide, *311

L-DOPA

and plasma free fatty acids and glucose, *1121
 and plasma growth hormone, insulin, and thyroxine, *911

DOPAMINE

and insulin secretion, *184
 -sensitive adenylyl cyclase
 and synaptic transmission, *773

DOPAMINE BLOCKING AGENTS

and insulin release, 783-784

D. PNEUMONIAE

and liver cycloleucine, *316

DULCITOL

and nerve conduction defect in galactose-fed rats, 295-300

DWARFISM

ateliotic
 and growth hormone treatment effect on glucose tolerance and adipose tissue cellularity, *366
 and plasma insulin response to glucose, *1045-1046
 diabetic sexual ateliotic
 and microangiopathy, 872-873
 hypopituitary
 and growth hormone therapy, *982-983
 pseudo, 633
 pseudohypopituitary, *1046

E

EDEMA

cerebral, *1203
 and diabetic ketosis, *180-181

ELECTROPHORESIS

agar, 816
 of glycoproteins and collagen
 in connective tissue study of diabetic rats, 736, 738-739
 and neutral regular insulin study, 236, 241

ELIPTEN, *837

EMBRYO, *See also* Fetus

pancreas islets study, 511-533

EMIOCYTOSIS

and insulin release, 535, 603

ENCEPHALOMYOCARDITIS VIRUS

and diabetes-like syndrome, *247
 and mouse pancreas, *338-339

ENDOCRINE GLANDS

adenomatosis
 and familial nesidioblastosis, *1122
 and diabetic microangiopathy, 872-873

ENDOPEPTIDASE

trypsin-like
 and proinsulin conversion to insulin, 577-578

ENZYMES

N-acetyl-beta-glucosaminidase
 and diabetes, 1168-1171
 adenylyl cyclase
 and nervous system function, *773
 adenylyl cyclase and cyclic AMP phosphodiesterase
 localization in rat islets of Langerhans, *328
 adenylate cyclase and phosphodiesterase
 and insulin release, *328-329
 aldose reductase
 and insulin release, *327
 assays
 and diabetic pregnancy, 34-35
 and cyclic AMP
 and insulin, 439-445
 cyclic AMP phosphodiesterase, *328
 and insulin, 415-416

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64
 February, 65-128
 March, 129-192
 April, 193-256
 May, 257-320

Supplement 1, 321-384
 Supplement 2, 385-714
 June, 715-778
 July, 779-842

August, 843-922
 September, 923-986
 October, 987-1050
 November, 1051-1130
 December, 1131-1210

SUBJECT INDEX 1972

- enterokinase
 and glucagon, *771
 and galactose metabolism, 202, 208
 glutathione-insulin transhydrogenase,
 *353
 glycogen synthetase
 and insulin, 428-437
 glycogen synthetase and phosphorylase
 and diabetes, 1185-1190
 glycolytic
 and insulinoma, *773
 hexokinase, *1205
 and insulin degradation, 468
 by placenta, *374-375
 and proinsulin assays, *122
 and insulin and proinsulin degradation,
 1093-1100
 in jejunal mucosa
 and alloxan diabetes and fasting in
 rats, *188
 lipoprotein lipase
 in rat heart and adipose tissue, *344
 liver
 and alcoholism, *983
 liver acetic thiokinase
 and lipogenesis, *982
 liver adenylate cyclase
 and glucagon, *981
 liver threonine dehydratase, *980-981
 pancreatic
 and diet, *186
 and serum anti-insulin, *911
 phosphodiesterase
 and cyclic AMP and cyclic GMP,
 *838
 phosphofructokinase
 and cyclic AMP and dibutyl cyclic
 AMP, *363
 of placental polyol pathway, *330
 and proinsulin conversion to insulin,
 577-578, 581-583
 proteolytic
 and fat cell lipolysis, 423
 and leucine incorporation into pro-
 tein, *336
- EPINEPHRINE**
 adenylyl cyclase response to, *772
 and calcium transport, *327
 and cyclic AMP, 441, 445
 excretion
 and idiopathic hypoglycemia, *1200
 and glucagon secretion, *332-333
 and glycogen synthase, 436
 and insulin
 and adipose tissue lipolysis, 427
- and insulin release
 and glucose administration, *348
 and insulin response to glucose, *773
 and insulin secretion, *770
 and lipolysis
 and mercury, *771
 and protein synthesis
 and cyclic AMP, *119
 -responsive adenylyl cyclase
 and insulin, *1117-1118
 -stimulated lipolysis
 in siblings of diabetics, *361
- ERYTHROBLASTOSIS FETALIS**
 and fetal pancreas, *253-254
 and glucose metabolism, plasma insu-
 lin and growth hormone se-
 cretion, *1199-2000
- 17B-ESTRADIOL**
 and tRNA methylases, *253
- ESTROGEN**
 and diabetic pregnancy, 31-32
 and growth hormone secretion, *774-
 775
- ETHANOL**
 and alanine
 and gluconeogenesis, *1202
 blood clearance of
 and alcoholism, *983
 and diabetes, *1042
 -induced fatty liver
 and pyrazole and glucose, *247
 -induced hypoglycemia, 958
 and insulin release
 in healthy subjects, 158-161
 and intestinal triglyceride synthesis,
 *769-770
 metabolism
 and hypo-, hyper, and euthyroid
 rats, *181
 and muscle damage, *838
 and phenformin
 in obesity and prediabetes, *363
 and skeletal muscle lactate metab-
 olism, *367
- ETHINONINE**
 and pancreas mitotic activity, 1055
- EXERCISE**
 and amino acid levels
 in fasted and fed rats, *119
 and amino acid metabolism, *770-771
 and cardiovascular system
 and weight reduction, *980
- decreased
 and glucose intolerance, 101-107
 and glucagon secretion, *1198-1199
 and glucose metabolism, *179, *776
 and glucose turnover in depancreatized
 dogs
 and insulin and glucagon infusion,
 *382-383
 -induced glucagon secretion
 and catecholamines, *334
 and insulin and glucose uptake, *980
 and insulin secretion
 and obesity, *909
 and phenolamine, *119
 and lactic acid levels
 and phenformin and Tolinase therapy,
 *351
 walking
 and blood glucose levels in normals
 and diabetics, 89-99
- F**
- FAMILY HISTORY**
 and alcohol-induced glucose intoler-
 ance, *184
 and chemical diabetes in children, 45
 and diabetes following mumps in sib-
 lings, *182
 and diabetes prevention, *337-338
 and endocrine adenomatosis, *1122
 and epinephrine-stimulated lipolysis,
 *361
 and myotonic dystrophy
 and insulin secretion, *378
 and prediabetes, *359
 and renal glycosuria, *248
 and sensory perception thresholds in
 relatives of diabetics, *1199
- FASTING.** See Starvation
- FAT CELLS.** See also Adipose tissue
 adenylate cyclase
 and insulin, *772
 and antilipolytic action of tolbutamide,
 *836
 and insulin action study, 454
 insulin binding with membranes of,
 398-401
 and insulin and lipolytic hormones
 and mercury, *771
 insulin receptor of
 and insulin resistance, *1042
 leucine incorporation into protein by,
 *336

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64	Supplement 1, 321-384	August, 843-922
February, 65-128	Supplement 2, 385-714	September, 923-986
March, 129-192	June, 715-778	October, 987-1050
April, 193-256	July, 779-842	November, 1051-1130
May, 257-320		December, 1131-1210

SUBJECT INDEX 1972

- lipolysis
and insulin, 414-424
- lipolysis and cyclic AMP
and amitriptyline, *1045
and tolbutamide, *835
- metabolism
and dibutyryl cyclic AMP, *343
and insulin, *351-352, 403-411
- purification of plasma membranes
and adenyl cyclase response to hormones, *772
- and receptor sites for insulin and cyclic nucleotides, *336
- size and number
assay method, *247
and enlargement of epididymal fat pads, *247
- white
concanavalin A binding to, *336-337
- FATS**
and insulin release, 613-615, 617-618
tolerance
and oral contraceptives, *316
- FATTY ACIDS**
free
and anti-insulin serum, 280-288
and glucagon, *60
and glucose ingestion, 1104-1105
and β -hydroxybutyrate, *836
and hypertriglyceridemia and phenformin, *380
and phenformin, *1045
release from adipose tissue, *59-60
renal, *314
responses to catecholamines, adrenaline and noradrenaline and, *912
and streptozotocin, *59
and insulin release, 613-615, 617-618
metabolism
and pancreas alpha and beta cells, *909
by sheep liver and viscera, *118
and thrombin, *312
oxidation, oxidative phosphorylation
and diabetic rat liver mitochondria ultrastructure, 257-268
release by adipose tissue
and insulin, 414-424
synthetase activity
and glucose and insulin, *914
- FETUS**
cerebral development
and diet and growth hormone studies, *189
and diabetic fetopathy, 687
endocrine pancreas
cytological studies, *253-254
fibroblasts
glucose oxidation in, *360
growth
and maternal diabetes, *912
insulin response
and arginine, *251
lamb
and metabolism studies, *187
and maternal diabetes, 31, *315, 687, *912
mortality
and diabetic pregnancy, 31
mortality and morbidity
and maternal blood sugar levels, *1201-1202
pancreas, 620, 621, 623-624
insulin content, 193-201
insulin release studies, *345-346
islets study, 511-533, 536
and placental nitrogen conservation, *340
and streptozotocin therapy, *316
subhuman primate
and theophylline, *180
- FIBRINOLYSIS**
and diabetic coma, *913
- FIBROBLASTS**
cultured
glucose oxidation in, *360
of granulation tissue
and antismooth muscle serum, *314
- FLUID SECRETION STUDIES, *315**
- FLUPHENAZINE**
-induced hyperglycemia, *184
- FOOD AND DRUG ADMINISTRATION**
and labeling of oral hypoglycemic drugs, 833, 1116-1117
- FORMALDEHYDE**
-treated insulin, *55
- FREEZE ETCHING TECHNIC, *326, 619-620**
- FRUCTOSE**
and diabetes, *314
dietary
and diabetic children, *349-350
and fetal metabolism, *187
gluconeogenesis from, *358
and insulin secretion, 543, 561
and liver glucose production
and insulin-induced hypoglycemia, 797-803
metabolism
in fasted and streptozotocin diabetic rat, *122
in nervous tissues
and blood sugar control, 1173-1178
serum triglycerides response to
and age, *835
small intestine permeability for, *249
- D-FRUCTOSE**
and insulin response to glucose, 540
transport
and biguanides, *119
- FUCOSE**
protein-bound
and diabetes, 863-870
- G**
- GALACTOSE**
and insulin release, 543, 561
and nervous system defects, 295-300
toxicity, *315
and brain metabolism, 202, 208
- D-GALACTOSE**
and alloxan toxicity, *123
and insulin response to glucose, 540
intestinal uptake, *249
transport
and biguanides, *119
- GALACTOSEMIA**
and brain metabolism, 202, 208
and diabetic microangiopathy, *352
- GAMMA GLOBULIN**
and insulin complexes
and diabetic microangiopathy, 872-879
- GANGRENE**
and femorotibial bypass, *322-323
and insulin response, *836
and limb salvage arterial surgery, *187

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320

Supplement 1, 321-384
Supplement 2, 385-714
June, 715-778
July, 779-842

August, 843-922
September, 923-986
October, 987-1050
November, 1051-1130
December, 1131-1210

SUBJECT INDEX 1972

- GASTRECTOMY**
and glucagon and insulin response, *1047
- GASTRIN**
and insulin secretion, 535
- GASTROENTERITIS**
and hypoglycemia, *248
- GASTROINTESTINAL SYSTEM**
absorption
and diabetes, *252-253
and cholecystokinin
and secretin, *252
and diet-induced jejunal lipodystrophy, *248
diseases
and "elemental liquid" diets, *773-774
and duodenal acidification
and pepsin secretion study, *250
enzyme activity
in rats, *59
gastric emptying rate
and oral glucose tolerance tests, *381
glucagon and insulin responses, *1047
glucagon-like immunoreactivity, *837-838
assays, *1206
and insulin and glucose, *58
glucose and galactose absorption, 1107
growth and hexose transport
in diabetic rats, *59
hormones
and insulin response to triglyceride, 928
and insulin administration
and plasma immunoreactive insulin, 203-207
jejunal mucosa
and glycolytic and pentose phosphate pathway enzymes, *188
lipodystrophy
diet-induced, *1044
lipoprotein production, *121
mechanical stimulation of
and serum insulin response to glucose, *60
microflora
and calcium and magnesium absorption, *775
and oral insulin, 643-647
permeability to glucose
and synthetic surfactants, *182-183
and portacaval shunting
and glucose tolerance and serum immunoreactive insulin response, *179
- small bowel
and insulin response to glucose absorbed from, *54
small intestine
permeability for fructose, *249
sugar transport
and biguanides, *119
surgery
and glucose homeostasis, *1199
transport
and glucagon, *983
triglyceride synthesis
and ethanol, *769-770
xylitol absorption, *350-351
- GEESE**
and liver metabolism
and glucagon, *55
- GENES**
and autosomal recessive inheritance of renal glycosuria, *248
and familial hypercholesterolemia, *1121
and longevity in mice, *914
- GERBILS**
and diet-induced intestinal lipodystrophy, *1044
and hyperlipemia, *60
pancreas structure in newborns, 1051-1059
- GIRAFFES**
muscle capillaries basement membrane width in, *254
- GLIBENCLAMIDE**
and amino acid metabolism, *56
-glucose-response-test, *913
intrapancreatic infusion
and insulin release, 209-215
and pancreatic beta cell uptake of amino acids, *772
pharmacodynamic aspects, *249, *249-250
studies, *55
- GLIBORNURIDE**
pharmacodynamic aspects, *249, *249-250
- GLICLAZIDE**
and microangiopathy, *357
- GLISOXEPIDE**
pharmacodynamic aspects, *249, *249-250, *912
- GLOMERULOSCLEROSIS, DIABETIC**
immunohistopathological study of, 163-173
without diabetes, *769
- GLUCAGON**
action
and cyclic AMP, *251
and adenosine 3'5'-monophosphate levels, *54
and adenylyl cyclase activation in islet cell adenoma, *912
adenylyl cyclase response to, *772
biosynthesis, *58-59
and carbohydrate homeostasis, *357
and carbohydrate metabolism, insulin and growth hormone secretion
in congestive heart failure patients, 939-944
chronic administration of
and glucose tolerance and insulin hyperresponsiveness, *374
and cyclic AMP, 440
and pancreatectomy, 453
and diabetes
and infection, *324
and diuresis, *769
and enterokinase secretion, *771
gastrointestinal response to, *1047
and gastrointestinal transport, *983
and gluconeogenesis, *331
and hypoglycemic coma, 961-962
immunoreactive
in islet cell tumors, *333
and immunoreactive insulin
and blood glucose, *360-361
infusion
and glucose turnover in depancreatized dogs, *382-383
and insulin immunoreactivity, *313
-insulin ratio
and liver metabolism, *341
and insulin release
and arginine, *312
and insulin response, 1
in *acomys cahirinus*, 1064, 1069
and islet cell adenoma cyclic AMP content, *346-347
kidney sensitivity to
and starvation, *334
-like immunoreactivity
assays, *1206
and insulin secretion and glucose concentration, *58

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64	Supplement 1, 321-384	August, 843-922
February, 65-128	Supplement 2, 385-714	September, 923-986
March, 129-192	June, 715-778	October, 987-1050
April, 193-256	July, 779-842	November, 1051-1130
May, 257-320		December, 1131-1210

SUBJECT INDEX 1972

- and liver adenosine 3',5'-monophosphate and glucose, *187
 and liver cirrhosis, *121-122
 and liver gluconeogenesis
 and D-glyceraldehyde and dihydroxyacetone, *330-331
 -mediated plasma insulin responses
 and theophylline, *180
 metabolism, *333
 and diabetes, *332
 and myocardial oxygen consumption
 and potassium balance, *118-119
 physiology and pathophysiology, *60
 and plasma amino acids, *340-341
 and plasma lipids and blood platelets, *311-312
 and related synthetic peptides, 843-855
 release
 and human chorionic somatomammotropin, 1072-1075
 resistance
 and lipemia, *357
 -responsive adenyl cyclase
 macromolecular inhibitor of, *180
 secretion, *314
 adrenergic control of, *332-333
 and alanine, *183
 and aminophylline, 289-293
 and catecholamines, *334
 and diet, *912-913
 and exercise, *1198-1199
 during glucose infusions in starvation and diabetes, *359
 and growth hormone, *313
 and insulin deficiency, *183
 and pituitary and adrenal glands, *375
 selectively blocked
 and liver adenylate cyclase, *981
 serum insulin response to
 in mongrel and beagle dogs, *356
- GLUCAGON I-131**
 and glucagon metabolism studies, *333
- GLUCOCORTICOIDS**
 and ACTH, growth hormone or thyroxine and ketosis, 414
 and diabetic ketosis, 946-954
 and gluconeogenesis, *252
 and liver gluconeogenesis
 and diabetes, *339-340
 and liver mitochondrial structure, 258
- GLUCONEOGENESIS**
 and alanine
 and diabetes, *341-342
 and ethanol, *1202
 from arginine, 308-310
 and cyclic AMP
 and insulin, 439-445
 from fructose and glycerol
 in liver of high-protein fed rats, *358
 and glucagon, *183
 and glucocorticoids, *252
- GLUCORECEPTOR MECHANISMS,**
 555-568, 570, 611-613
- GLUCOSAMINE**
 and insulin release, *328, 543, 544, 561, 570
- D-GLUCOSAMINE**
 and insulin response to glucose, 540-541
- GLUCOSE. See also** Glucose intolerance; Glucose tolerance; Glucose tolerance tests
 absorption
 and gut glucagon-like immunoreactivity, *837-838
 absorption from small bowel
 and insulin response, *54
 and adenyl cyclase activity, *179
 and alloxan
 and insulin secretion, *326
 and alloxan toxicity, *123
 and amino acid metabolism, *56
 and arginine
 and serum insulin and growth hormone, *316
 beta cell sensitivity to
 and prediabetes and diabetes, 224-233
 binding to intestinal epithelial brush borders
 and diabetes, *252-253
 brain metabolism
 in newborn rat, *775
 and calcium metabolism, *327
 disappearance rates
 in infants of diabetic mothers, *1046
 and methysergide maleate, *316
 disposal
 and myopathy, *118
 and ethanol-induced fatty liver, *247
 and fatty acid metabolism, *835
 and fatty acid synthetase activity, *914
- and fetal metabolism, *187
 glibenclamide-response-test, *913
 and glucagon, *60
 and glucagon-like immunoreactivity, *58
 homeostasis
 and gastric surgery, *1199
 and glucagon, *314
 and hypoglycemia, 815
 and hypoglycemic coma, 961
 infusion
 insulin and glucagon patterns during, *359-360
 ingestion
 and metabolism, 1102-1108
 ingestion in children
 and calcium, magnesium and phosphorus flux, *376
 and insulin
 and hypoglycemia, *373
 and lipoatrophy, *381-382
 -insulin relationships, 704, 707-710
 and insulin secretion, *55, 143, 157-161, *370, 606-613, 617-618, 713, 989
 in *acomys cahirinus*, 1062
 and adenylate cyclase and phosphodiesterase, *328-329
 and ammonium ion, *248
 and arginine, *312, *1045
 and carbohydrate and lipid metabolism, *1119
 and chlormadinone acetate, *313
 and cyclic AMP, *1042
 and cytochalasin B., *327
 and diabetes and obesity, *187-188
 and diphenylhydantoin and diazoxide, 856-861
 and epinephrine, *770, *773
 and human chorionic somatomammotropin, 1072-1075
 and immunohistological detection of insulin in pancreatic tissue, *246
 and iodoacetate and antimycin A, *56
 and juvenile diabetes "remission," *1205
 and konnyaku ingestion, *60
 and kwashiorkor, *1119-1120
 and methysergide, 780-787
 and ouabain, *246
 and peripheral vascular disease, arteritis, and Raynaud's phenomenon, *836-837
 in rat islets, *1205

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64	Supplement 1, 321-384	August, 843-922
February, 65-128	Supplement 2, 385-714	September, 923-986
March, 129-192	June, 715-778	October, 987-1050
April, 193-256	July, 779-842	November, 1051-1130
May, 257-320		December, 1131-1210

SUBJECT INDEX 1972

and serotonin and dopamine, *184
 and small vessel disease, *836
 stimulus-secretion coupling of, 594-603
 and tolbutamide, 684
 intestinal permeability to
 and synthetic surfactants, *182-183
 intestinal transport
 and biguanides, *119
 and islet cell adenoma cyclic AMP content, *346-347
 kinetics
 in dogs, *188
 levels
 and alcohol hypoglycemia, 65-69
 and liver cirrhosis and insulinemia, *121-122
 and liver gluconeogenesis, *371
 loading
 and diet and fasting, *1046
 and iodinated insulin, *55
 and obesity, *54
 and maternal diabetes
 and infant hypoglycemia, *1202-1203
 metabolism
 adipose tissue, 1151-1161
 and carcinoid syndrome, *1200
 and cyclic and dibutyl AMP, 1028-1030
 and erythroblastosis fetalis, *1199-2000
 and insulin, *184
 in isolated pancreas islets, 538-545
 in isoproterenol-stimulated rat salivary glands, *982
 during leg exercise, *776
 and methylene blue, *350
 and obesity, 6-11
 and pancreas alpha and beta cells, *909
 in rat skin, *189
 and shock, *1201
 and ventromedial hypothalamic nuclei destruction, *1204-1205
 oral
 and alimentary lipemia, *58
 and insulin secretion, *909, *911
 output
 and insulin and adenosine 3',5'-monophosphate, *254
 oxidation
 in cultured fibroblasts, *360
 and exercise and dietary carbohydrate, *179
 of isolated islets in tissue culture, 548, 550-551

and norepinephrine and theophylline, 416-417
 pancreatic islet response to, *344-345
 and plasma glucagon, growth hormone and insulin
 during exchange transfusion, *1120
 and plasma insulin
 and diabetes, 1012
 and theophylline, *180
 and plasma and pancreatic insulin, *375-376
 production
 and mannose, fructose and hydroxybutyrate, 797-803
 proinsulin response to
 and age, obesity, and degree of carbohydrate intolerance, *356
 prolonged infusion
 and insulin secretion, *372
 regulation
 and hypertension, *776
 renal, *314
 repression in rat liver
 cyclic 3'5'-AMP during, *187
 responses
 and diphenylhydantoin therapy, *355-356
 and serum insulin levels
 and trauma, *183
 -stimulated insulin release
 and glucoreceptor mechanisms in islets of Langerhans, 555-568
 and insulin storage, 585-592
 and sulfonyleureas, *249-250
 transport
 in fat cells, 403
 in rat adipose tissue, *1042
 turnover
 in depancreatized dogs, *382-383
 uptake
 and exercise, *980
 by isolated perfused rat brain, *1206
 uptake by brain
 and perfusion technics, *1123
 uptake by fat tissue
 and β -hydroxybutyrate, *836
 utilization
 and chromium, *313
 and growth hormone, *342-343
 and thyrotoxicosis, *370-371
 GLUCOSE INTOLERANCE
 alcohol-induced, *184
 and catecholamine-secreting tumors, *838
 and chromium deficiency, *313
 and decreased physical activity, 101-107

and gastrectomy, *1047
 and hypokalemia, *1043-1044
 and myocardial infarction, *119
 and obesity, *1118
 and phenytoin, *187
 GLUCOSE TOLERANCE
 and acute uremia and metabolic acidosis, 1109-1114
 and alcohol, *247-248
 and ammonium chloride-induced acidosis, 794-796
 and arterial calcification, *252
 and carbohydrate and lipid metabolism, *1119
 and chronic glucagon administration, *374
 and encephalomyocarditis infection, *247
 and glibenclamide, *55
 and growth hormone treatment in ateliotic dwarfism, *366
 and insulin response
 in partially pancreatectized dogs, *339
 intravenous
 and myocardial infarction, *184
 and metformin, *771
 and microangiopathy, *321
 and myotonic dystrophy, *378
 and nicotinic acid, *313
 and obesity, 759, *1205
 and portacaval shunt in rats, *179
 and prediabetes, 686
 and renal lesions, *769
 seasonal variations in, *312-313
 and submaxillary gland extirpation, 722-731
 and temperate sprue, *773

GLUCOSE TOLERANCE FACTOR
 and insulin, *1043

GLUCOSE TOLERANCE TESTS
 and acute pancreatitis, *911
 and bedrest and exercise, 102-106
 and caffeine
 and prediabetes, *365
 and chemical diabetes in childhood, 46-47
 and Chinese, *353
 in diabetics and obese patients, 1012
 and diphenylhydantoin therapy, *353-356
 and ethanol and phenformin, *363
 among Florida Seminoles, *776
 and gastric emptying, *381
 and glucose metabolism, 1102

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64
 February, 65-128
 March, 129-192
 April, 193-256
 May, 257-320

Supplement 1, 321-384
 Supplement 2, 385-714
 June, 715-778
 July, 779-842

August, 843-922
 September, 923-986
 October, 987-1050
 November, 1051-1130
 December, 1131-1210

SUBJECT INDEX 1972

- in guinea pigs, *338
 and Huntington's chorea, *1121
 and hypertension, *776
 and liver cirrhosis, *356
 in *Macaca nigra*, 1078-1088
 and myocardial infarction, *119
 in neonates of diabetic mothers, *912
 in obese children, *1042-1043
 and obesity, *1205
 oral
 and diabetes screening errors, *254
 discriminant analytical technic, *251
 and serum insulin and growth hormone levels in children, 16-20
 standardization of, 1197-1198
 and peripheral vascular disease, arteritis, and Raynaud's phenomenon, *837
 and phenformin
 and diabetic obesity, *362
 and Pima Indians, *180
 plasma catecholamines during, *348
 and plasma insulin and uric acid and nicotinic acid, *313
 and plasma lipids
 in normals and prediabetics, *383
 and pregnancy, *186
 and serum immunoreactive insulin levels and age, *183-184
- D-GLUCOSE
 and alloxan toxicity, *123
 brain uptake of
 and phlorizin, *315
 and insulin release, 559-561
 transport
 and biguanides, *119
- GLUCOSE C-14
 metabolism
 and 6-aminonicotinamide, *1198
- GLUCOSE-6-PHOSPHATE DEHYDROGENASE
 in jejunal mucosa
 and alloxan diabetes, *188
- GLUCOSE U-C-14
 metabolism
 in fasted and streptozotocin diabetic rats, *122
 utilization
 rat strain differences in, *770
- GLUCOSURIA
 and chemical diabetes screening, 47
 and dietary fructose, *349
- GLUTAMATE
 metabolism, *57
- GLUTATHIONE
 and alloxan, 81-83
- GLUTATHIONE-INSULIN TRANSHYDROGENASE, *353, 1095-1100
- GLYBENCLAMIDE
 and hypophysectomized dogs, *378-379
- GLYBURIDE. *See* Glibenclamide
- D-GLYCERALDEHYDE
 and liver gluconeogenesis, *330-331
- GLYCERIDE-GLYCEROL SYNTHESIS
 of mammalian adipose tissue, 1154-1155
- GLYCEROL
 gluconeogenesis from, *358
 and insulin secretion, 923-928
 release
 and weight reduction, 758
- GLYCEROL KINASE
 in adipose tissue
 and body weight, *911-912
 and insulin regulation, *122
- L-GLYCEROL 3-PHOSPHATE
 and lipid synthesis in rat skin, *189
- GLYCINE
 metabolism, *57
- GLYCOGEN
 placental metabolism
 and diabetes, 1185-1190
- GLYCOGEN STORAGE DISEASE
 and hypoglycemia, *248
- GLYCOGEN SYNTHASE
 and insulin, 428-437
- GLYCOGENOLYSIS
 and arginine infusion, 308-310
 and cyclic AMP
 and insulin, 439-445
- GLYCOLATE
 urinary
 and streptozotocin diabetes, *372
- GLYCOLYSIS
 and insulin secretion, 4
- GLYCOPROTEIN
 in connective tissue study of diabetic rats, 736, 738-739, 740-741
- GLYCOPROTEIN FUCOSE
 and diabetes, 863-870
- GLYCOSAMINOGLYCANS
 metabolism
 and alloxan diabetes, 1162-1166
- GLYCOSURIA
 and diabetes prevalence among Chinese, *353
 in diabetes survey of rural population in India, 1193-1196
 and insulin, *186
 and nicotinic acid, *313
- GOLGI APPARATUS, 620
 and insulin biosynthesis, 574-577, 582, 583
 and insulin secretion, 510
- GROWTH HORMONE
 activity
 and lipoatrophy, *381-382
 and body composition of hypopituitary dwarfs, *982-983
 and carbohydrate homeostasis, *357
 and cerebral development in rat fetus, *189
 and diabetes, 699-700, *1203
 and diabetic ketosis, 946-954
 and diabetic retinopathy, *349
 diurnal
 and unstable diabetes, *1203
 and glucagon secretion, *313
 and glucose tolerance and adipose tissue cellularity
 in ateliotic dwarfs, *366
 homeostasis abnormalities
 and generalized lipodystrophy, *771
 -induced diabetes
 and Huntington's chorea, *374-375
 insufficiency
 beta-1-24 corticotropin tests of, *775-776
 and insulin response to arginine and tolbutamide, *378
 and juvenile diabetes, *312
 levels
 in small normoglycemic and hypoglycemic infants, *250
 and lipid and carbohydrate homeostasis, *342-343

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64	Supplement 1, 321-384	August, 843-922
February, 65-128	Supplement 2, 385-714	September, 923-986
March, 129-192	June, 715-778	October, 987-1050
April, 193-256	July, 779-842	November, 1051-1130
May, 257-320		December, 1131-1210

SUBJECT INDEX 1972

and lipotrophic diabetes, 829, 830
 and lipolysis
 and iodinated insulin, *55
 metabolic clearance rates
 and juvenile diabetes, 175-177
 metabolic response to
 and short stature, *119-120
 and metabolism of obese patients, *1046
 neonatal
 and maternal protein restriction, *1047
 and pancreas compartments of insulin, *372
 release
 in sleep, *776, *913
 secretion
 and Cushing's syndrome, *1122
 and L-dopa, *911
 and erythroblastosis fetalis, *1199-2000
 and glucagon, in congestive heart failure patients, 939-944
 and prostaglandins, *313
 regulation by growth hormone, 22, 30
 and serum secretin, *1118
 sex-based variation of, *774-775
 synthesis
 and lipids, *187

GUINEA PIGS

adipose tissue
 glucose metabolism and insulin response, 1151-1161
 and diabetes, *338
 immune response to insulin, *58
 perfused liver
 and gluconeogenesis inhibition study, *910

H

HALOPERIDOL

and hypoglycemia, 960
 and insulin secretion, 783-784

HAMSTERS. *See also* Chinese hamsters; *Mystromys albicaudatus*

adipose tissue
 glucose metabolism and insulin response, 1151-1161
 and insulin secretion
 and glucose and tolbutamide, *370
 and islet cell tumors
 and cyclic 3'5' AMP, *185
 and insulin studies, *313

HEART

myocardial oxygen consumption and potassium balance
 and glucagon, *118-119
 perfused rat
 and lipoprotein lipase release, 149-155
 rat
 lipoprotein lipase, *344
 rat aorta
 and sodium acetate incorporation, *186

HEART DISEASE. *See also* Arteriosclerosis; Myocardial infarction

congestive heart failure
 and glucagon infusion, 939-944
 ischaemic
 and clofibrate, *838, *910

HEMOCHROMATOSIS

and diabetes, *1199
 and diabetic angiopathy, *123

HEMORRHAGE

and argon laser photocoagulation, *189
 and diabetes, 108-112
 and insulin release, *982
 and shock
 insulin response to, *364

HEPARIN

and lipolysis, *342
 and lipoprotein lipase
 and oral contraceptives, *316
 release from alloxan diabetic rat heart, 149-155

HEPATECTOMY

and angiotensinogen and renin levels, *253

HEPATITIS

autoimmune, *314

HEREDITY

and autoimmune disorders, *914
 and diabetes, *250
 and fasting triglycerides and cholesterol in offspring of diabetic couples, *1044-1045
 and Huntington's chorea, *1121
 and diabetes onset
 and diet, *770
 and diabetic-like microangiopathy, *373
 and endocrine adenomatosis, *1122
 and hypercholesterolemia, *1121
 and lactose tolerance, 871
 and lipodystrophy and growth hormone abnormality, *771

and obesity
 and insulin resistance and release, *316
 and renal glucosuria, *248
 and resistance to oral anticoagulants, *183

HEXOKINASE

and insulin release, 565
 in rat prostate glands
 and hormonal control, *185

HEXOSE

protein-bound
 and diabetes, 867
 transport
 in diabetic rats, *59
 uptake by brain, *315

HEXOSE MONOPHOSPHATE SHUNT

and dibutyl cyclic AMP, 1033-1034

HISTAMINE

and insulin secretion, *248

HISTONE PHOSPHORYLATION

and cyclic AMP
 and insulin, 439-445

HORMONES

adenyl cyclase response to, *772
 and amino acids
 and infantile malnutrition, *182
 androgen
 and diabetic impotence, 23-28
 and calcium and insulin binding mechanisms, *1121-1122
 and cyclic AMP, *251
 and diabetic pregnancy, 31-35
 gastrointestinal
 and insulin response to triglycerides, 928
 and hexokinase control in rat prostate glands, *185
 human chorionic somatomammotropin
 and insulin and glucagon release, 1072-1075
 and insulin secretion, 539
 lipolytic
 fat cell response to, mercury and, *771
 lipolytic and glucocorticoid
 and diabetic ketosis, 946-954
 in pancreas, 536
 parathyroid
 and plasma insulin, *773
 and protein synthesis
 and cyclic AMP, *119
 sex
 and growth hormone secretion, *774-775

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64	Supplement 1, 321-384	August, 843-922
February, 65-128	Supplement 2, 385-714	September, 923-986
March, 129-192	June, 715-778	October, 987-1050
April, 193-256	July, 779-842	November, 1051-1130
May, 257-320		December, 1131-1210

SUBJECT INDEX 1972

- sex steroids
and liver triglyceride biosynthesis, *365
- HUNTINGTON'S CHOREA
and diabetes, *374, *1121
- HYDROCORTISONE
and liver mitochondrial structure, 258
and rat fatty liver, *183
- HYDROCORTISONE SODIUM SUC-
CINATE
and hypoglycemic coma, 961-962
- β -HYDROXYBUTYRATE
and lipolysis, *836
and liver glucose production
and insulin-induced hypoglycemia,
797-803
metabolism, *343
- 3-HYDROXYBUTYRATE
brain utilization of, *247
- D-3-HYDROXYBUTYRATE
uptake
by isolated perfused rat brain, *1206
- 3-HYDROXYBUTYRATE DEHYDROG-
ENASE
in diabetic liver mitochondria, *184-185
- 5-HYDROXYTRYPTAMINE
and insulin secretion, *251-252
- HYPERALIMENTATION
intravenous
in children, *837
- HYPERAMMONEMIA
and glucose metabolism
and insulin, *184
- HYPERBILIRUBINEMIA
neonatal
and phenobarbitone therapy, *1123
- HYPERCALCEMIA
and hyperparathyroidism, *773
- HYPERCHOLESTEROLEMIA
and diabetes
and diet, *366
diet-induced, *1044
familial, *1121
- HYPERCOAGULABILITY
and diabetes, 108-112
- HYPERGLUCAGONEMIA
alanine-induced
and alpha-adrenergic blockade, *1043
and insulin, 301-307
- HYPERGLYCEMIA
and alcohol ingestion, *247-248
and L-asparaginase therapy, *1119
and chemical diabetes, *1121
compared with ketosis, 257
and diabetes
in tuco-tuco, *1206
and diet, *770
in obese mice, *119
and glucagon, *360-361
and glucagon secretion
and alanine, *183
and growth hormone metabolic clear-
ance rates, 176
and hemorrhagic shock, *364
and hyperglucagonemia, 301-307
and hypoglycemia
and anti-insulin antibodies produc-
tion, 814-825
and hypothalamic stimulation, *771
insulin-resistant
and aminophylline, *775
and intravenous alimentionation, *837
and islet of Langerhans structure, *1043
and liver cirrhosis, *356
and metabolic acidosis and acute ure-
mia, 1109-1114
and myocardial infarction
and tolbutamide therapy, *122-123
in *Mystromys albicaudatus*, 716-721
neonatal
and insulin studies, *181
and obesity
and high-fat diet in mice, *182
and pentobarbital, *836
phenothiazine-induced, *184
and phenytoin toxicity, *187
and postheparin lipolytic activity, *342
and splanchnic nerve stimulation
and andralectomy, *770
and streptozotocin, *59
and synthetic glucagon peptides, 845-
846
and uterine relaxants, *1045
and vascular disease, 679-680
- HYPERINSULINISM
and adipose tissue resection, 13-15
and chemical diabetes, *1121
and diabetes
and connective tissue changes, 733-
743
and diabetic pregnancy, *912
and insulin insensitivity, 6
and insulin resistance
in genetically obese rats, *838
and liver cirrhosis, *356
and liver glucose production, *380-381
- and obesity, *314, *380, 613, 617-618
and blood proinsulin, 663-664
and diet, *249
and obesity and hyperlipidemia
induced in monkeys, *1201
- HYPERLIPEMIA
alcoholic, *770
and diabetes, *123
in gerbils, *70
- HYPERLIPIDEMIA
and calcium, *980
and cholesterol metabolism
and clofibrate, *1200-1201
and metformin, *771
and obesity and hyperinsulinemia
induced in monkeys, *1201
- HYPERLIPOPROTEINEMIA, 744-752
combined
and diabetes and vascular disease,
*376
and cortisone acetate, *1044
pediatric familial type II
and diet, *1043
type II, *1121
and diet, *366
- HYPEROSMOLALITY
and diabetes
and ketogenesis, *369-370
in galactose-fed chicks, *315
- HYPERPARATHYROIDISM
and infant hypocalcemia, *914
and plasma insulin, *773
- HYPERPHAGIA
dietary prevention of, *337-338
and polydipsia
and adrenalectomy and hypophys-
ectomy, *358-359
- HYPERTENSION
and glomerulonephritis
without diabetes, *769
and glucose regulation, *776
- HYPERTHYROIDISM
and thyroid function tests, 1012
- HYPERTRIGLYCERIDEMIA
endogenous
and plasma triglycerides synthesis,
*55
and insulin deficiency, *366-367
and phenformin
and insulin and free fatty acids, *380
and plasma free fatty acid metabolism,
*835

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320

Supplement 1, 321-384
Supplement 2, 385-714
June, 715-778
July, 779-842

August, 843-922
September, 923-986
October, 987-1050
November, 1051-1130
December, 1131-1210

- and postheparin lipolytic activity, *342
and pregnancy, *365
and streptozotocin diabetes
and diet, *353-354
- HYPOCALCEMIA**
in infants of diabetic mothers, *914
- HYPOCHOLESTEREMIC DRUGS**
and tumor-bearing mice, *857
- HYPOGLYCEMIA**
and alcohol
and basal insulin secretion, 65-69
and arginine-induced insulin release,
*312
and biguanides
and insulin, *123
and cataracts
in infants, *182
and diabetes
and kidney insufficiency, *1120-1121
drug-induced, 955-962
and exchange transfusions of citrated
blood, *185
factitious, *980
and glioxepid, *912
and hyperglycemia
and anti-insulin antibodies produc-
tion, 814-825
and hyperparathyroidism, *773
idiopathic
and epinephrine excretion, *1200
and infants, *248
and beta cell nesidioblastosis, *189
and glucose administration in diabetic
mother, *1202-1203
and growth hormone levels, *250
and insulin
and central nervous system, *337
and growth hormone, 22, 30
and intravenous glucose, 610
and iodinated insulin, *55
ketotic
diagnosis in children, *56
and lactic acidosis, *1198
liver response to
and mannose, fructose and hydroxy-
butyrate, 797-803
and metformin, *771
and monamine oxidase inhibitor, *251-
252
neonatal, *179-180, *910
nondiabetic reactive and asymptomatic
biochemical
and insulin-glucose dynamics, *373
and oral insulin, 644, 645
and pancreatoduodenectomy
and pregnancy, *188
- and phenobarbitone, *1123
reactive
and phenformin therapy, *367-368
and tolbutamide, *1123
- HYPOGLYCIN A**
and Jamaican vomiting sickness, *316
- HYPOGONADISM**
hypogonadotropic
and diabetic impotency, 23, 26
- HYPOINSULINEMIA**
and alpha-adrenergic activity, *348
- HYPOKALEMIA**
and glucose intolerance, *1043-1044
- HYPOLIPEMIA**
in pregnant rhesus monkeys, *912
- HYPOLIPIDEMIA**
in "acatalasemic" mice *56
- HYPOPHYSECTOMY**
and aminophylline
and hyperglycemia, *775
and diabetic pregnancy, 972-974
and diabetic retinopathy, *349
and glucagon secretion, *375
and insulin secretion, *253
and pancreatectomy
and diabetic ketosis in rats, 946-954
and tolbutamide and glybenclamide,
*378-379
- HYPOPITUITARISM**
and dwarfism
and growth hormone, *982-983
and growth hormone levels, *776
and hypoglycemia, *248
- HYPOTHALAMIC-HYPOPHYSEAL
SYSTEM**
and insulin, *1200
- HYPOTHALAMUS**
damage
and obesity, *1206
lesions
and insulin resistance and hyperinsu-
linemia, *838
and lipolysis, *55
stimulation
and plasma glucose, insulin and glu-
cagon, *771
ventromedial destruction
in diabetic rats, *1043
and glucose metabolism, *1204-1205
- HYPOTHYROIDISM**
and diabetes, *769
- I**
- IMMUNE COMPLEX DISEASE**
and diabetic microangiopathy, *352
- IMMUNOELECTROPHORESIS**
and diabetic glomerulosclerosis, 163-173
and insulin antibodies assays, 816, 819
- IMPOTENCE**
and diabetes
and androgenic function studies, 23-
28
- IMURAN**
and immune response to insulin, *58
- INDIA**
diabetes survey of rural population of,
1192-1195
- INFANTS**
big
and glucose tolerance during preg-
nancy, *186
congenital neuroblastoma and islet hy-
perplasia, *1122
and Cushing's syndrome, *120
of diabetic mothers
and carbohydrate metabolism, *912,
*1046
and caudal dysplasia, *1042
and drug-induced hypoglycemia, 955
and hypocalcemia, *914
and erythroblastosis fetalis
and glucose metabolism, plasma in-
sulin and growth hormone se-
cretion, *1199-2000
and exchange transfusion
of citrated blood, *185
and glucose, *1120
and hyperbilirubinemia
and phenobarbitone therapy, *1123
and hypoglycemia, *248
and cataract, *182
and glucose administration in dia-
betic mother, *1202-1203
hypoglycemic and normoglycemic
and growth hormone levels, *250
and ketoacidosis, *181
and malnutrition
and metabolic and hormonal re-
sponses to amino acids, *182
and marasmus
and chromium and glucose utiliza-
tion, *313
mortality
and glucose tolerance during preg-
nancy, *186
and neonatal hypoglycemia, *179-180,
*910

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64	Supplement 1, 321-384	August, 843-922
February, 65-128	Supplement 2, 385-714	September, 923-986
March, 129-192	June, 715-778	October, 987-1050
April, 193-256	July, 779-842	November, 1051-1130
May, 257-320		December, 1131-1210

SUBJECT INDEX 1972

- temporary, *181
 newborn
 and permanent diabetes, *249
 premature
 and intravenous hyperalimentation, *837
 and serum insulin and growth hormone response to arginine and glucose, *316
 and severe idiopathic hypoglycemia and beta cell nesidioblastosis, *189
 and type II hyperlipoproteinemia and plasma and blood cholesterol, *1043
- INFECTION**
 and diabetes
 and plasma glucagon levels, *324
 rhinocerebral phycomycosis, *195
- INFRARED THERMOGRAPHY**
 and circulation studies in diabetics, *981
- INSULIN**
 action, 454-455, 485
 and amino acid sequences, 457-459
 and atomic structure, 509
 computer studies of, *347
 and insulin-dextran complex studies, *1122
 and insulin receptor, 396-401
 and lead intoxication, *381
 molecular basis of, 468-474, 695-700
 related to atomic structure, 492-505
 acute hypoglycemic action
 and insulin-dependent diabetes, *182
 acute response to glucose
 and epinephrine, *773
 and adipose tissue lipolysis, 427
 administration
 to gastrointestinal tract in rabbit, 203-207
 amino acid sequences, 485
 analogs synthesis, *772-773
 antibodies, *57, *182, *379, 649-656, 657-659, 660, 677, *775, 764-765, *769, 814-825, 914, 930-934
 antisera
 proinsulin cross-reactivity with, 465-466
 assays
 in monkeys, 1078-1089
 in obese rats, *1123
 and atherosclerosis, 684
 "big"
 and streptozotocin therapy for islet cell carcinoma, *1204
 "big" and "little", 677
 binding
 to lymphocytes and fibroblasts, 426-427
 binding activity
 in diabetics and nondiabetics, *775
 and hormones, *1121-1122
 -binding proteins, 426
 bioassays
 and insulin stability determinations, 805-812
 biosynthesis
 and amino acids, *772
 and cytochalasin B, 602-603
 monolayer newborn rat pancreas for study of, 627-630
 and blood glucose levels
 and exercise, 98-99
 and carbohydrate homeostasis, *357
 circulating antibodies to
 polyethylene glycol screening test for, *379
 concentrations
 and diabetic lipemia, *376-377
 content
 of beta cell tumors, 535
 of fetal rat pancreas, 193-201
 and cyclic AMP and dibutyl cyclic AMP activity, 1028
 and cyclic AMP levels, 453
 deamino-A¹ sheep
 synthesis, *981
 deficiency
 and glucagon secretion, *183
 and hypertriglyceridemia, *366-367
 and ketosis, 257-258
 and liver glucose production, *380-381
 and liver ribosomal aggregation, 84-88
 degradation
 and chemicals and hormones, 468-469
 and fat cells, 403-411
 by human placenta, *374-375
 in rat liver, *382
 in rats, 1091-1100
 -degrading enzymes
 and proinsulin assay, *122
 -dependent diabetes
 and blood glucose production and oxidation, *375
 and pheochromocytoma, *838
 derivatives, 427-473
 and diabetes control
 and retinopathy, *382
 and diabetes management, 632-636, 678
 and diabetes mortality, 633-636
 and diabetic pregnancy, *315
 dimer, 494, 496-497
 macromolecular modeling system for, 506-508
 disappearance rates
 in nondiabetics and diabetics, *1047
 discovery of, 385-395
 distribution and binding
 in dog hindlimb, *775
 dosage
 and diabetes in neonate, *249
 and drug-induced hypoglycemia, 959-960
 exogenous
 and insulin secretion in normal and obese hyperglycemic mice, *344
 and fat cells
 and lipolysis, 414-424
 and mercury, *771
 and fatty acid synthetase, *914
 fish
 amino acid sequences, 459
 and fructose metabolism, *314
 and gamma globulin
 and diabetic microangiopathy, 872-879
 and glucagon, *60
 -glucagon ratio
 and liver metabolism, *341
 and glucose
 and hypoglycemia, *373
 and glucose metabolism
 in hyperammonemic rats, *184
 in rat diaphragm and epididymal fat pads, 935-938
 in rat skin, *189
 -glucose relationships, 704, 707-710
 and glucose tolerance factor, *1043
 and glycogen synthase, 428-437
 and glycolytic enzymes, *773
 and glycosuria, *186
 graded infusions of
 and plasma glucose, serum growth hormone and cortisol responses, *379
 guinea pig and coypu
 amino acid sequences, 457-458
 hexamer structure, 497-499
 hyperresponsiveness
 and chronic glucagon administration, *374
 and hypertriglyceridemia
 and phenformin, *380
 immune response to, *58
 immunoassays
 and antibodies study, 814-825

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64
 February, 65-128
 March, 129-192
 April, 193-256
 May, 257-320

Supplement 1, 321-384
 Supplement 2, 385-714
 June, 715-778
 July, 779-842

August, 843-922
 September, 923-986
 October, 987-1050
 November, 1051-1130
 December, 1131-1210

SUBJECT INDEX 1972

- immunohistological detection in pancreatic tissue, *246
- immunoreactive
- circulating components of, 673-676
 - and glucose dosage, 1105-1106
 - and intravenous glucagon, *360-361
 - and neonatal hyperglycemia, *181
 - and obesity, 13-15
 - and serum nonsuppressible insulin-like activity, 278
 - during thyrotoxic periodic paralysis attacks, *1047
- induced hypoglycemia
- and mannose, fructose and hydroxybutyrate, 797-803
 - and plasma growth hormone, *312
- infusion
- and glucose kinetics in dogs, *188
 - and glucose turnover in depancrea-
tized dogs, *382-383
- and insulin antibodies
- in dogs, *182
- interaction with liver membranes, *334-335
- intestinal response to, *1047
- in islet cell carcinoma, *909-910
- jet injections of, 39-44
- and late-onset diabetes, 763
- levels
- and obesity, *380
- like activity
- of arginyl compounds, *1122-1123
 - in fibrosarcoma, *352-353
 - nonsuppressible, 271-278
- and lipid synthesis, *189
- and liver adenylate cyclase, *772
- and liver enzymes, 713
- and liver epinephrine-responsive adenyl cyclase, *1117-1118
- and liver gluconeogenesis, *371
- and liver glucose-6-phosphate dehydrogenase, 49, 53
- and liver metabolism, 453, *1200
- and intracellular cyclic AMP level, 439-445
- and liver plasma membranes, *335
- and liver protein synthesis, 453
- liver response to
- and prediabetes, *323-324
- metabolic clearance of, 1003-1011
- modified
- activity of, 502-504
- monomer structure, 493-494
- neutral Regular, 235-245, 637-638
- new forms of, 637-647, 648
- nonavian
- and cardiovascular response in chickens, *59
- nonhypoglycemic, *55
- oral, 643-647, 648
- and oxytetracycline
- and hypoglycemia, 960
- pancreas compartments of,
- and growth hormone, *372
- and pancreatic alpha-cell function
- and diabetes, 301-307
- and pancreatic blood flow and insulin output, *1204
- and placental glycogenesis, *1199
- and plasma amino acids, *340-341
- plasma growth hormone unresponsiveness to, *981
- and plasma insulin, glucose and free fatty acids, *325
- and plasma tryptophan in rats, *909
- polyalanyl derivatives of, *835
- and potassium flux and glucose output, *254
- and pressor response to angiotensin and norepinephrine
- and alloxan diabetes, *354-355
- and proinsulin, *57, *314
- conformational studies, 486-491
- proinsulin conversion to, 572-579, 581
- proinsulin-like component of, *313
- proinsulin ratio
- and diabetes, 664
- and propranolol
- and hypoglycemic coma, 960
- and protein synthesis, 447-451
- in anterior pituitary gland, *1200
 - and cyclic AMP, *119
- and protein turnover in skeletal muscle, *341
- purified pork
- and insulin allergy, 638-643
- and pyruvic dehydrogenase, 427
- rat
- amino acid sequences, 458-459
 - and rat adipocytes, *60
 - and rat fatty liver, *183
 - and rat mammary cell metabolism, *315
- reactions
- and pituitary reserve capacity, *981
- receptor sites in fat cells, *336
- receptors
- in central nervous system, *337
 - of liver plasma membranes, *335
- and regulation of glycerol kinase, *122
- release
- and acromegaly, *1118
 - "acute phase," 157-161
- and adenylate cyclase and phosphodiesterase, *328-329
- and age, *184
- and aldose reductase inhibitors, *327
- and alpha adrenergic receptors, *348
- and alpha-adrenergic receptor blockade, *181
- and amino acids, *56
- and 6-aminonicotinamide, *1198
- and antimetabolic agents, 987-997
- arginine-induced, *312
- and autonomic nervous system, 624-627
- and cyclic 3'5' AMP, *185
- and diazoxide, *360
- and diphenylhydantoin and diazoxide, *327
- and encephalomyocarditis infection, *247
- and fats and fatty acids, 613,615, 617-618
- in fetal pancreas, *345-346
- and glucoreceptor mechanisms, 570
- glucosamine-induced, *328
- and glucose, 143, 713, *1042
- and glyburide infusion, 209-215
- and human chorionic somatomammotropin, 1072-1075
- and intracellular pH of pancreatic beta cells, *911
- and iodoacetate and antimycin A, *56
- in islet cell adenomas, *346-347
- and islet glucoreceptor mechanisms, 555-568
- L-leucine and L-phenylalanine induced, *369
- methamphetamine induced, *252
- by monoamineoxidase inhibitor, *363-364
- and ouabain, *246
- and packet storage, 585-592
- and pancreatic calcium uptake, *837
- and pancreatic islet citrate levels, 999-1001
- perfusion studies, 987-997
- and phenformin, *1045
- and phenytoin, *187
- and prostaglandins, *329, *369
- and protein and amino acids, 613, 617-618
- and pyridine nucleotide, *983
- stimulus-secretion coupling of, 594-603, 605
- and uremia, *910-911
- release and content
- in rat islets, *1205
- release and inhibition
- in fetal rat pancreas, *121

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64	Supplement 1, 321-384	August, 843-922
February, 65-128	Supplement 2, 385-714	September, 923-986
March, 129-192	June, 715-778	October, 987-1050
April, 193-256	July, 779-842	November, 1051-1130
May, 257-320		December, 1131-1210

SUBJECT INDEX 1972

- requirements
and infection, *324
- reserves
and diabetic instability, *836
- resistance
and alcohol, *247-248
and fat cell insulin receptors, *1042
in genetically obese rats, *838
and hemochromatosis, *1199
in obese mice, *314-315
and obesity, *249, *314
and proinsulin antibodies, *368
and steroid-induced ketoacidosis, *54
- resistance factor
secretion by hyperfunctioning pancreatic islets, *370
- resistance and release
and obesity, *316
- resistant hyperglycemia
and aminophylline, *775
- response
by adipose tissue, 1151-1161
to amino acids, 2-deoxy-D-glucose, mannoheptulose and, 1-5
to arginine and tolbutamide, *378
and diphenylhydantoin, therapy, *355-356
to hemorrhagic shock, *364
in partially depancreatized dogs, *339
and prediabetes, 685-687
of pregnant women and their fetuses, *251
and small-vessel disease, *836
to sucrose and glucose, *58
to tolbutamide and propranolol, *122
- response to glucose
and carbohydrate and lipid metabolism, *1119
and chlormadinone acetate, *313
and myocardial infarction, *119
and peripheral vascular disease, arteritis and Raynaud's phenomenon, *836-837
and prediabetes and diabetes, 224-233
from small bowel, *54
and tolbutamide, 684
- secreting tumors, *1120
- secretion, *188, 510, 535
in *acomys cahirinus*, 1060-1070
and alcohol hypoglycemia, 65-69
and alpha-ketomonocarboxylic acids, *359
and amines and pancreatic beta cells, *248
and amino acids, 570-571
and aminophylline, 289-293
and ammonium ion, *248
and arginine, *1045
and beta adrenergic and cholinergic agents, *332
and body composition in obese patients, *1118
and carcinoid syndrome, *1200
and chemical diabetes, *1121
and diazoxide, *1045
and diet, *912-913
and diphenylhydantoin, *982
and diphenylhydantoin and diazoxide, 856-861
and epinephrine, *770
and glibenclamide, *913
and Glisoxepid, *912
and glucagon, in congestive heart failure patients, 939-944
and glucagon-like immunoreactivity, *58
and glucose, 606-613, 617-618
and glucose and alloxan, *326
glucose-induced, and juvenile diabetes "remission," *1205
during glucose infusions in starvation and diabetes, *359-360
and glucose and tolbutamide, *370
and isolated insulin antibodies, *914
in isolated pancreas islets, 538-545
and kwashiorkor, *1119-1120
and lipoatrophy, *381-382
and long-chain triglycerides, 923-928
and metal ions, 570
and metformin, *914
and methylene blue, *350
and methysergide maleate, *315-316
and monoamines, *251-252
and myotonic dystrophy, *378
nutrient regulation of, 606-615, 617-618
and obesity after exercise, *909
and oral glucose administration, *909, *911
and ouabain, *913
and pancreatic beta-cell webs, *838
and pancreatic monoamines, *345
and phentolamine, *119
and prediabetes, 688-691
and prolonged glucose infusion, *372
seasonal variations in, *312-313
and serotonin antagonists, *352, 779-787
and serotonin and dopamine, *184
and slow-rise and square wave stimuli, *55
and sodium beta-hydroxybutyrate, *373-374
and sulfonylureas, *1120
and synthetic glucagon, 845-846
and thyrotoxicosis, *370-371
and thyroxine and hypophysectomy, *253
and tolbutamide, *1123
and xylitol and glucose, *187-188
- secretion and content
of isolated islets in tissue culture, 548-549, 551-553
- sensitivity
and ammonium chloride-induced acidosis, 794-796
scoring system for clinical evaluation of, *361-362
- sensitivity of adipose tissue
and obesity, 6-11
- sepharose-bound
and muscle, adipose tissue and cultured liver cells, *335-336
- serum-bound
and insulin antibodies, 930-934
and sodium acetate incorporation into lipids of rat aorta, *186
- storage
threshold distribution hypothesis for, 585-592
- structure, 1131-1149
- synthesis, 469-471
- therapy
and antigenicity, 649-656, 657-659, 660, 677
and tissue cyclic AMP levels, 426
- tolerance
and dosage, *121
and submaxillary gland extirpation, 722-731
- tolerance tests
during bedrest, 104-105
and triglyceride synthesis, *351-352
- tryptophan complex
isolation of, *1045
- U100 Lente, 832, 954
and unstable diabetes
and biguanides, *123
and zinc, 487-489
- INSULIN RECEPTOR, 396-401
- I-131 INSULIN
and fat cell metabolism, 403-411
metabolic clearance studies of, 1003-1011
- uptake
and exercise, *980
- INSULINASE, 1095-1100
- INSULINEMIA
and liver cirrhosis

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320

Supplement 1, 321-384
Supplement 2, 385-714
June, 715-778
July, 779-842

August, 843-922
September, 923-986
October, 987-1050
November, 1051-1130
December, 1131-1210

SUBJECT INDEX 1972

- and glucose, tolbutamide and glucagon administration, *121-122
- INSULINOMAS**
and blood proinsulin-like components, 665
and glycolytic enzymes, *773
- INSULITIS**
and late-onset diabetes, 762-767
- IODINE**
—treated insulin, *55
- IODOACETAMIDE**
and amino acid metabolism, *56
- IODOACETATE**
and insulin release, *56
in fetal rat pancreas, *121
- IONOGRAMS**
and tissue glycogen synthase study, 429, 431
- IRON**
deficiency
and acetoacetate-induced anemia, *311
- ISLETS OF LANGERHANS. See also**
Pancreas, islets
adenyl cyclase, *179
alpha and beta cells
and glucose and fatty acid oxidation, *909
of fetal pancreas, *253-254
glucoreceptor mechanisms, 555-568
hyperplasia
and congenital neuroblastoma, *1122
immunohistological detection of insulin in, *246
and insulin biosynthesis, 572-579, 581-583
insulin secretion
and insulin antibodies, *914
isolated in tissue culture
metabolism studies, 546-553
localization of adenylyl cyclase and cyclic AMP phosphodiesterase, *328
structure, *1043
- L-ISO PROPYLNORADRENALINE**
and insulin secretion, *252
- ISOPRENALINE**
insulin response to
in *acomys cahirinus*, 1065, 1069
- ISOPROTERENOL**
—stimulated rat salivary glands
and glucose metabolism, *982
- ISOXSUPRINE**
and hyperglycemia, *1045
- J**
- JAMAICAN VOMITING SICKNESS,**
*316
- K**
- KETOACIDOSIS**
alcoholic, *56-57
in infancy, *181
- KETOACIDOSIS, DIABETIC, 794,**
*1203
and L-asparaginase, *1119
and bicarbonate therapy, *323
and blood coagulation, 108-110
and blood ketone body estimation method, *1117
and blood lactate and ketone bodies, *186-187
and blood lactic and pyruvic acids, *350
and brain utilization of ketone bodies, *247
and coma, *60
and insulin, 632-633
steroid-induced, *54
- KETOGENESIS**
and hyperosmolar diabetic syndrome, *369-370
regulation, *1203
- KETONE BODIES**
in amniotic fluid
and maternal caloric deprivation, *1202
brain utilization of
in normal and ketoacidotic rats, *247
formation, *1203
and diabetes, 257-268
and lipolysis suppression, *377
metabolism
in fasted and diabetic rats, *246
in perfused skeletal muscle, *343
and renal ammoniogenesis, *251
and renal metabolism, *314
and unstable diabetes, *836
uptake by dog kidney, *251
- KETONURIA**
and dietary fructose, *349-350
and ketoacidosis in infancy, *181
and lipoatrophic diabetes, 827-830
- and nicotinic acid, *313
- KETOSIS**
and cerebrospinal fluid pressure, *180-181
and hypoglycemia
diagnosis of, *56
and insulin deficiency, 414
and ketogenesis regulation, *1203
and kidney function, *121
lipoatrophic diabetes without, 827-830
and lipolytic and glucocorticoid hormones, 946-954
and liver mitochondria, 257-268
- KETOSTIX**
and blood ketone body estimation, *1117
- KIDNEY**
amino acids
and exercise, *119
ammoniogenesis
and ketone bodies, *251
and antidiuretic action of chlorpropamide, *189
and bladder dysfunction, *364
and diabetic glomerulosclerosis, 163-173
in diabetic guinea pigs, *338
diabetic-like microangiopathy, *373
disease
and diabetes, in Pima Indians, *365-366
dog
and ketone bodies uptake, *251
failure
and sulfonylurea blood-sugar-reducing action, *1120-1121
function
and bacteriuria, *118
and diabetic ketosis, *121
glomerular lesions
and proteinuria, *1120
glomerulonephritis
without diabetes, *769
glomerulosclerosis
in diabetic baboons, *338
diabetic-like, *373
gluconeogenesis
and ammonia production, *57
and cyclic AMP, *910
glycosaminoglycans
and alloxan diabetes, 1163-1166
glycosuria
and heredity, *248
hypokalemic nephropathy, *1042
and insulin and proinsulin degradation, 1091-1100

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64	Supplement 1, 321-384	August, 843-922
February, 65-128	Supplement 2, 385-714	September, 923-986
March, 129-192	June, 715-778	October, 987-1050
April, 193-256	July, 779-842	November, 1051-1130
May, 257-320		December, 1131-1210

SUBJECT INDEX 1972

and liver cholesterol synthesis in rat, *1047
 metabolism, *314
 microangiopathy, *357
 polyalanyl insulin, *835
 of progeny of protein-deficient rats, *1041
 and starvation
 and mineralcorticoid and glucagon sensitivity, *334
 transplantation
 and diabetes, *322
 and pancreas transplantation, *355
 uric acid excretion
 and nicotinic acid, *313

KIMMELSTIEL-WILSON DISEASE
 and glomerulosclerosis without diabetes, *769

KWASHIORKOR
 and insulin secretion, *1119-1120

L

LACTASE
 and race, 871

LACTATE
 and blood sugar and liver glycogen formation, *189
 and liver gluconeogenesis and phenylethylbiguanide, *910
 metabolism
 and ethanol, *367

LACTIC ACID
 and serum and plasma osmolality, *838

LACTOSE TOLERANCE TESTS
 in Nigeria, 871

LACTOSURIA
 in diabetes survey, 1193

LEAD
 intoxication
 and insulin action, *381

LESIONS
 arterial
 and diabetes, *187
 beta-cell
 and encephalomyocarditis infection, *247
 glomerular
 and proteinuria, *1120
 microangiopathic, *357
 neurologic
 and impotency, 23-28

skin
 and diabetes, *251
 testicular
 and diabetic impotence, 25-28

LEUCINE
 incorporation into protein, *336
 and insulin release, 3-4, *56
 and insulin secretion, 539
 metabolism
 and glucose, *56
 pancreatic islet cell electrical activity in response to, *345
 uptake by pancreatic beta cells, *772

L-LEUCINE
 -induced insulin release, *369

LEUCINE-C-14
 incorporation into growth hormone and lipids, *187

LEUKEMIA
 and L-asparaginase therapy
 and transient diabetes, *1119

LEYDIG CELLS
 and diabetic impotence, 25-26

LIPEMIA
 alimentary
 and sucrose and glucose, *58
 and diabetes
 and insulin concentrations, *376-377
 and glucagon resistance, *357

LIPIDS
 biliary
 and pregnancy, *912
 and growth hormone synthesis, *187
 metabolism
 in dogs, *312
 and glucose tolerance and insulin response to glucose, *1119
 and menstrual cycle, *1204
 and prediabetes, 687
 and streptozotocin, *59
 mobilization
 and tumors in obese mice, *774
 rat aorta
 and sodium acetate incorporation, *186
 synthesis
 and starvation, alloxan diabetes and insulin, *189

LIPOATROPHIC DIABETES
 and urine polypeptides, *837
 without ketosis, 827-830

LIPOATROPHY
 and growth hormone activity
 and glucose and insulin abnormalities, *381-382

LIPODYSTROPHY
 and growth hormone abnormalities, *771
 intestinal
 diet-induced, *1044

LIPOGENESIS
 and high-fat diet, *182
 and liver acetic thiokinase, *982

LIPOLYSIS
 adipose tissue
 and body weight, 754-760, *911-912
 and cyclic AMP, 1034
 epinephrine-stimulated
 in siblings of diabetics, *361
 and growth hormone, *342-343
 and β -hydroxybutyrate, *836
 in hypophysectomized rats, 950-951
 inhibition, *55
 and insulin, 414-424
 and cyclic AMP, 403
 in isolated fat cells
 and amitriptyline, *1045
 ketone suppression of, *377
 and mercury, *771
 and phenformin, *362
 postheparin, *54, *342
 in white fat cells
 and tolbutamide, *835

LIPOMATOSIS
 and adipose tissue resection, 13-15

LIPOPROTEIN LIPASE, *188
 and insulin, *377
 and plasma triglyceride removal, *342
 post heparin
 and oral contraceptives, *316
 in rat heart and adipose tissue, *344
 release
 from alloxan diabetic rat heart, 149-155

LIPOPROTEINS
 release
 and cyclic AMP and insulin, 439-445

LIPOTROPHIN
 and lipolysis
 and iodinated insulin, *55

LIVER
 acetic thiokinase
 and lipogenesis, *982

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64
 February, 65-128
 March, 129-192
 April, 193-256
 May, 257-320

Supplement 1, 321-384
 Supplement 2, 385-714
 June, 715-778
 July, 779-842

August, 843-922
 September, 923-986
 October, 987-1050
 November, 1051-1130
 December, 1131-1210

SUBJECT INDEX 1972

- adenylate cyclase
 and insulin, *772
 and selectively blocked glucagon, *981
- and alcoholic ketoacidosis, *56-57
- amino acids
 and exercise, *119
- cells
 and sepharose-bound insulin, *335-336
- cholesterol
 and temperature, *314
- cholesterol synthesis
 and kidney inhibitory factor, *1047
- chromium
 and diabetes, *1046
- cirrhosis
 and angiopathy, *123
 and diabetes and hemochromatosis, *1199
 and hyperinsulinemia, *356
 and insulinemia, *121-122
- cycloleucine
 and D. pneumoniae, *316
- cytosol
 and ethanol and sorbitol metabolism, *181
- enzymes
 and alloxan diabetes, *188
 and cold exposure, *58
 and insulin, 713
- epinephrine-responsive adenylyl cyclase activity
 and insulin, *1117-1118
- ethanol-oxidizing and drug metabolizing enzymes
 and alcoholism, *983
- fatty
 alcohol-induced, *770
 and pyrazole and glucose, *247
- free fatty acid metabolism
 and anti-insulin serum, 280-288
 and diabetic ketosis, 947-948, 950-954
- glucagon-responsive adenylyl cyclase macromolecular inhibitor of, *180
- gluconeogenesis
 from fructose and glycerol, *358
 and glucagon, *331
 and glucocorticoids, *339-340
 and D-glyceraldehyde and dihydroxyacetone, *330-331
 and insulin and glucose, *371
 and phenylethylbiguanide, *910
- and glucose homeostasis, 686-687
- glucose output
 and acute hypoglycemic action of insulin, *182
- glucose production
 and insulin deficiency and hyperinsulinemia, *380-381
 and mannose, fructose and hydroxybutyrate, 797-803
- glucose-6-phosphate dehydrogenase and carbohydrate and insulin, 49, 53
- and glycerol kinase
 and regulation by insulin, *122
- glycogen formation
 and lactate, *189
- and glycoprotein synthesis, 868-870
- and growth hormone metabolism, 177
- homeostasis
 and L-asparagine, *254
- 3-hydroxybutyrate dehydrogenase
 and diabetes, *184-185
- and hyperglycemic response to splanchnic nerve stimulation, *770
- injury
 and pancreatic mitosis, 1054-1055
- and insulin and proinsulin degradation, 1091-1100
- ketogenesis
 and gluconeogenesis, 50-52
- lipids
 and diet, *1202
- lipogenesis
 and diet, *60
 and free fatty acid conversion to triglyceride fatty acid, *835
- membranes
 insulin interaction with, *334-335
- metabolism
 and glucagon:insulin ratio, *341
 and insulin, 453, *1200
 and insulin and cyclic AMP levels, 439-445
 and rapid indicator-dilution technic studies, *180
 and streptozotocin, *59
 and tissue injury, *315
- mitochondria
 and diabetic ketosis, 257-268
- mitochondrial swelling
 and ammonia toxicity, *835-836
- α -oxoglutarate carboxylation and diabetes, *981
- perfused rat
 and amino acid metabolism, *57
 and glucocorticoids and gluconeogenesis, *252
 potassium flux and glucose output studies, *254
- perfused sheep, *57-58
- and plasma angiotensinogen and renin levels, *253
- plasma membrane
 and calcium and insulin binding mechanisms, *1122
 and insulin receptors of, *335
- protein synthesis
 and alloxan diabetes, *339
 and insulin and cyclic AMP, 453
- rat
 and carbohydrate metabolism and adrenergic agents, *1203
 and cyclic 3'5'-AMP during glucose repression, *187
 and diabetic ketosis, 257-268
 and diet, *183
 and glucagon and adenosine 3'5'-monophosphate levels, *54
 and insulin degradation, *382
 nuclear proteins and diabetes, *377
- ribosomes
 and insulin deficiency, 84-88
 and protein synthesis, *339
- sensitivity to endogenous insulin
 and prediabetes, *323-324
- splanchnic nerve stimulation and adrenalectomy, *770
- threonine dehydratase
 and tris aminmethane and orthophosphate, *980-981
- triglycerides
 biosynthesis, and pregnancy and sex steroids, *365
 and ethanol, *247
 and glucagon, *55
 and oral contraceptives, *316

M

MACROANGIOPATHY

and atherosclerosis, 679-680

MAGNESIUM

flux
 and glucose ingestion in children, *376

and insulin action, 696, 697-698
 and insulin secretion, 570

intestinal absorption, *775

loss
 and ammonia toxicity, *836

MALATE

labeled
 and gluconeogenesis study, *252

MALNUTRITION

infantile
 and amino acid responses, *182

kwashiorkor
 and insulin secretion, *1119-1120

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64
 February, 65-128
 March, 129-192
 April, 193-256
 May, 257-320

Supplement 1, 321-384
 Supplement 2, 385-714
 June, 715-778
 July, 779-842

August, 843-922
 September, 923-986
 October, 987-1050
 November, 1051-1130
 December, 1131-1210

SUBJECT INDEX 1972

- marasmus
and glucose utilization and chromium, *313
- maternal
and lactosuria, 1195
- MAMMARY GLAND
metabolism
and insulin, *315
- MANGANESE
-induced hypoglycemia, 960
- MANNOHEPTULOSE
and amino acid metabolism, *56
and glucose protection from alloxan toxicity, *123
and insulin release, 544, 570-571
in fetal rat pancreas, *121
and insulin response to amino acids, 1-5
and insulin synthesis, 570
and pancreas metabolism, 562-564
- D-MANNOHEPTULOSE
and insulin response to glucose, 541
- MANNULOSE
and insulin secretion, 539, 543
and liver glucose production
and insulin-induced hypoglycemia, 797-803
- D-MANNULOSE
and alloxan toxicity, *123
- MARASMOUS
and glucose utilization
and chromium, *313
- MARIHUANA
and hypoglycemia, 961
- MARKS, HENRY E., 178
- MARMOSETS
and diet-induced jejunal lipodystrophy, *248
- MAURICAC SYNDROME, 633
- MEBANAZINE
and insulin
and hypoglycemia, 960
- MENSTRUATION
and carbohydrate and lipid metabolism, *1204
and growth hormone secretion, *774-775
- MENTAL ILLNESS
and sulfonyleureas, 959
- MENTAL RETARDATION
and galactosemia, 202, 208
- 6-MERCAPTOPYRINE
and immune response to insulin, *58
- MERCURY
and fat cell response to insulin and lipolytic hormones, *771
- METABOLISM
adipose tissue
and glycerol kinase regulation by insulin, *122
and insulin, 414-424
and obesity, 6-11, *54
and adipose tissue fat cell size and number, *180
in African pygmies, *1045-1046
amino acids
and exercise, *770-771
and glucagon and insulin, *340-341
and glucose, *56
and infantile malnutrition, *182
in perfused rat liver, *57
and starvation during pregnancy, *1118-1119
and arginine derivatives, *1122-1123
and blood proinsulin and C-peptides, 669
brain, *315
and galactose toxicity, 202, 208
and hepatic response to insulin-induced hypoglycemia, 802-803
and ketoacidosis, *247
brain glucose
in newborn rat, *775
calcium, *326-327
carbohydrate
and adrenergic agents, *1203
and age, *183-184
and alcohol, *247-248
and catecholamines and methylprednisolone, *772
and diabetic microangiopathy, 872
in infants of diabetic mothers, *1046
and metformin, *914
in newborn infants of diabetic mothers, *912
and pancreatic enzymes, *186
and psoriasis, *250
carbohydrate and lipid
and glucose tolerance and insulin response to glucose, *1119
and menstrual cycle, *1204
and streptozotocin, *59
cholesterol
and clofibrate, *1200-1201
and insulin, *186
- ethanol and sorbitol
in hypo-, hyper-, and euthyroid rats, *181
- fat cell
and dibutyryl cyclic 3', 5' AMP, *343
and insulin, *351-352
- fat and lactate
and phenformin, *1045
- fatty acids
by sheep liver and viscera, *118
and thrombin, *312
- fetal
and starvation, *187
- forearm
and tolbutamide, *1206
- free fatty acids, *835
- fructose
and insulin, *314
- gastrin
and secretin, *249
and glomerular basement membrane thickening, *913
- glucagon, *333
- glucose
of adipose tissue, 1151-1161
and carcinoid syndrome, *1200
and dosage, 1102-1108
and erythroblastosis fetalis, *1199-1200
and exercise and dietary carbohydrate, *179
in hyperammonemic rats, *184
and insulin and proinsulin, 935-938
in isolated pancreas islets, 538-545
in isoproterenol-stimulated rat salivary glands, *982
and leg exercise, *776
and methylene blue, *350
in rat skin, *189
and shock, *1201
and ventromedial hypothalamus nuclei destruction, *1204-1205
- glucose and fatty acids
and pancreas alpha and beta cells, *909
- glucose C-14
and 6-aminonicotinamide, *1198
- U-C-14-glucose, xylitol, fructose, and sorbitol
in fasted and streptozotocin diabetic rats, *122
- glycosaminoglycans
and alloxan diabetes, 1162-1166
- growth hormone
and juvenile diabetes, 175-177
and short stature, *119-120
and insulin clearance, 1003-1011

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320

Supplement 1, 321-384
Supplement 2, 385-714
June, 715-778
July, 779-842

August, 843-922
September, 923-986
October, 987-1050
November, 1051-1130
December, 1131-1210

SUBJECT INDEX 1972

- of isolated pancreas islets in tissue culture, 546-553
 isolated perfused sheep liver, *58
 ketone bodies
 in fasted and diabetic rats, *246
 in perfused skeletal muscle, *343
 kidney, *910
 lactate
 and ethanol, *367
 lipid
 in dogs, *312
 and lipoatrophy, *381-382
 liver, 50-52
 and anti-insulin serum, 280-288
 and diabetic ketosis, 257-268
 and glucagon, *55
 and glucagon:insulin ratio, *341
 and insulin, 453, *1200
 and insulin and cyclic AMP levels, 439-445
 and rapid indicator-dilution technic studies, *180
 and tissue injury, *315
 mammary cell
 and insulin, *315
 and obesity
 and exogenous growth hormone, *1046
 ornithine, *771
 pancreatic beta cell
 and phlorizin, *910-911
 pancreatic islet
 and glucose, *344-345
 placental glycogen
 and diabetes, 1185-1190
 and prediabetes, 685-693
 proinsulin, *347
 protein
 and insulin, 447-451
 renal, *314
 triglyceride and insulin, 923-928
- METABOLITES**
 and glucose
 in perfused pancreas, 564-565
 islet cell, 571
 and insulin secretion, *344-345
- METAFORMIN**
 and carbohydrate metabolism
 in obese, nondiabetic women, *914
 and hyperlipidemia, *771
 and hypoglycemia, *771
- METHAMPHETAMINE**
 -induced insulin release, *252
- METHIONINE**
 and pancreas mitotic activity, 1055
 and pancreatic beta cell uptake of amino acids, *772
 and rat fatty liver metabolism, *183
- L-METHIONINE**
 and pancreas α -amino-isobutyric acid transport, *181
- METHOTREXATE**
 and immune response to insulin, *58
- 3-O-METHYL-D-GLUCOSE**
 excretion
 and metformin, *771
 intestinal uptake, *249
 transport
 and biguanides, *119
- N-METHYLBENZYLAMINE**,
 and insulin secretion, *248
- METHYLCHOLANTHRENE**
 -induced thyroiditis
 and autoimmunity, *253
- METHYLENE BLUE**
 and glucose metabolism and insulin secretion, *350
- METHYLPHENIDATE**
 and tumor-bearing mice, *837
- METHYLPREDNISOLONE**
 and carbohydrate metabolism, *772
- METHYSERGIDE MALEATE**
 and insulin secretion, *315-316, 779-787
- MICROANGIOPATHY**
 and bacteriuria, *118
 and diabetes, 680-681
 and age, *837
 diabetic
 and concurrent bullous and atrophic skin lesions, *251
 in humans and animals, *357
 and insulin and gamma globulin interactions, 872-879
 and muscle capillary basement membrane changes, 881-896, 899-905
 and polyol metabolism, galactosemia, and immune complex disease, *352
 and serum protein changes, *371
 diabetic-like, *373
 and glucose tolerance, *321
- MICROSCOPY**
 electron
 and abetalipoproteinemia, *60
- of beta cell tumors, 535
 capillary basement membrane, *118
 of depancreatized baboon kidney, *338
 of diabetic rat liver, 259-260, 264-268
 of endocrine pancreas in newborn rodents, 1051-1059
 of glomerular basement membrane of juvenile diabetics, *913
 and intestinal lipoprotein production, *121
 and islets of Langerhans, *1043
 of mouse pancreatic beta cells, 1068-1070
 and muscle capillary basement membrane changes, 882, 884-896
 of pancreas of diabetic monkeys, 1086, 1087
 and pancreatic islets, 595-603
 of testicular tissue, 25-28
- light
 of isolated islets in tissue culture, 547-553
- light and electron
 of human embryonic and fetal pancreatic islets, 511-533
 and islet cell changes in streptozotocin diabetic rabbits, 129-137
- pancreas
 and long-term juvenile diabetes, 115-116
 of pancreatic islets
 from cyproheptadine-treated rats, 71-78
 in late-onset diabetes, 763-767
- MINERALOCORTICOID**
 kidney sensitivity to
 and starvation, *334
- MINERALS**
 calcium, magnesium and phosphorus flux
 and glucose ingestion in children, *376
 and insulin secretion, 570
 lead intoxication
 and insulin action, *381
 zinc
 and insulin, 497-498, 509
- MONKEYS**
 and glucose tolerance tests
 and bedrest and exercise, 105
 and induced obesity, hyperinsulinemia and hyperlipidemia, *1201

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64
 February, 65-128
 March, 129-192
 April, 193-256
 May, 257-320

Supplement 1, 321-384
 Supplement 2, 385-714
 June, 715-778
 July, 779-842

August, 843-922
 September, 923-986
 October, 987-1050
 November, 1051-1130
 December, 1131-1210

SUBJECT INDEX 1972

- Macaca nemestrina*
and streptozotocin diabetes induced
by direct pancreatic infusion,
138-141
- Macaca nigra*
spontaneous diabetes in, 1077-1089
- rhesus
and insulin response to hemorrhagic
shock, *364
and jet insulin injections, 39-44
- MONOAMINE OXIDASE
in mouse pancreas, *120
- MONOAMINE OXIDASE INHIBITORS
and hypoglycemia, *251-252
and insulin release, *363-364
- MONOAMINES
and insulin secretion, 779-787
- MONOGLYCERIDASE
postheparin, *54
- MONOGLYCERIDE HYDROLASE
in obese hyperglycemic mice, *186
- MORTALITY
and Cushing's syndrome in infancy,
*120
and diabetes, *1044
and arteriosclerosis, *1123
and insulin, 633-636
- fetal
and maternal blood sugar levels,
*1201-1202
and galactose toxicity in chicks, 208
and heart disease
and clofibrate therapy, *838
and lactic acidosis, *1198
and renal transplantation
and diabetes, *322
and sulfonyleurea treatment, *120
and tolbutamide
in UGDP study, 1036-1037
and x-irradiation in mice, *914
- MOUSE
acomys cahirinus
and defective immunoreactive insulin
secretion, 1060-1070
and alloxan
and diphenylhydantoin, 80-83
and anti-insulin serum
and pancreatic islet studies, *911
- diabetic
and glomerular lesions and protein-
uria, *1120
and diabetic-like microangiopathy, *373
and encephalomyocarditis virus infec-
tion
and diabetes-like syndrome, *247
hyperglycemic
and pancreas α -amino isobutyric acid
transport, *181
and insulin release
and methamphetamine, *252
- islets
and insulin release, *328-329, *914
longevity and mortality distribution
studies, *914
and microangiopathy, *357
mutant "acatalasemic"
and hypolipidemia, *56
- obese, *1044
and adipose tissue glycerol kinase
and lipolysis, *911-912
and glycerol kinase regulation, *122
and insulin resistance, *314-315
and plasma growth hormone, *122
with transplanted tumors, *774
- obese hyperglycemic
and adipose tissue monoglyceride hy-
drolase, *186
and caloric restriction studies, *835
and diet, *119
and exogenous insulin, *344
and high-fat diet, *182
and insulin release and citrate studies,
999-1001
- obese and lean
and islets of Langerhans adenylyl cy-
clase and phosphodiesterase,
*179
- pancreas
and encephalomyocarditis virus in-
fection, *338-339
- tumor-bearing
and hypocholesteremic drugs, *837
- MUCOPOLYSACCHARIDES
metabolism
and psoriasis, *250
- MUMPS
and diabetes, *182, 766
- MUSCLE
alanine synthesis
and exercise, *770-771
amino acids
and exercise, *119
ammonia production, *1203
antibody to
binding to fibroblasts, *314
capillaries basement membrane changes,
*254
and aging and diabetes, 881-896,
899-905
- capillary permeability and blood flow
and diabetes and prediabetes, *769
and ethanol, *838
and insulin and proinsulin degradation,
1091-1100
- myopathy
and capillary basement membrane
thickening, *118
- phosphofructokinase
and cyclic AMP and dibutyl cyclic
AMP, *363
and sepharose-bound insulin, *335-336
- skeletal
ketone-body metabolism in, *343
lactate metabolism and ethanol, *367
protein turnover in, *341
- MYOCARDIAL INFARCTION, 763
and clofibrate therapy, *838, *910
and glucose tolerance, *184
and glucose tolerance tests, *312-313
and hormone and metabolic disturb-
ances, *119
and hyperglycemia
and tolbutamide therapy, *122-123
- MYOTONIC DYSTROPHY
and insulin secretion, *378
- MYSTROMYS ALBICAUDATUS
pancreatic islet structure studies, *1043
spontaneous diabetes mellitus in, 715-
721

N

- NAUSEA
and oral insulin, 645
- NEPHRECTOMY
and uremia
and insulin release, *910-911
- NERVOUS SYSTEM
and adenylyl cyclase, *773
autonomic
and insulin release, 624-627
central
insulin-sensitive receptor in, *337
conduction
in galactose-fed rats, 295-300
and diabetic impotence, 23
disease
and hypoglycemia, *248
and growth hormone release, *913
and impotence
and diabetes, 23-28
and lipolysis
and β -hydroxybutyrate, *836
and phenothiazine-induced hypergly-
cemia, *184

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64	Supplement 1, 321-384	August, 843-922
February, 65-128	Supplement 2, 385-714	September, 923-986
March, 129-192	June, 715-778	October, 987-1050
April, 193-256	July, 779-842	November, 1051-1130
May, 257-320		December, 1131-1210

SUBJECT INDEX 1972

- sensory perception thresholds
and diabetes, *1199
splanchnic nerve stimulation, *770
tissue
and insulin binding proteins, 427
sorbitol and fructose, blood sugar
control and, 1173-1178
- NEUROBLASTOMA**
congenital
and islet hyperplasia, *1122
- NEUROPATHY, DIABETIC**
and diabetes management, 679
galactosemic, 295-300
of hands, *314
and impotence, 23-28
and prediabetes, *359
- NIALAMIDE**
and insulin release, *363-364
- NICOTINAMIDE**
and streptozotocin-induced beta-cell
toxicity, *325-326
- NICOTINAMIDE ADENINE NUCLEO-
TIDES**
and insulin, *315
- NICOTINIC ACID**
and glucose tolerance, plasma insulin,
and uric acid excretion, *313
- NIGERIA**
lactase activity levels in, 871
- NITROGEN**
conservation
placental, *340
- NITROGEN MUSTARD**
and steroid-induced ketoacidosis, *54
- NORADRENALINE**
and blood glucose and free fatty acid
responses to catecholamines,
*912
- NOREPINEPHRINE**
and fat cell metabolism, 420
and glucose tolerance tests, *348
and insulin release
and prostaglandins, *329
pressor response to
and insulin treatment in alloxan dia-
betic rats, *354-355
and theophylline
and cyclic AMP, 417
- NUCLEOTIDES**
and glucagon, 440
- NUTRITION, *59. See also Diet; Malnu-
trition; Starvation**
and insulin secretion, 606-615, 617-618
postnatal
and kidney cellular development in
progeny of protein-deficient
rats, *1041
- O**
- OBESITY**
and adipose tissue
fat cell size and metabolism, *54
glycerol kinase and lipolysis, *911-
912
monoglyceride hydrolase, *186
and caloric restriction, *835
and cardiovascular disease, *980
in children
and glucose tolerance tests, *1042-
1043
and diabetes, *246, *250
and low calorie diet with phenter-
mine resin, *361
and phenformin, *362
and diabetes prevalence, *776
and ethanol
and phenformin, *363
and exercise
and insulin secretion, *909
and food intake
and plasma glucagon, *331-332
and glucose tolerance, 1012, *1205
and growth hormone administration,
*1046
and hyperglycemia
and high-fat diet in mice, *182
and hyperinsulinemia, *380, 613, 617-
618
and adipose tissue resection, 13-15
and beta cell hyperplasia and in-
sulin resistance, *314
and blood proinsulin, 663-664
and diet, *249
and hyperinsulinemia and hyperlipi-
demia
induced in monkeys, *1201
and hypothalamic damage, *1206
and insulin assays, *1123
and insulin resistance, *314-315, *370
and insulin resistance and release, *316
and insulin secretion
and alcohol hypoglycemia, 65-69
and body composition, *1118
and xylitol and glucose, *187-188
and insulin sensitivity of adipose tissue,
6-11
- and metformin
and carbohydrate metabolism, *914
in new strain of mouse, *1044
and plasma growth hormone response
to hypoglycemia and arginine,
*312
and proinsulin response to oral glucose,
*356
and weight reduction
and adipose tissue lipolysis and cellu-
larity, 754-760
- OBITUARIES**
Beardwood, Joseph T., Jr., 839
Marks, Henry E., 178
- OCTANOATE**
and fat cell lipolysis, 418, 419, 421
and growth hormone synthesis, *187
- OLEATE**
and fat cell lipolysis, 418, 419
- OLIGOMYCIN**
and insulin release
in fetal rat pancreas, *121
- ORAL CONTRACEPTIVES**
and plasma lipids, lipoproteins, and in-
travenous fat tolerance, and
post-heparin lipoprotein lip-
ase activity, *316
- ORAL HYPOGLYCEMIC AGENTS**
and diabetic mortality, *1044
di-isopropylammonium dichloracetate,
*358
labeling laws, 833, 1116-1117
and vascular disease, *57
- ORNITHINE**
utilization
by chick, *771
- ORPHENADRINE**
-induced hypoglycemia, 961
- ORTHOPHOSPHATE**
and liver threonine dehydratase, *980-
981
- OUABAIN**
and glucose-induced biphasic insulin
release, *246
and insulin secretion, *913
- OXYGEN**
consumption by splanchnic bed, 50-51
myocardial consumption of
and glucagon, *118-119
uptake
in diabetic rat liver, 257-268
of isolated islets in tissue culture,
547-548, 550

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64	Supplement 1, 321-384	August, 843-922
February, 65-128	Supplement 2, 385-714	September, 923-986
March, 129-192	June, 715-778	October, 987-1050
April, 193-256	July, 779-842	November, 1051-1130
May, 257-320		December, 1131-1210

SUBJECT INDEX 1972

OXYTETRACYCLINE
and insulin
and hypoglycemia, 960

P

PALMITATE
and glucose metabolism, 419
and growth hormone synthesis, *187
metabolism
and ketosis, 258, 259, 261, 267

PANCREAS
acinar atrophy and fibrosis
and hemolytic anemia, *773-774
of *acomys cahirinus*, 1068-1070
and alloxan
and diphenylhydantoin, 81-83
alpha and beta cells
and glucose and fatty acid oxidation,
*909
alpha cell function
and diabetes, 301-307
amino acid metabolism
and glucose, *56
anglerfish islets
and glucagon biosynthesis, *58-59
beta cell dysfunction
and diabetes, 703-704
beta cell metabolism
and phlorizin, *910-911
beta cell nesidioblastosis
in idiopathic hypoglycemia of in-
fancy, *189
beta cell C-peptide
immunoreactivity studies, 1013-1025
beta cell responses, 619-630
beta cell structure, 536
beta cell tumors, 535
beta cell webs
and insulin secretion, *838
beta cells
alanine, arginine and leucine uptake
by, *772
and alloxan and streptozotocin, *326
and amines, *248
and α -amino-isobutyric acid trans-
port, *181
and arginine, *312
calcium uptake assays, *837
and cyclic AMP, *329
of cyproheptadine-treated rats, 71-78
embryonic, 523, 528, 531-533
and encephalomyocarditis infection,
*247
and glucose-induced insulin release,
594-603, 605
and glucose protection from alloxan
toxicity, *123

insulin detection study, *246
and insulin secretion, *914
intracellular pH, *911
and obesity, *314
replication, *346
and sensitivity to glucose in predia-
betes and diabetes, 224-233
and sulfonylurea-induced insulin re-
sponse, *122
vital damage, 713-714
blood flow and insulin output
and exogenous insulin, *1204
citrate levels
and insulin release and inhibition,
999-1001
cultured fetal human, *345-346
of diabetic monkeys, 1086, 1087
duct-ligated
response to glucose, *344-345
early research, 385-395
endocrine
structure in newborn rodents, 1051-
1059
endocrine cells
in embryos, 519-523
enzyme activity
in rats, *59
enzymes
and dietary regulation, *186
exocrine
and diet, *186
fetal, 620, 621, 623-624
fetal and embryonic, 536
fetal endocrine
cytological studies, *253-254
fetal rat
insulin content study, 193-201
insulin release and inhibition stud-
ies, *121
glucagon
and sulfonylureas, 216
glucagon and insulin secretion
and beta adrenergic and cholinergic
agents, *332
golden hamster cell cultures
and insulin secretion study, *370
insulin
and glucose, *375-376
insulin output and blood flow
and prostaglandins, *369
insulin release
and calcium, 591-592
and hemorrhagic shock, *982
and insulin secretion, 510
and diphenylhydantoin and diazox-
ide, 856-861
and species variation, *184
and sulfonylureas, *1120

islet cell adenoma
and adenylyl cyclase activation by glu-
cagon and tolbutamide, *912
cyclic AMP content, glucose, glu-
cagon, tolbutamide and theo-
phylline and, *346-347
and factitious hypoglycemia, *980
islet cell carcinoma
circulating insulin in, *909-910
and streptozotocin, *1204
islet cell tumors
and immunoreactive glucagon, *333
and plasma proinsulin, *1204
proinsulin content, 675-676
and proinsulin-like component of in-
sulin, *313
islet hyperplasia, 536
congenital, *1122
islet insulin secretion
and exogenous insulin, *344
islets
and 6-aminonicotinamide, *1198
and anti-insulin serum, *911
calcium efflux from, *326-327
cyclic AMP levels, starvation and,
*329
in diabetic guinea pigs, *338
and electrical activity in response to
leucine and tolbutamide, *345
embryogenesis, 511-533
hypertrophy and beta cell hyper-
plasia in long-term juvenile
diabetics, 114-116
and insulin release, 571
and insulin release and content,
*1205
and insulin resistance factor secretion,
*370
insulin secretion and glucose metab-
olism, 538-545
and late-onset diabetes, 762-767
metabolism, 546-553
monoamines, *120
pyridine nucleotide depletion, 789-
792
response to glucose, *344-345
and streptozotocin diabetes, 129-137
structure, 536-537, *1043
ultrastructure studies, *120
isolated perfused rat
and human chorionic somatomam-
motropin effects on insulin
and glucagon release, 1072-
1075
isolated rat islets
perfusion, 987-997
monoamines
and insulin secretion, *345, 779-787

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320

Supplement 1, 321-384
Supplement 2, 385-714
June, 715-778
July, 779-842

August, 843-922
September, 923-986
October, 987-1050
November, 1051-1130
December, 1131-1210

SUBJECT INDEX 1972

- monolayer cultures
and insulin biosynthesis studies, 627-630
- mouse
and monoamines, *251-252
- perfused canine
and glucagon secretion studies, *314
- perfused rat
and insulin release studies, *55, *56, *369
- rat
endocrine function in monolayer cultures of, *368
and ouabain and insulin release, *246
- rat islets
and alloxan and glucose interactions, *326
and methylene blue, *350
scintiphotoscanning, *351
and streptozotocin-induced beta cell toxicity
and nicotinamide and pyridine nucleotides, *325-326
- streptozotocin infusion
in *Macaca nemestrina*, 138-141
- transplantation
in diabetic subject, *355
- tumors
insulin secreting, *1120
- PANCREATECTOMY**
and discovery of insulin, 385-394
and glucagon
and cyclic AMP, 453
and glucose turnover
and insulin and glucagon infusion, *382-383
and hypophysectomy
and diabetic ketosis in rats, 946-954
and liver free fatty acid metabolism, 280
and liver 3-hydroxybutyrate dehydrogenase, *184
subtotal
and chlormadinone acetate, *313
- PANCREATITIS**
acute
diabetes incidence after, *911
and oral insulin, 646-647
- PANCREOZYMIN**
and insulin release, 928
- PARAPLEGIA**
and impotence
and androgenic function, 23-28
- PARATHORMONE**
action
and cyclic AMP, *251
- PARATHYROIDECTOMY**
and plasma insulin levels, *773
- PARKINSON'S DISEASE**
and L-dopa
and plasma growth hormone, insulin, and thyroxine, *911
- PENTOSE PHOSPHATE PATHWAY**
and insulin, *315
and insulin release, 143
overactivity
and psoriasis, *250
and xylitol absorption, *352
- PEPSIN**
secretion
and secretin and duodenal acidification, *250
- C-PEPTIDE**
in blood, 661-670
circulating immunoreactivity studies
and diabetes, 1013-1025
proinsulin conversion to, 572-579
- PEPTIDES**
diabetogenic, 714
synthetic
and glucagon, 843-855
C-terminal, 714
- PEROXIDASE**
and hypolipidemia, *56
pH
arterial
and acidosis diagnosis, 1110
of inflammatory exudates
in acidotic diabetic rabbits, *1201
intracellular
of pancreatic beta cells, *911
- PHENFORMIN**
and ethanol
and obesity and prediabetes, *363
and fat and lactate metabolism and insulin production
and starvation, *1045
and glibenclamide, *55
and lactic acid levels
and anoxia and exercise, *351
and lactic acidosis, *1198
lipid-lowering effect of, *380
and lipomatosis, 15
and obese diabetics, *362
and reactive hypoglycemia, *367-368
UGDP study of, 976-978
and vascular disease, *57
- PHENOBARBITONE**
and blood sugar, *1123
- PHENOTHIAZINE**
-induced hyperglycemia, *184
- PHENOXYBENZAMINE**
and diazoxide-induced insulin secretion, *1045
and insulin secretion, 783-784
- PHENTERMINE RESIN**
and low-calorie diet
and obese diabetics, *361
- PHEHTOLAMINE**
induced alpha-adrenergic blockade
and insulin release, *181
and insulin secretion, *248
and exercise, *119
- L-PHENYLALANINE**
and cholecystokinin release, *252
-induced insulin release, *369
- β-PHENYLETHYLAMINE**
and insulin secretion, *248
- PHENYLETHYLBIGUANIDE**
and liver gluconeogenesis, *910
- PHENYLISOTHIOCYANATE**
degradation studies, *835
- PHENYTOIN**
and hyperglycemia, *187
- PHEOCHROMOCYTOMA**
and insulin-dependent diabetes, *838
- PHLORIZIN**
and brain uptake of D-glucose, *315
and intestinal fructose uptake, *249
and pancreatic beta cell metabolism, *910-911
- PHOSPHATE**
-induced hypoglycemia, 961
- PHOSPHENOLPYRUVATE**
formation, *189
- PHOSPHODIESTERASE**
and cyclic AMP and cyclic GMP, *838
and insulin release, *328-329
in islets of Langerhans
of obese and lean mice, *179
- PHOSPHENOLPYRUVATE CARBOXYKINASE**
and cyclic AMP
and insulin, 439-445
- PHOSPHOFRUCTOKINASE**
and cyclic AMP and dibutyryl cyclic AMP, *363

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64	Supplement 1, 321-384	August, 843-922
February, 65-128	Supplement 2, 385-714	September, 923-986
March, 129-192	June, 715-778	October, 987-1050
April, 193-256	July, 779-842	November, 1051-1130
May, 257-320		December, 1131-1210

SUBJECT INDEX 1972

- 6-PHOSPHOGLUCONATE DEHYDROGENASE
in jejunal mucosa
and alloxan diabetes, *188
- PHOSPHOLIPIDS
levels
and alloxan diabetes, 1163-1166
- PHOSPHORUS
flux
and glucose ingestion in children, *376
- PHOSPHORYLASE
and synthase, 430
- PHOSPHORYLATION
fatty acid
and diabetes, 257-268
- PHOTOCOAGULATION
argon laser
and diabetic retinopathy, *189
- PHYTOHEMAGGLUTININ
peripheral blood lymphocyte response to
and diabetes, 906-907
- PIMA INDIANS
and diabetes, *180
and kidney disease, *365-366
and viral hypothesis, 766
- PITUITARY GLAND
ablation
during diabetic pregnancy, 972-974
diabetogenic polypeptide from, *837
and glucagon secretion, *375
growth hormone synthesis
and lipids, *187
protein synthesis
and insulin, *1200
reserve capacity
and diabetes, *981
- PLACENTA
glycogen metabolism
and diabetes, 1185-1190
glycogenesis
and insulin, *1199
insulin degradation by, *374-375
lactogen
and diabetic pregnancy, 32-33
and insulin and glucagon release, 1072-1075
and maternal diabetes, *315
and nitrogen conservation during pregnancy, *340
polyol pathway, *329-330
- enzymes of, *330
and streptozotocin, *316
- PLASMA
amino acids
and exercise, *119
glucagon and insulin control of, *340-341
and starvation, *179
angiotensinogen and renin regulation by liver, *253
L-asparagine
and hepatic homeostasis, *254
catecholamine
during oral glucose tolerance test, *348
cholesterol
and diet, *1043
cholesterol and triglycerides
and clofibrate, *1200-1201
fasting growth hormone levels
and diabetic retinopathy, *322
free fatty acids
conversion to plasma triglyceride fatty acid, *835
and glucagon infusion in congestive heart failure patients, 942, 944
and menstrual cycle, *1204
uptake by liver, 947-948, 950-954
free fatty acids and glucose
and L-dopa, *1121
free fatty acids, glucose, insulin, and ketones
and sodium linoleate infusion, 1179-1184
free fatty acids and insulin
in malnourished infants, *182
free fatty acids and ketone
and insulin secretion, 923
free fatty acids metabolism
and anti-insulin serum, 280-288
glucagon
and diabetes, *324
and exercise, *1198-1199
and food intake, *331-332
and infection, *324
and sulfonylureas, 216-223
glucagon, growth hormone and insulin
and glucose during exchange transfusions, *1120
glucose
and graded insulin infusions, *379
and growth hormone secretion, *774-775
glucose and free fatty acids
and pentobarbital, *836
- glucose, free fatty acids, cortisol and growth hormone
and growth hormone administration, 22, 30
glucose and immunoreactive insulin
and adipose tissue resection, 13-15
glucose, insulin and glucagon
and hypothalamic stimulation, *771
growth hormone
clearance, 175-177
and juvenile diabetes, *312
in obese mice, *122
during sleep, *776
growth hormone, insulin and thyroxine
and L-dopa, *911
growth hormone responses
and Cushing's syndrome, *1122
growth hormone and sulfation factor
in African pygmies, *1045-1046
hyperosmolality
and hyperglycemia, *837
immunoreactive insulin
in *acomys cahirinus*, 1060-1070
during continuous blood glucose monitoring in diabetics, *324-325
and insulin administration to gastrointestinal tract, 203-207
and surgery for islet cell adenomas, *185
and weight reduction, *1118
insulin
and adipose tissue fat cell size and number, *180
and atherosclerosis, *253
and diet, *249
and erythroblastosis fetalis, *1199-1200
and glucose, *375-376
and hyperparathyroidism, *773
and hypokalemia, *1043-1044
in kwashiorkor, *1119-1120
and metabolic insulin clearance, 1003-1011
and metformin, *771
and methamphetamine, *252
and nicotinic acid, *313
and obesity and exercise, *909
and pancreatic alpha cell response to hyperglycemia, 301-307
response to glucose, 226-233
and theophylline, *180
insulin and blood glucose
and obesity, *54
insulin, glucose and free fatty acids
and insulin-treated diabetes, *325
insulin and glucose response to glucose loading

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64	Supplement 1, 321-384	August, 843-922
February, 65-128	Supplement 2, 385-714	September, 923-986
March, 129-192	June, 715-778	October, 987-1050
April, 193-256	July, 779-842	November, 1051-1130
May, 257-320		December, 1131-1210

- and diet and fasting, *1046
 insulin and triglycerides
 seasonal variations in, *312-313
 insulin and uric acid
 and nicotinic acid, *313
 isovaleric acid and α -methylbutyric acid
 and hypoglycin A, *316
 lipase activity
 and heparin, 152-153
 lipids
 and diet, *366
 and glucagon, *311-312
 and glucose tolerance tests, *383
 and pregnancy in rhesus monkeys,
 *774
 lipids and lipoproteins
 and oral contraceptives, *316
 membrane vesicles
 and glucose transport, *1042
 membranes of fat cells
 and insulin, 403-411
 osmolality
 and serum osmolality, lactic acid
 values and, *838
 and platelet aggregation, *355
 proinsulin
 assay, *122
 and islet cell tumors, *1204
 proinsulin-like components of, 673-676
 testosterone
 and diabetic impotence, 23-24
 triglyceride removal
 and hyperglycemia, *342
 triglycerides
 and adipose tissue fat cell size and
 number, *180
 and exercise, *909
 and fasting, *54
 and glucagon, *55
 synthesis, *55
 triglycerides and cholesterol
 and cortisone acetate, *1044-1045
 tryptophan
 and insulin, *909
 very-low-density lipoprotein study, 744-
 752
- POLYDIPSIA**
 and hyperphagia
 and adrenalectomy and hypophysec-
 tomy, *358-359
- POLYETHYLENE GLYCOL**
 and insulin antibodies screening test,
 *379
- POLYOL**
 metabolism
 and diabetic microangiopathy, *352
- POLYOL PATHWAY**
 activity
 in isolated capillary preparation, *330
 placental, *329-330
 enzymes, *330
- POLYPEPTIDES**
 diabetogenic
 from pituitaries, *837
 synthesis, 476-484
- POSTHEPARIN LIPOLYTIC ACTIVITY**
 deficiency in
 and hyperglycemia, *342
- POTASSIUM**
 and antinatriuretic effects of carbohy-
 drate, *772
 flux
 and insulin and adenosine 3', 5'-
 monophosphate, *254
 and insulin action, 697-698
 and insulin secretion, 570
 myocardial
 and glucagon, *118-119
 and prostaglandins
 and growth hormone secretion, *313
 uptake and loss
 and cyclic AMP and insulin, 439-445
- POTASSIUM PARA-AMINO BENZOATE**
 and hypoglycemia, 960
- PREDIABETES**
 and beta cell sensitivity to glucose, 224-
 233
 and caffeine
 and glucose tolerance tests, *365
 in children, 45-47
 in Chinese hamster
 and prevention of diabetes, *337-338
 and diabetes prevention, *337-338, 693
 and diabetic neuropathy, *359
 and ethanol
 and phenformin, *363
 and glucose tolerance, *321
 and hypoglycemia
 and insulin-glucose dynamics, *373
 and insulin secretion, *314, 688-691
 and liver sensitivity to endogenous in-
 sulin, *323-324
 and low insulin response, 685-687
 and plasma lipids during glucose tol-
 erance tests, *383
 and retinal blood flow, *354
 and transition to diabetes, 691-693
- PREDNISOLONE**
 and immune response to insulin, *58
- PREGNANCY**
 and amino acid metabolism
 and starvation, *1118-1119
 and biliary lipids, *912
 and caloric deprivation
 and maternal and amniotic fluid sub-
 strate level, *1202
 and glucose tolerance test indications,
 *186
 and human chorionic somatomammo-
 tropin
 and insulin and glucagon release,
 1074-1075
 and hypoglycemia following pancreato-
 duodenectomy, *188
 and insulin response
 and arginine, *251
 and liver triglyceride biosynthesis, *365
 and maternal protein restriction
 and postnatal growth hormone pro-
 duction and bone develop-
 ment, *1047
 and placental nitrogen conservation,
 *340
 in rhesus monkeys
 and plasma lipid levels, *774
 and uterine relaxants
 and hyperglycemia, *1045
- PREGNANCY, DIABETIC**
 and blood sugar levels
 and perinatal mortality and morbidity,
 *1201-1202
 and fetal and placental composition,
 *315
 and glucose tolerance tests in neonates,
 *912
 and hypophysectomy for diabetic ret-
 inopathy, 972-974
 and insulin deficiency
 and endogenous hypertriglyceride-
 mia, *366-367
 and laboratory studies, 31-35
 and lactosuria, 1195
 and phocomelic diabetic embryopathy
 syndrome, *1042
 and pituitary reserve loss, *981
 and placental glycogen metabolism,
 1185-1190
 and streptozotocin, *316
- PROGESTERONE**
 and diabetic pregnancy, 34
- PROGESTIN**
 and carbohydrate tolerance, *313
- PROINSULIN**
 action, *57

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64	Supplement 1, 321-384	August, 843-922
February, 65-128	Supplement 2, 385-714	September, 923-986
March, 129-192	June, 715-778	October, 987-1050
April, 193-256	July, 779-842	November, 1051-1130
May, 257-320		December, 1131-1210

SUBJECT INDEX 1972

- in adipose tissue, 485
and structure, 505
amino acid sequences, 461-463, 465-466
antibodies
and insulin resistance, *368
and antibodies to insulin, 656-657
assay, *122
biosynthesis
and glucose, 538
biosynthesis, intracellular transport, and
conversion to insulin and C-
peptide, 572-579, 581-583
in blood, 661-670
content of beta cell tumors, 535
conversion to insulin, *314
degradation
in rats, 1091-1100
and glucose metabolism
in rat diaphragm and epididymal
fat pads, 935-938
and insulin
conformational studies, 486-491
-like component of insulin, *313
and hypokalemia, *1043-1044
-like plasma components, 673-676
metabolism, *347
and C-peptide immunoreactivity, 1013-
1025
porcine
synthesis of related polypeptides, 476-
484, 485
response to oral glucose
and age, obesity, and degree of car-
bohydrate intolerance, *356
structure
and action, 509
synthesis, 509
transport, 510
- PROLINE**
and ornithine utilization studies in
chick, *771
- PROPOXYPHENE**
and hypoglycemia, 960-961
- PROPRANOLOL**
and insulin
and hypoglycemic coma, 960
and insulin secretion, 783-784
and blood sugar, *1120
and liver carbohydrate metabolism,
*1203
and tolbutamide-induced insulin re-
sponse, *122
- PROSTAGLANDINS**
and blood flow and insulin output, *369
and growth hormone secretion, *313
- and insulin release, *329
- PROSTATE GLAND**
hexokinase
and testosterone, *185
- PROTEIN KINASE**
and cyclic AMP, 571
- PROTEINS**
adipose tissue noncollagen
as index of cell number, *1201
and amino acid flux into liver tissue,
*316
-bound carbohydrates
and diabetes, 863-870
deficiency
in pregnant rats, *1041
dietary
and glucagon and insulin secretion,
*912-913
and glucagon biosynthesis, *58-59
hepatic synthesis
and tissue injury, *315
insulin binding, 426
and insulin release, 613, 617-618
leucine incorporation of, *336
of plasma very-low-density lipoprotein
selenomethionine incorporation into,
744-752
rat liver nuclear
and diabetes, *377
restriction in pregnant rats
and postnatal growth hormone pro-
duction and bone develop-
ment, *1047
synthesis
and alloxan diabetes, *339
and cyclic AMP and hormones, *119
and fatty acid synthetase activity,
*914
and insulin, 447-451
and insulin and cyclic AMP, 453
synthesis in anterior pituitary
and insulin, *1200
turnover in skeletal muscle
and insulin, *341
- PROTEINURIA**
and glomerular lesions, *1120
in Pima Indians, *365-366
- PROTEOLYSIS**
and cyclic AMP
and insulin, 439-445
- PSEUDODIABETES**
and myopathy
and capillary basement membrane
thickening, *118
- PSORIASIS**
and carbohydrate metabolism, *250
- PURINE NUCLEOTIDE CYCLE**
and ammonia production, *1203
- PYRAZOLE**
and ethanol-induced fatty liver, *247
- PYRIDINE NUCLEOTIDES**
depletion
and streptozotocin-induced diabetes,
789-792
and insulin release
from toadfish insulin secretion gran-
ules, *983
and streptozotocin-induced beta cell
toxicity, *325-326
- PYRUVATE**
metabolism
and glucose, *56
- PYRUVIC DEHYDROGENASE**
and insulin, 427

R

- RABBIT**
acidotic diabetic
and pH of inflammatory exudates,
*1201
and antibodies to insulin, 651-656, 657-
659, 660
and blood sugar
and insulin storage times, 812
and insulin administration to gastroin-
testinal tract, 203-207
and insulin response to amino acids
and 2-deoxy-D-glucose and manno-
heptulose, 1-5
and iodinated insulin, *55
and neutral Regular insulin, 242-245
renal gluconeogenesis and ammonia
production in, *57
and serum insulin levels
and trauma, *183
and streptozotocin diabetes
and islet cell changes, 129-137
and thryotoxicosis
and glucose utilization and insulin
secretion, *370-371
- RACE**
and alcohol sensitivity, *254
and lactose tolerance tests, 871
- RADIOIMMUNOLOGY**
in synthetic glucagon studies, 844-845,
846-848, 855

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64	Supplement 1, 321-384	August, 843-922
February, 65-128	Supplement 2, 385-714	September, 923-986
March, 129-192	June, 715-778	October, 987-1050
April, 193-256	July, 779-842	November, 1051-1130
May, 257-320		December, 1131-1210

SUBJECT INDEX 1972

- RAT. *See also* *Mystromys albicaudatus*
 and acetoacetate
 and anemia, *311
 adipocytes
 fatty acid synthetase activity, *914
 adipose tissue
 glucose metabolism and insulin response, 1151-1161
 and alloxan diabetes
 and arteriosclerosis, *1123
 and glycosaminoglycans metabolism, 1162-1166
 and jejunal mucosa enzymes, *188
 and liver ribosomal aggregation, 84-88
 and pressor response to angiotensin and norepinephrine, *354-355
 and 6-aminonicotinamide as diabetogenic agent, 143-148
 and ammonium chloride-induced acidosis
 and glucose tolerance and insulin sensitivity, 794-796
 and blood sugar
 and nervous system sorbitol and fructose, 1173-1178
 brain
 glucose and D-3-hydroxybutyrate uptake, *1206
 brain hexokinase, *1205
 brain utilization of ketone bodies, *247
 and carbohydrate and lipid metabolism and streptozotocin, *59
 cyproheptadine-treated
 and pancreatic beta cell alterations, 71-78
 diabetic
 and calcium absorption, *983
 and connective tissue changes, 733-743
 and insulin resistance, *1042
 and intestinal growth and hexose transport, *59
 and ketosis, 946-954
 and liver metabolism, 257-268
 and α -oxoglutarate carboxylation in liver mitochondria, *981
 and ventromedial hypothalamic destruction, *1043
 diabetic pregnancy in, *315
 and streptozotocin therapy, *316
 diaphragm and epididymal fat pads
 and insulin and proinsulin studies, 935-938
 and diet
 and blood constituents and hepatic lipids, *1202
 and hypertriglyceridemia, *353-354
 and effects of maternal protein restriction, *1047
 and ethanol-induced fatty liver and pyrazole and glucose, *247
 fasted and fed
 and amino acid levels, *119
 feeding response
 and brain calcium, *1046
 fetal development
 and diet and growth hormone, *189
 galactose-fed
 and nerve conduction defects, 295-300
 gastrointestinal transport
 and glucagon, *983
 genetically obese
 and hyperinsulinemia and insulin resistance, *838
 and glibenclamide, *55
 and glucose oxidation
 and diet and exercise, *179
 and glucose-U-C-14 and acetate 1-C-14 utilization for fat synthesis, *770
 heart
 lipoprotein lipase, *344
 high protein fed
 and liver gluconeogenesis, *358
 hyperammonemic
 and glucose metabolism, *184
 and hyperglycemia
 and aminophylline, *775
 hypo-, hyper-, and euthyroid
 and ethanol and sorbitol metabolism, *181
 and hypothalamic stimulation
 and plasma glucose, insulin, and glucagon, *771
 and insulin and proinsulin degradation, 1091-1100
 and insulin secretion
 and phenolamine, *119
 islets of Langerhans
 adenylyl cyclase and cyclic AMP phosphodiesterase, *328
 and alloxan and glucose, *326
 and ketone body metabolism, *246
 and kidney function
 and diabetes, *121
 and liver gluconeogenesis
 and glucose and insulin, *371
 and liver triglyceride biosynthesis
 and pregnancy and sex steroids, *365
 mammary cell metabolism
 and insulin, *315
 and microangiopathy, *357
 neonatal
 and diet and exocrine pancreas development, *186
 newborn
 brain glucose metabolism in, *775
 and noradrenaline or adrenaline
 and blood glucose and free fatty acid responses to catecholamines, *912
 obese
 and insulin resistance and release, *316
 obese hyperglycemic
 and pancreatic beta cell uptake of amino acids, *772
 pancreas islet structure, 536-537
 and pancreatic hydrolases
 from birth to weaning, *59
 parabiotic
 differential feeder for, *983
 plasma glucose and free fatty acids
 and sodium pentobarbital, *836
 and plasma tryptophan
 and insulin, *909
 and portacaval shunting
 and glucose tolerance and serum immunoreactive insulin response, *179
 protein-deficient
 and kidney cellular development in progeny of, *1041
 salivary glands
 isoproterenol-stimulated, *982
 and serum triglycerides response to sucrose and age, *835
 streptozotocin diabetic
 and U-C-14 glucose, xylitol, fructose, and sorbitol metabolism, *122
 and hyperphagia and polydipsia, *358-359
 and liver nuclear proteins, *377
 and urine glucolate, *372
 and tolbutamide
 and insulin secretion and hypoglycemia, *1125
 and uremia
 and insulin release, *910-911
 and ventromedial hypothalamic nuclei destruction
 and glucose metabolism, *1204-1205
 and obesity, *1206
 Zucker "fatty"
 and insulin and obesity studies, *1123
 RAYNAUD'S PHENOMENON
 and insulin response to glucose, *837
 RESPIRATION
 and ketotic diabetes, 264-267

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64	Supplement 1, 321-384	August, 843-922
February, 65-128	Supplement 2, 385-714	September, 923-986
March, 129-192	June, 715-778	October, 987-1050
April, 193-256	July, 779-842	November, 1051-1130
May, 257-320		December, 1131-1210

SUBJECT INDEX 1972

- RETICULOENDOTHELIAL SYSTEM
lipid metabolism and vascular clearance in dogs, *312
- RETINA
blood flow
in children of diabetics and prediabetics, *354
of diabetic monkeys, 1086
glycosaminoglycans
and alloxan diabetes, 1163-1166
and microangiopathy, *357
- RETINOPATHY, DIABETIC
and argon laser photocoagulation, *189
and bacteriuria, *118
and blood platelet adhesiveness and aggregation, *120-121
and diabetes control program, *382
factors in progression of, *187
and hypophysectomy, *349
and pregnancy, 972-974
in identical twins, *321-322
and plasma growth hormone levels, *322
and platelet aggregation, *355
- REYE'S SYNDROME
and hypoglycemia, *248
- RHESUS MONKEYS
and pregnancy
and biliary lipids, *912
and plasma lipid levels, *774
- RHINOCEREBRAL PHYCOMYCOSIS
and diabetes, *185
- RNA
binding to hepatic ribosomes
and insulin deficiency, 84-88
and insulin action, 455
-messenger
and insulin and liver metabolism, 453
pancreatic
and diet in neonatal rats, *186
synthesis
and fatty acid synthetase activity, *914
transfer-
and insulin and protein synthesis, 449
viruses, 714
- tRNA METHYLASES
regulation, *253
- RP 22410. See Glisoxepid
- RUBELLA
congenital
and diabetes incidence, *248-249
- S
- SALICYLATES
and hypoglycemia, 959-960
- SALIVARY GLANDS
isoproterenol-stimulated
and glucose metabolism, *982
- SCHWANN CELL
and aldose reductase, 299
- SCINTIPHOTOSCANS OF PANCREAS, *351
- SECRETIN
and diuresis, *769
and insulin release
and acromegaly, *1118
and pepsin secretion, *250
release, *252
and serum gastrin immunoassays, *249
- SELENIUM SCAN
and insulinoma diagnosis, *1206
- SELENOMETHIONINE
incorporation into apoprotein of plasma very-low-density lipoprotein, 744-752
- SEMINIFEROUS TUBULES
and diabetic impotence, 26
- SEMINOLES
diabetes survey among, *776
- SEPHAROSE
-bound insulin
and muscle, adipose tissue and cultured liver cells, *335-336
- SEROTONIN
antagonists
and insulin secretion, 779-787
and insulin secretion in acromegaly, *352
and carbohydrate tolerance
and insulin secretion, *1200
and insulin secretion, *184, *316
- SERUM
N-acetyl-beta-glucosaminidase
and diabetes, 1168-1171
antiglucagon
in synthetic glucagon study, 844-855
anti-insulin
assays, *769
and enzyme histochemical studies of pancreatic islets, *911
and hyperglucagonemia, *183
and liver free fatty acid metabolism in dogs, 280-288
- betalipoproteins
and abetalipoproteinemia, *60
-bound insulin
and insulin antisera, 930-934
cholesterol
and atherosclerotic disease, *253
cholesterol and triglycerides
and caffeine, *365
and calcium, *980
creatinine
and potassium
and acidosis diagnosis, 1110
creatinine
in Pima Indians, *365-366
free fatty acids
and weight reduction, 758
free fatty acids and glucose
and L-dopa, *1121
free fatty acids, insulin, and growth hormone
and myocardial infarction, *119
gastrin immunoassays
and secretin, *249
glucose
in *Mystromys albicaudatus*, 715-721
glucose, ketones, immunoreactive insulin and free fatty acids
and sodium beta-hydroxybutyrate, *373-374
glycoproteins
and diabetes, 863-870
growth hormone and cortisol responses to graded insulin infusions, *379
immunoreactive insulin
and age, *183-184
and exercise, 104
in genetically obese rats, *838
in monkeys, 1078-1079, 1081
in obese rats, *1123
and portacaval shunt, *179
response to glucagon, glucose and tolbutamide, *121-122
insulin
and arginine, 308-310
and insulinoma, *250
in obese hyperglycemic mice, *119
and trauma, *183
insulin, cholesterol and triglyceride levels
in obese diabetics, *361
insulin and growth hormone
and arginine and glucose, *316
during oral glucose tolerance tests in children, 16-20

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320

Supplement 1, 321-384
Supplement 2, 385-714
June, 715-778
July, 779-842

August, 843-922
September, 923-986
October, 987-1050
November, 1051-1130
December, 1131-1210

SUBJECT INDEX 1972

- insulin responses
 differences between mongrel and beagle dogs, *356
 and small-vessel disease, *836
 insulin response to glucose and konnyaku ingestion, *60
 lipids
 in "acatalasemic" mice, *56
 and atherosclerosis, *253
 and metformin, *771
 in monkeys, 1078-1079
 nonsuppressible insulin-like activity, 271-278
 osmolality
 and galactose toxicity syndrome, *315
 and plasma osmolality, lactic acid values and, *838
 C-peptide and proinsulin, 1013-1025
 phospholipids
 and diabetes, *123
 proinsulin and insulin, *347
 protein
 and diabetic microangiopathy, *371
 triglycerides
 response to fructose, age and, *835
 and sucrose and glucose, *58
- SEX
 and adipose tissue fat cell size and number, *180
 and blood glucose levels and exercise, 89-99
 and diabetic mortality, *1044
 and glucose tolerance tests in children, 19
 and growth hormone secretion, *774-775
 and muscle capillary basement membrane changes, 883-896, 899-905
 and serum glucose
 in *Mystromys albicaudatus*, 718, 719, 720
- SEXUAL FUNCTION
 and diabetes, 23-28
- SHEEP
 renal glucose, free fatty acid and ketone body metabolism in, *314
- SHOCK
 and fibrinolysis and peritoneal dialysis, *913
 hemorrhagic
 and insulin release, *364, *982
 traumatic
 and glucose metabolism, *1201
- SKIN
 bullous and atrophic lesions and diabetes, *251
 and diabetes
 and hyperinsulinism, 733-743
 fibroblasts
 glucose oxidation in, *360
 and glucose metabolism and insulin, *189
 glycosaminoglycans
 and alloxan diabetes, 1163-1166
 and lipid synthesis and starvation, alloxan diabetes and insulin, *189
 psoriasis
 and carbohydrate metabolism, *250
 toad
 and proinsulin action study, *57
- SLEEP
 growth hormone release during, *913
- SMOKING
 and hypoglycemia, 961
- SODIUM
 extracellular
 and glucose metabolism, 543
 and insulin secretion, 570, 861
 and pancreatic α -amino isobutyric acid transport, *181
 transport
 and proinsulin action, *57
- SODIUM ACETATE
 incorporation into lipids of rat aorta and insulin, *186
- SODIUM ACETATE I-C-14
 incorporation into rat aorta and insulin, *186
- SODIUM BETA-HYDROXYBUTYRATE
 and insulin secretion, *373-374
- SODIUM LINOLEATE
 and plasma free fatty acids, glucose, insulin and ketones, 1179-1184
- SODIUM PENTOBARBITAL
 and plasma glucose and free fatty acids, *836
- SORBITOL
 brain synthesis
 and cerebral edema during diabetic ketosis, *180-181
 and insulin release, 565
 metabolism
 in fasted and streptozotocin diabetic rat, *122
 and hypo-, hyper-, and euthyroid rats, *181
 in nervous tissues
 and blood sugar control, 1173-1178
- SORBITOL DEHYDROGENASE
 in human placenta, *330
- L-SORBOSE
 intestinal uptake, *249
- SPASMOLYTIC DRUGS
 and vein reactivity in diabetes, *909
- SPLANCHNIC NERVE
 stimulation
 and adrenalectomy, *770
- SPRUE
 temperate, *773
- STARVATION
 and amino acid metabolism during pregnancy, *1118-1119
 and carbohydrate, *772
 and diabetes treatment, 634
 and fat and lactate metabolism and insulin production, *1045
 and fetal metabolism, *187
 and glucagon secretion, *331-332
 and insulin and glucagon patterns, *359-360
 and insulin-induced hypoglycemia, 797-803
 and jejunal mucosa enzymes, *188
 and ketone body metabolism, *246
 and kidney gluconeogenesis, *910
 and kidney sensitivity to mineralocorticoid and glucagon, *334
 and lipid synthesis in rat skin, *189
 and lipolysis
 and iodinated insulin, *55
 and liver ketogenesis, 50-52
 and liver metabolism
 and glucagon:insulin ratio, *341
 and metabolism
 in streptozotocin diabetic rats, *122
 and plasma and tissue amino acids, *179
 and postheparin lipolytic and monoglyceridase activities, *54
 and tissue and islet cyclic AMP levels, *329
- STEROIDOGENESIS
 in isolated adrenal cells, *983
- STEROIDS
 -induced diabetic ketoacidosis, *54
- STREPTOZOTOCIN
 and beta cell membrane changes, *326

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64	Supplement 1, 321-384	August, 843-922
February, 65-128	Supplement 2, 385-714	September, 923-986
March, 129-192	June, 715-778	October, 987-1050
April, 193-256	July, 779-842	November, 1051-1130
May, 257-320		December, 1131-1210

SUBJECT INDEX 1972

- and carbohydrate and lipid metabolism, *59
 and diabetic pregnant rats, *316
 and glucose metabolism
 and insulin secretion, *1200
 -induced beta cell toxicity
 and nicotinamide and pyridine nucleotides, *325-326
 -induced diabetes
 and fetal and placental composition, *315
 and islet cell carcinoma
 and "big" insulin, *1204
 and islet cell tumors
 and plasma proinsulin, *1204
 and pancreatic beta cells, 77-78
- STREPTOZOTOCIN DIABETES**
 and connective tissue changes in rats, 733-743
 and glucose and fatty acid metabolism, *909
 and hyperosmolar diabetic syndrome
 and ketogenesis, *369-370
 and hyperphagia and polydipsia
 and adrenalectomy and hypophysectomy, *358-359
 and hypertriglyceridemia
 and diet, *353-354
 and islet cell changes, 129-137
 and kidney function, *121
 and liver mitochondria α -oxoglutarate carboxylation, *981
 and liver nuclear proteins, *377
 in *Macaca nemestrina*
 induced by pancreatic infusion, 138-141
 and metabolism, *122
 and pyridine nucleotide depletion in pancreatic islets, 789-792
 and urine glycolate, *372
 and ventromedial hypothalamic destruction, *1043
- STRESS**
 and glucose tolerance, *184
- SUBMAXILLARY GLAND**
 extirpation
 and glucose and insulin tolerance, 722-731
- SUCCINATE**
 and amino acid metabolism, *56
- SUCROSE**
 and diabetes, *770
 dietary
 and blood constituents and hepatic lipids, *1202
- oral
 and alimentary lipemia, *58
- SUGAR**
 and alloxan toxicity, *123
 and insulin release, 559-561, 570
 transport
 and biguanides, *119
- SUGAR ALCOHOL**
 formation
 and nerve conduction defects, 295-300
- SULFATION FACTOR**
 and dwarfism, *1046
- SULFONYLUREAS**
 and blood sugar
 and kidney failure, *1120-1121
 and chemical diabetes in children, 47
 and diabetes treatment, *120
 glibenclamide, *55
 and hypoglycemic coma, 955-962
 and insulin release, 160-161
 and blood sugar, *1120
 and labeling laws, 833
 pharmacodynamic aspects, *249, *249-250
 and plasma glucagon suppression, 216-223
 -response test, *913
- SURGERY**
 adipose tissue resection
 and diabetes and hyperinsulinism of symmetric lipomatosis, 13-15
 adrenalectomy
 and insulin response to hemorrhagic shock, *364
 and splanchnic nerve stimulation, *770
 and adrenalectomy and hypophysectomy
 and diabetic hyperphagia and polydipsia, *358-359
 and bladder dysfunction, *364
 femorotibial bypass
 and diabetes, *322-323
 for gangrene, *187
 gastrectomy
 and intestinal glucagon and insulin responses, *1047
 gastric
 and glucose homeostasis, *1199
 and glucagon secretion, *313
 hypophysectomy
 during diabetic pregnancy, 972-974
 and diabetic retinopathy, *349
 and glucagon secretion, *375
- and tolbutamide and glybenclamide injections, *378-379
 and islet cell adenomas
 and blood glucose and plasma immunoreactive insulin assays during, *185
 pancreatectomy
 in baboons, *338
 and glucose turnover, *382-383
 pancreatectomy and hypophysectomy
 and diabetic ketosis in rats, 946-954
 and liver 3-hydroxybutyrate dehydrogenase, *184-185
 pancreatoduodenectomy
 and hypoglycemia following pregnancy, *188
 parathyroidectomy, *773
 partial pancreatectomy
 and glucose tolerance and insulin response, *339
 portacaval shunt, *179
 and serum insulin levels, *183
 submaxillary gland extirpation
 and glucose and insulin tolerance, 722-731
 ventromedial hypothalamic destruction, *1043
 and glucose metabolism, *1204-1205
 and obesity, *1206
- SYNALBUMIN**, 714
- T**
- TEMPERATURE**
 and cholesterol turnover, *314
 and insulin secretion, *312-313
 and liver enzymes activities, *58
- TESTES**
 and diabetic impotence, 25-26
- TESTOSTERONE**
 and rat prostate hexokinase, *185
- α -THALASSEMIA**
 and fetal pancreas, *253-254
- THEOPHYLLINE**
 and calcium metabolism, *327
 and glucose stimulated insulin release, 559-560, 561
 and insulin response, 1
 in *acomys cahirinus*, 1065, 1069-1070
 and islet cell adenoma cyclic AMP content, *346-347
 and norepinephrine
 and cyclic AMP, 416-417

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64	Supplement 1, 321-384	August, 843-922
February, 65-128	Supplement 2, 385-714	September, 923-986
March, 129-192	June, 715-778	October, 987-1050
April, 193-256	July, 779-842	November, 1051-1130
May, 257-320		December, 1131-1210

SUBJECT INDEX 1972

- and plasma insulin responses
in subhuman primate fetus and neonate, *180
- THROMBIN**
and fatty acid metabolism, *312
- THYROID FUNCTION TESTS**, 1012
- THYROID GLAND**
and ethanol and sorbitol metabolism, *181
and glibenclamide, *55
and thyrotoxicosis
and insulin secretion and glucose utilization, *370-371
- THYROIDITIS**
methyl-cholanthrene-induced and spontaneous
and autoimmunity studies, *253
- THYROTOXIC PERIODIC PARALYSIS**
and immunoreactive insulin, *1047
- THYROXINE**
and insulin secretion, *253
and rat fatty liver, *183
- TISSUE**
adipose. *See* Adipose tissue
amino acids
and starvation, *179
and ammonia production, *1203
connective
and diabetes and hyperinsulinism, 733-743
cyclic AMP levels
and insulin, 426
and starvation, *329
epididymal fat pads
enlargement modes, *247
glycosaminoglycans
and alloxan diabetes, 1162-1166
and jet insulin injections, 41-42
liver
metabolic response to injury, *315
liver plasma membranes
and insulin, *334-335, *1200
mouse diaphragm
DNA content, *184
nervous system
and blood sugar control, 1173-1178
rat adipose tissue and muscle phosphofructokinase, *363
rat diaphragm
insulin-like activity bioassays, 272-273
rat diaphragm and epididymal fat pads
and insulin and proinsulin, 935-938
- rat epididymal fat pads
protein synthesis studies, *1119
testicular
and diabetic impotence, 24-28
- TISSUE CULTURES**
of isolated islets, 546-553
- TOADFISH**
islets
and pyridine nucleotide, *983
- TOLBUTAMIDE**
and adenylyl cyclase activation in islet cell adenoma, *912
and 6-aminonicotinamide, *1198
anti-lipolytic action, *836
blood clearance
and alcoholism, *983
dosage
in UGDP study, 1037-1038
and forearm metabolism, *1206
and hyperglycemia
and arterial disease, *122-123
hyperresponsiveness to
and diazoxide pretreatment, *360
and hypophysectomized dogs, *378-379
-induced hypoglycemia
and hyperparathyroidism, *773
-induced insulin release, 989
and cytochalasin B., *327
and iodoacetate and antimycin A., *56
and propranolol, *122
in rat islets, *1205
and insulin immunoreactivity, *313
insulin response to
and diethylstilbestrol and growth hormone, *378
and insulin response to glucose, 684
and insulin secretion, *55, *370
and blood sugar, *1120
and hypoglycemia, *1123
and islet cell adenoma cyclic AMP content, *346-347
and labeling laws, 833, 1116-1117
and lipolysis and cyclic AMP in white fat cells, *835
and liver cirrhosis
and insulinemia, *121-122
and microangiopathy, *357
and pancreas islet cell electrical activity in response to, *345
pharmacodynamic aspects, *249, *249-250
and plasma glucagon, 216-223
plasma insulin response to
and diabetes, 1012
response
and diazoxide, *311
- UGDP study of, 976-978, 1036-1037
- TOLBUTAMIDE TEST**
and insulinoma, *250, *1206
- TOLINASE**
and lactic acid levels
and anoxia and exercise, *351
- TRANSPLANTATION**
of fetal rat pancreas into maternal hosts
and insulin content study, 193-201
kidney
and diabetes, *322
of pancreas
and diabetes, *355
- TRAUMA**
and liver metabolism, *315
- TRIGLYCERIDES**
long-chain
and insulin secretion, 923-928
synthesis
and ethanol, *769-770
and insulin, *351-352
and ketogenesis, *1203
- TRYPSIN**
and fat cell lipolysis, 423
-treated fat cells
and insulin degradation, 409
- TRYPTOPHAN**
-insulin complex
isolation of, *1045
- TUBERCULOSIS**
and diabetes, 634
- TUCO-TUCO**
diabetic syndrome in, *1205
- TUMORS**
adrenal
and Cushing's syndrome in infancy, *120
beta cell, 535
catecholamine-secreting
and glucose intolerance, *838
endocrine adenomatosis
and familial nesidioblastosis, *1122
fibrosarcoma
insulin-like activity in, *352-353
and glucose metabolism
and insulin secretion, *1200
and hypocholesteremic drugs in mice, *837
insulinoma
diagnosis, *1206
and glycolytic enzymes, *773

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64	Supplement 1, 321-384	August, 843-922
February, 65-128	Supplement 2, 385-714	September, 923-986
March, 129-192	June, 715-778	October, 987-1050
April, 193-256	July, 779-842	November, 1051-1130
May, 257-320		December, 1131-1210

SUBJECT INDEX 1972

- islet cell
 and blood proinsulin-like components, 665
 and cyclic 3'5' AMP formation and degradation, *185
 and hypoglycemia, *248
 immunoreactive glucagon in, *333
 and insulin and glucose patterns, *250
 and plasma proinsulin, *1204
 proinsulin content, 675-676
 and proinsulin-like component of insulin, *313
 and surgery, *185
- islet cell adenomas
 and adenylcyclase activation by glucagon and tolbutamide, *912
 and effects of glucose, glucagon, tolbutamide and theophylline on cyclic AMP content of, *346-347
 and surgical procedures, *185
- in obese mice
 and lipid mobilization and food uptake, *774
- pancreatic
 insulin-secreting, *1120
- TWINS
 and chemical diabetes study, 45
 identical
 and diabetic retinopathy, *321-322
- TYROSINE AMINO TRANSFERASE
 and cyclic AMP
 and insulin, 439-445
- U**
- UMBILICAL CORD
 glucose
 and infant hypoglycemia, *1202-1203
- UNIVERSITY GROUP DIABETES PROGRAM, *57
 evaluation of, 976-978, 1035-1039
 and labeling laws for oral hypoglycemic drugs, 1116-1117
- UREMIA
 and carbohydrate tolerance, 1109-1114
 and experimental diabetic ketosis, *121
 and insulin release, *910-911
- UREOGENESIS
 and cyclic AMP
 and insulin, 442-443
- URIC ACID
 excretion
 and nicotinic acid, *313
- URINE
 catecholamines
 and ouabain, *913
 epinephrine and norepinephrine
 and idiopathic hypoglycemia, *1200
 glycolate
 and streptozotocin diabetes, *372
 17-ketosteroid excretion
 and diabetic impotence study, 24
 sodium and potassium
 and growth hormone, *1046
 tests
 and lipotrophic diabetes, 830
- UTERUS
 relaxants
 and hyperglycemia, *1045
- V**
- VASCULAR DISEASE
 and blood glucose control, 976-978
 and diabetes, 678-683
 and blood coagulation, 108-112
 and combined hyperlipoproteinemia, *376
 and insulin, 633
 and serum phospholipids, *123
 and diabetes duration, *314
 and oral hypoglycemic agents, *57
 peripheral
 and insulin response to glucose, *836-837
 and insulin response studies, *836
- VASCULAR SYSTEM
 aorta
 glycosaminoglycans, 1163-1166
 clearance
 and reticuloendothelial system in dogs, *312
 and disseminated intravascular coagulation
 and diabetes, 108-112
- VASOPRESSIN
 action
 and cyclic AMP, *251
 and antidiuretic action of chlorpropamide, *189
- VEIN
 reactivity
 and diabetes, *909
- VENOPATHY, DIABETIC, *909
- VINBLASTINE
 and insulin release, 989-991, 996-997
- VIRUSES
 and diabetes, 713-714
 encephalomyocarditis
 and mouse pancreas, *338-339
 and insulinitis in late-onset diabetes, 766-767
- VITAMINS
 B
 and hemoglobin synthesis, *311
 K
 and resistance to oral anticoagulant drugs, *183
- W**
- WEIGHT. *See also* Body, weight; Obesity
 gain
 and high-fat diet, *182
 loss
 and calorie restriction in obese hyperglycemic mice, *835
 and insulin sensitivity, 6-11
 and low calorie diet with anorectic agent, *361
 reduction
 and adipose tissue lipolysis and cellularity, 754-760
 and phenformin, *362
 and serum glucose
 in *Mystromys albicaudatus*, 718, 719, 720
- X**
- XANTHOMA
 and familial hypercholesterolemia, *1121
- X-IRRADIATION
 and mortality and longevity in mice, *914
- XYLITOL
 absorption
 in healthy men, *350-351
 and insulin release, 561, 565
 and diabetes and obesity, *187-188
 metabolism
 in fasted and streptozotocin diabetic rat, *122
 and pancreas metabolism, 562-564
- D-XYLOSE
 excretion
 and metformin, *771
 transport
 and biguanides, *119
- Z**
- ZINC
 and insulin, 487-489, 497-498, 509, 570

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64	Supplement 1, 321-384	August, 843-922
February, 65-128	Supplement 2, 385-714	September, 923-986
March, 129-192	June, 715-778	October, 987-1050
April, 193-256	July, 779-842	November, 1051-1130
May, 257-320		December, 1131-1210

AUTHOR INDEX 1972

In this index are the names of authors of articles that have appeared in **DIABETES** and those whose articles have been abstracted in the Journal during 1972. Entries marked with an asterisk (*) indicate authors of material that appeared in the **ABSTRACTS** only. The **Subject Index** appears on page 1.

A

Abe, Hiroshi, 203-208
 Abildgard, F., *769
 Abrams, M. E., *980, *1047
 Ackerman, Eugene, *775, *836
 Adams, Donald A., *349
 Adams, Yvonne L., *179
 Adelman, Neil, 1-5
 Adibi, Siamak A., *179
 Adnitt, P. I., *187, *771
 Agot, H., *912
 Ahlborg, Gunvor, *776
 Ahrens, E. H., Jr., *1200-1201
 Ahrens, Richard A., *179
 Aiach, M., *776
 Åkerblom, Hans K., *349-350
 Alavi, Iltifat, A., *54
 Alberti, K. G. M. M., *59, *350, *1117
 Alexander, James K., *980
 Alexander, Kenneth R., *1123
 Allen, Lindsay H., *1041
 Allen, Michael, *772
 Alpert, Joseph S., *769
 Alric, R., *912
 Alvarez, Enrique, *359
 Amherdt, Mylene, *326, *346, 1060-1071
 Ammon, H. P. T., 143-148, *350, *365, *1198, *1205
 Amsterdam, Daniel, *338-339
 Andersen, Dana K., *252
 Andersen, O., *769
 Anderson, James H., Jr., *311
 Anderson, James W., *188
 Anderson, P. A., *352
 Andersson, Arne, 546-554
 Andres, Reubin, *347
 Ansah, B., *1204
 Antoniadis, Harry N., 930-934, *1123
 Aoki, T., *323
 Aranda, J. V., *185
 Arieff, Allen, *774
 Arky, Ronald A., *54, *334, *772
 Arons, Daniel L., *54

Asano, T., *350-351
 Ashcroft, Stephen J. H., 538-545
 Ashkar, F. S., *351
 Ashmore, James, 426-427, 453, *982
 Assal, J.-Ph., *179, *323, *361-362, *366
 Assan, Roger, 843-855, *1120
 Assemany, Salma R., *1042
 Atkin, E., 149-156
 Atkins, T., *179
 Avruch, Joseph, *1042
 Avruskin, T. W., *381
 Azumi, Kazuo, *776

B

Bagdade, John D., 65-70
 Bagul, C. D., *351-352
 Baker, David H., *771
 Baker, Lester, *189
 Baker, Nome, *914
 Baker, R. W. R., 1173-1178
 Balasse, Edmond O., 280-288
 Baldwin, R. L., *315
 Ball, Michael F., *1118
 Balodimos, Marios C., *118, *769
 Barbezat, Gilbert O., *769
 Barbier, P., *123
 Baroja, Isabel M., 289-294, *837-838
 Barter, Philip J., *835
 Bassett, John M., 538-545
 Batalla, M. A., *118
 Batchelder, Timothy, *372
 Bates, Margaret W., *246
 Battaglia, Frederick C., *187
 Bauer, G. Eric, *58-59
 Bayley, T. J., *773
 Beall, Robert J., *983
 Beard, Alice, *179-180
 Beaser, S. B., *370
 Becker, Kenneth L., *328-329, *375-376
 Begin-Heick, Nicole, *912
 Behrens, Otto K., viii Supplement 2, 685
 Beisel, W. R., *316

Beitch, Janis, 506-508
 Belfiore, Francesco, 1168-1172
 Bender, S. A., *1046
 Bengtsson, Calle, *180
 Bengtsson, Kristina, *1198
 Bennet, G. Vann, *1042
 Bennett, Peter H., *180, *365-366
 Benson, Bryant, 935-938
 Berenson, Gerald S., 733-743
 Bergan, J., *355
 Bergman, E. N., *118, *314
 Berkowitz, Stuart, *980
 Berman, Mones, *347
 Bernardis, Lee L., *771, *1043, *1204-1205
 Bernick, Sol, *248
 Bernstein-Hahn, L., 23-30
 Berridge, Michael J., *315
 Best, Charles H., 385-395
 Bewsher, Peter D., *186
 Beyer, J., *249, *249-250
 Beyer, W. R., *370
 Bhai, Idrees, *311
 Bhatia, S. K., *365
 Bhawanji, Jain, *359-360
 Bianchi, R., *376
 Bianchine, Joseph R., *1121
 Bianco, Jesus A., *118-119
 Bier, Dennis M., 280-288
 Bierman, Edwin L., 65-70, *342, *380
 Binkiewicz, A., *377
 Bitensky, Mark W., *80, *981, *1117-1118
 Bitsch, Vibeke, *186-187, *1045
 Bivens, C. H., *352
 Björntorp, Per, *54, *180, *312-313, *771, *909
 Black, W. L., *367
 Blackard, William G., *187, *188, 311, *360
 Blanks, M. C., *337-338
 Block, Marshall B., 661-672, 1013-1026
 Blohmé, Göran, *180

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64	Supplement 1, 321-384	August, 843-922
February, 65-128	Supplement 2, 385-714	September, 923-986
March, 129-192	June, 715-778	October, 987-1050
April, 193-256	July, 779-842	November, 1051-1130
May, 257-320		December, 1131-1210

AUTHOR INDEX 1972

- Blondel, B., *346, *368
 Bloodworth, J. M. B., Jr., *321, *352
 Bloom, A., *120-121
 Bloom, Gail, *346-347
 Blum, André L., *54
 Blumenthal, Stanley A., *180-181, *1205
 Blundell, T. L., 492-505
 Boberg, J., *316
 Boder, George B., 535-537
 Bomboy, J. D., *332, *340-341
 Bommer, G., *911
 Bonar, J. R., *352-353
 Boquist, Lennart, 1051-1059
 Borchers, Raymond, *980-981
 Borek, Ernest, *253
 Borensztajn, J., *344
 Borin, Bruce M., *837
 Borner, E., *769
 Borowitz, J. L., *184
 Bortz, W., *375
 Boshell, B. R., *351-352, *371
 Breur Richard I., *1199
 Boucher, B., *1047
 Boulanger, M., *357
 Boulter, Philip R., *334
 Boveris, A., *184-185
 Bowen, V. R., *328-329
 Bowers, Mary, *325
 Bradley, R. F., *118
 Brancato, Paul, *338-339
 Brandenburg, Dietrich, 468-475
 Brange, J., 649-656
 Braun, Theodor, *60
 Bravo, Ivan R., *180
 Bray, George A., *838, *1206
 Bressler, Ruben, 713-715
 Breur, Richard I., *1199
 Bricaire, H., *775-776
 Brickman, Fred, 733-743
 Bridgeman, J. F., *769
 Birdgen, W. D., *120-121
 Brisson, Guy R., *119, *326-327, *1042
 Brock, Frances E., *58
 Bromer, William W., 485, 509
 Brooks, Mary R., *914
 Brophy, P. D., *1046
 Brown, Joseph D., *835, *1045
 Brunfeldt, K., *769
 Brunzell, John D., *342, *348
 Brush, James S., *122
 Bruylands, J., *59
 Bryant, Gilleen M., *910
 Buber, V., *1119
 Buchanan, Keith D., *1122, *1206
 Buckman, M., *1043
 Burch, Thomas A., *180
 Burgess, J. A., *248-249
 Burkle, P. A., *246
 Burns, T. W., 89-100
 Burr, I. M., *246
 Burrill, Karen C., *982
 Buse, John, *911
 Buse, Maria G., *911
 Buselmeier, T. J., *322
 Bussey, Dietrich, *248
 Butcher, Fred R., *54
 Butt, J., *250-251
 Butterfield, W. J. H., *980
 Buzzi, Alfredo, *359
 Byrd, Gerald W., *311
- C**
- Caccamo, Anna, *312
 Cahill, George F., Jr., 703-712
 Camanni, F., *122
 Camerini-Davalos, R. A., *321, *373
 Cameron, Donald P., 1060-1071
 Campbell, G. D., *250
 Camus, J., *59
 Canary, John J., *1118
 Canever, J. V., *120-121
 Canfield, Robert E., *835
 Canivet, J., *838
 Cantrell, Jerald W., 872-880
 Car, Joseph R., *358-359
 Caren, Raymond, *311-312
 Carlson, L. A., *316, *980
 Carmelutti, Margherita, *312
 Carrera Vescio, L., *253
 Carrol, Carthage J., *366-367
 Carroll, Kevin F., *835, 923-929
 Carter, Edward A., *769-770
 Carter, James R., Jr., *1042
 Caspary, W. F., *119
 Cassar, J., *1199
 Castillo, E. J., *184-185
 Castillo, L., *775
 Castleman, Benjamin, *1042
 Cavalli-Sforza, L. L., *1045-1046
 Cederquist, Dena, *983
 Celener, David, *359
 Celik, Ziya, *364
 Cerasi, Erol, 224-234, *312, *323-324, 685-694, *770
 Cerchio, Gerard, *982
 Cerletty, James M., *773
 Chabot, V., *1119
 Chance, Ronald E., 461-467, 657-660
 Chandler, Michael L., *353
 Chang, M. L. W., *770
 Chao, Ping-Yu, *353
 Chapal, J., *1045, *1120
 Chapman, Betty B., *837
 Charles, M. Arthur, *327
 Chase, G. R., 89-100
 Cheek, Donald B., *1201
 Chen, S., *344
 Chernick, Sidney S., 946-954
 Cherrington, A., *382-383
 Cherry, Thomas, *1204
 Chevalier, M., *835
 Chez, Ronald A., 39-44, *180
 Chick, William L., *1120
 Chisholm, D. J., *1118
 Chiumello, Giuseppe, *312
 Chlouverakis, C., *119, *353-354, *835
 Chochinov, Ronald H., *341-342, *1199
 Chow, Kye-Wing, *835-836
 Christacopoulos, P. D., *354
 Christensen, Halvor N., *55-56
 Christiansen, Aa. Hein, 649-656
 Christlieb, A. Richard, *354-355
 Christophe, J., *59, *119, *182
 Cibeira, Jose B., *359
 Clancy, Barbara A., *983
 Clark, Charles M., Jr., 946-954
 Clayton, Barbara E., *119-120
 Clements, Rex S., Jr., *180-181, *330
 Clifford, A. J., *184
 Clough, G., *913
 Cloutier, Mark D., *982-983
 Cochran, Alan, *982
 Coddling, J. C., *339, *1204
 Coffman, Jay D., *769
 Cohen, A. M., *770
 Cohn, Major L., 39-44
 Cole, Harold S., 16-22
 Colinas, Rodolfo, *359
 Colle, E., *185
 Collipp, Platon J., *366
 Colwell, A. R., Jr., 209-215
 Colwell, Arthur R., Sr., 839
 Colwell, John A., 13-15, 108-113, *355
 Colwill, James R., *187
 Conly, Patricia, 175-177
 Conn, Jerome W., *55-56, 216-223, *322, *324, *331-332, *837, *1204
 Constam, G. R., *120
 Conway, Martin, *1043
 Corbo, Lucille, *311-312
 Corkey, B. E., *344-345
 Cornblath, Marvin, *179-180, *181
 Cornell, Robert P., *312
 Corredor, D. G., *250
 Costrini, Nicholas V., *773
 Court, J. M., *1042-1043
 Cowan, Donald H., 906-907
 Cragan, Mary, *1200
 Craig, James W., *56
 Craig, L. S., *254
 Craighead, John E., *247
 Crawford, John S., *182

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64	Supplement 1, 321-384	August, 843-922
February, 65-128	Supplement 2, 385-714	September, 923-986
March, 129-192	June, 715-778	October, 987-1050
April, 193-256	July, 779-842	November, 1051-1130
May, 257-320		December, 1131-1210

AUTHOR INDEX 1972

Cremer, Guillermo M., *836
 Crespín, Stephen R., 1179-1184
 Creutzfeldt, W., *119
 Crofford, Oscar B., *332, *335, *340-341, 403-413
 Crowley, Leo, *773
 Cruz, Sidney R., 13-15, *355
 Cryer, Philip E., *181
 Cuatrecasas, Pedro, 396-402, *772, *1042
 Cummings, Nancy P., *355-356
 Cunningham, E. J., 89-100
 Curry, Donald L., *55
 Cutfield, J. F., 492-505
 Czech, Michael P., *336-337
 Czerwinski, C., *356, *360-361
 Czyzyk, Artur, *121-122, *909

D

Daggett, Willard M., *118-119
 Daikuhara, Yasuchi, *1122
 Dalferes, Edward R., 733-743
 D'Andrea, R. J., *314
 Daniel, P. M., *247
 Danowski, Thaddeus S., *250, *314, *1118
 Dashe, Alfred M., *349
 Davenport, Katherine, *378
 Davidoff, Frank, *367, *376-377
 Davidson, Mayer B., 6-12, *335-336
 Davis, Barbara H., *328-329, 1173-1178
 De Oya, Manuel, *55
 De Santis, R. A., *356, 360-361, *775
 Deconinck, J. F., *120
 Deisseroth, Albert, *376-377
 Del Greco, F., *355
 Del Guercio, M. José, *312
 Delcher, H. K., *336-337
 Demers, Laurence M., 1185-1191, *1199
 DePalma, Ralph G., 257-270
 Deren, Julius J., *249
 derKinderen, P. J., *1046
 Deschodt-Lanckman, M., *59
 Devetta, Mario, *312
 Devrim, Ahmet Sevim, *356
 Dhawer, V. P. S., *250
 DiGirolamo, Mario, *247, 1151-1161
 Diaz-Fierros, Maruxa, 289-294, *837-838
 Dilling, Louis A., *1119
 Dilman, V. M., *55
 Distefano, G., *316
 Ditzel, J., *1120
 Dixit, Padmakar K., *363-364
 Dobbie, J., *355
 Dodson, E. J., 492-505
 Dodson, G. G., 492-505

Dolger, Henry, *376
 Domanski, Robert, *247
 Donabedian, Richard, *312
 Dornhorst, Ann, *247-248
 Dorris, Susan, *57
 Doyle, Richard E., 715-721
 Drash, Allan L., 45-49, *60
 Dreizen, Samuel, *248
 Driscoll, John M., Jr., *837
 Drummey, Gladys D., *769-770
 Du Boistesselin, R., *357
 Duckworth, William C., *122, *355, *356, 935-938
 Dudl, R. James, *333-334, *357
 Duga, Judith, *369-370
 Duhault, J., *357
 Dunbar, J. C., *344
 Dunlop, Marjorie, *1042-1043
 Dupre, John, *374-375
 Dymock, I. W., *1199

E

Earley, L. E., *189
 Eaton, R. Phillip, *55, *357, 744-753, *1043
 Eckel, Robert E., *56
 Edelstein, Diane, *56
 Edwards, A. V., *770
 Edwards, Charles C., 1116-1117
 Edwards, J. C., *909
 Efenic, Suad, 224-234, *312, *770
 Egdahl, Richard H., *364, *775
 Ehrenreich, T., *373
 Ehrlich, Edward N., *57
 Eichner, Harvey L., *358
 Eisenstein, Albert B., *358
 Ekaraphanich, Sompol, *1122
 Ekholm, R., *120, *251-252
 El-Khodary, Ashraf Z., *1118
 Ellerman, Jeanette, *328, 555-569
 Ellis, Robert A., 506-508
 Elsas, Louis J., *248
 Empey, G., *1204
 Ensink, John W., *333-334, *357
 Epel, Rosa, 16-22
 Epple, August, *358-359
 Ericson, L. E., *120, *251-252
 Erlich, R. M., *248, *254
 Essner, Edward, *56
 Ettinger, Bruce, *189
 Etwiler, Donnell D., 967-971
 Evans, D. J., 114-116
 Evans, G. W., *1043
 Exton, J. H., *254, *339-340, 439-446
 Ezekiel, M., *775

F

Fabre, J., *1120-1121
 Fabre, L. F., Jr., *313
 Faerman, Isaac, 23-30, *359
 Fagerberg, S.-E., *981
 Fahlén, Martin, *312-313, *771, *909
 Fain, John N., 414-425, *836
 Fajans, Stefan S., *55-56, 216-223, *322, *324, *331-332, 678-684, *1204
 Falch, Dagfinn, 939-945
 Faloona, Gerald R., *58, *183, *912-913, *1198-1199
 Falorni, Adriano, *1199-1200
 Fariss, Bruce L., *1047
 Farmer, R. W., *313
 Farquhar, John W., *372, *380, *1121
 Fatourech, Vahab, *1203
 Federlin, K., *246
 Fekete, M., *1120
 Felber, J.-P., *1119
 Feldman, Jerome M., *184, *248, *252, *315-316, *345, *352, *370-371, 779-788, *1200
 Felig, Philip, 308-310, *323-324, *770-771, *776, *1118, *1202
 Feller, D. D., *836
 Felts, James M., *188
 Felts, P. W., *332, *340-341
 Feng, Louise Y., *1201
 Fernbach, Donald J., *1119
 Fernstrom, J. D., *909
 Ferris, Deward O., *185
 Fertel, Richard, *359
 Fertig, John W., *247
 Field, James B., *346-347, *980
 Filer, L. J., Jr., *315
 Fineberg, S. Edwin, *342-343, *372, *774-775
 Fink, C. Joan, 987-998
 Fink, Gloria, *329, *359-360
 Fischer, Edward P., *1201
 Fischer, Lawrence J., 71-79
 Fischer, M., *913
 Fischer, U., *909, *911
 Fisher, Edwin R., *1118
 Flatt, J. P., 50-52
 Fleischman, D. E., *838
 Fleming, Gary A., *181
 Floyd, John C., Jr., *55-56, 216-223, *322, *324, *331-332, *1204
 Foà, P. P., *313, *344
 Foglia, V. G., *253
 Folling, I., 814-826
 Fono, Peter, *188
 Forfang, Kolbjorn, 939-945
 Forrest, E., *1205-1206
 Forrest, Jill M., *248-249

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64
 February, 65-128
 March, 129-192
 April, 193-256
 May, 257-320

Supplement 1, 321-384
 Supplement 2, 385-714
 June, 715-778
 July, 779-842

August, 843-922
 September, 923-986
 October, 987-1050
 November, 1051-1130
 December, 1131-1210

AUTHOR INDEX 1972

Forsham, Peter H., *332-333, *358, *982, *1045
 Forster, Harald, 1102-1108
 Foster, Daniel W., *1203
 Foster, Richard O., 703-712
 Fox, Dora, 23-30, *359
 Fox, Orlando J., 157-162, *1044
 Fracassini, Francesco, *1199-1200
 Frank, B. H., 486-491
 Frayn, K. N., *771
 Fredholm, Bertil B., *836
 Fredrickson, Donald S., *1044-1045
 Freedlender, Arthur E., *183-184
 Freinkel, Norbert, *340
 Fremstad, Dag, 939-945
 French, Frank S., *1122
 Fresquez, Vidal, *982
 Frey, Harald M. M., 939-945
 Freychet, Pierre, *334-335, 673-677, *909-910, *1200
 Freytag, G., *911
 Friedmann, N., *254
 Fritsch, John M., 506-508
 Froesch, E. R., *122
 Frohman, Lawrence A., *771, *1043
 Frost, Philip, 794-796
 Fuchs, F. S., *913
 Fujimoto, Wilfred Y., *329, *345-346, *360
 Furnelle, J., *182
 Furner, R. L., *836
 Fussgänger, Rolf D., *313, 1072-1076

G

Gabbay, Kenneth H., 295-300, *327, *838
 Gabbe, Steven G., 1185-1191, *1199
 Gabbiani, Giulio, *314
 Gagliardino, J. J., *184
 Galloway, John A., 637-648, 657-660
 Gapp, D., *370
 Garaza Pereira, A. M., *184-185
 Garcia, Angel R., *360
 Garcia, Mariano J., *356, *360-361, *375
 Gardiner, Robert J., 946-954
 Gardner, Lytt I., *1042
 Garner, Ann M., *1204
 Garratt, C. J., *980
 Gary, A., *1046
 Gatewood, Laël C., *836
 Gattner, Hans-Gregor, 468-475
 Gaut, Z. N., *313
 Geever, Erving, *773-774
 Gentz, J., *179-180
 Genuth, Saul M., 1003-1012
 Georg, Ralph H., *56
 George, Jack M., *381-382, *771

Gepts, W., *120, *253-254
 Gerich, John E., *332-333
 Gerneth, J. A., *314
 Gerritsen, G. C., *337-338
 Gershberg, Herbert, *361
 Gerschenson, Lazaro E., *335-336
 Gertner, Melvin, *366
 Chazarian, Hagop G., *980-981
 Chilchik, Margaret W., *836, *836-837
 Gibson, G. E., *184
 Gillette, Paul C., *1119
 Gingell, Robert L., *181
 Ginsberg-Fellner, Fredda, *361, 754-761
 Giombetti, Robert, *120
 Gipstein, Robert M., *349
 Girgis, Medhat, *369-370
 Glasgow, Joseph L., *352
 Gleason, Ray E., *354, *361-362, *366, *373, *383, *1044-1045
 Glennon, Joseph A., *362
 Glick, Seymour M., 1-5
 Glocer, Leticia, *359
 Glueck, Charles J., *1043
 Goberna, Raimundo, *313
 Goeken, James A., *1043
 Goetz, F. C., *322, *350-351
 Gold, Ernest M., *378
 Goldberg, M. D., *250
 Goldberg, Paul, *364
 Goldfischer, Sidney, *56
 Goldman, Jack K., *1043, *1204-1205
 Goldman, Roger B., *771
 Goldstein, Jack, *1120
 Goldstein, Joseph L., *1121
 Gomez, F., *1119
 Gonzalez, Alejandro R., *250, *1118
 Goodall, McChesney, *1200
 Goodman, H. Maurice, *59-60
 Goodman, Michael N., *341, *343
 Goodner, Charles J., *362-363, *1200
 Gorden, Phillip, *313, 673-677, *909-910, *1043-1044
 Gordon, Edwin E., *369-370
 Gordon, Hymie, *771
 Gordon, Walter, *771
 Goren, Elihu N., *185
 Gorman, Ronnie E., *180, *981, *1117-1118
 Gossel, Thomas A., 80-83
 Gotlin, Ronald W., *250
 Gourgon, R., *838
 Graber, George, *771
 Graef, Irving, 178
 Grande, Francisco, *55
 Grasso, S., *316
 Grauel, Ludmila, *189
 Grayburn, J. A., *188

Grebin, Burton, *837
 Greene, Warner, 1109-1115
 Greengard, Paul, *773
 Greenwood, M. R. C., *316
 Greenwood, Ronald D., *249
 Greep, Roy O., *1199
 Greider, M., *355
 Grey, Neil, *249
 Greze, M., *776
 Gries, F. Arnold, *122, *911-912
 Griffiths, Anthony D., *910
 Grodsky, Gerold M., *327, 584-593, 856-862, *1045
 Groffman, H., *315
 Grossman, Morton I., *252, *769
 Gruber, Charles, *773-774
 Grundy, Scott M., *1200-1201
 Guder, Walter, *910
 Guglielmi, Hans, *1122-1123
 Gupta, Vicrum, *329-330
 Gürson, C. T., *313
 Gustafson, Anders, *771
 Guthrie, Richard, 45-49
 Gutman, Raul A., *329, *775
 Gutman, Samuel Wilkins, *359-360
 Guy, Matthew J., *249
 Guyton, Robert A., *118-119
 Gwinup, Grant, 722-732

H

Habbick, B. F., *56
 Haeckel, H., *910
 Haeckel, R., *910
 Haft, Jacob I., *376
 Hagen, Thad C., *1199
 Hager, Diana L., 594-604
 Hagstrom, Jack W. C., *120
 Hagura, Ryoko, 856-862, *1045
 Hahn, H. J., *914
 Haist, R. E., *339, *1204
 Hallund, O., 649-656
 Halpern, Alfredo, *363
 Hamilton, C. L., *1201
 Hamilton, M. A., *70
 Handschumacher, Robert E., *254
 Hann, Lucy, *362
 Hansky, J., *249
 Harano, Yutaka, 257-270
 Hardman, Joel G., *251
 Hare, John W., *340
 Harrill, Inez, *1202
 Harris, Alan, *772-773
 Harris, Grady W., 703-712
 Harrison, Lura A., *250
 Hashim, Sami A., 789-793
 Hashimoto, Tadashi, 476-484

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64	Supplement 1, 321-384	August, 843-922
February, 65-128	Supplement 2, 385-714	September, 923-986
March, 129-192	June, 715-778	October, 987-1050
April, 193-256	July, 779-842	November, 1051-1130
May, 257-320		December, 1131-1210

AUTHOR INDEX 1972

Haslbeck, Manfred, 1102-1108
 Haugen, H. N., *123
 Haupt, E., *249, *249-250
 Havel, Richard J., 280-288
 Haven, G. T., *1047
 Haworth, James C., *179-180, *1119
 Hayes, K. C., *1044
 Hayles, Alvin B., *982-983
 Hazelwood, Robert L., *59
 Hazlett, Barbara, 906-907
 Hazzard, William R., *348, *1121
 Heath, H., *120-121
 Hebbelinck, M., *119
 Hechter, Oscar, *60
 Heding, L. G., 649-656
 Hedner, Pavo, *981
 Hegre, Orion D., 193-202
 Hegsted, D. M., *60, *1044
 Heinemann, Martha, *122
 Heird, William C., *837
 Hellerström, Claes, 546-554, *909
 Hellman, Bo, *56, *181, *771-772, *837, *910-911, *999-1002
 Hemm, G., *246
 Hendler, Rosa, *323-324, *1118-1119
 Hengstenberg, Fay, *60
 Henry, James E., Jr., *363
 Herberg, L., *122
 Herman, Clifford M., *181
 Hernandez, Rodolfo E., *363
 Herrera, M. G., *60
 Herrold, Joyce, *381
 Hertelendy, F., *313
 Hetenyi, G., Jr., 797-804
 Heuser, Gunnar, *349
 Hiebert, John M., *364
 Hill, Donald E., *1201
 Hill, L. Leighton, *1119
 Hillbom, Matti E., *181
 Hime, J. M., *1205-1206
 Hinderaker, Paul H., *187
 Hingson, Robert A., 39-44
 Hirsch, Allen H., *185
 Hirsch, Jules, *316, *1201
 Hirschel, Bernhard J., *314
 Ho, Chen-Kung, 789-793
 Hochman, H., *377
 Hockaday, T. D. R., *350, *1119
 Hodge, J. S., *1120
 Hodgkin, Dorothy Crowfoot, 492-505, 1131-1150
 Hoffman, Richard S., *772
 Hohenegger, M., *121
 Hohmann, T. C., *314
 Holanders, Egils, 271-279
 Hollander, Daniel, *1122
 Hollinden, C. Stephen, 235-245

Holowach-Thurston, Jean, *359
 Holzmann, H., *250
 Hommel, H., *909, *911
 Horiuchi, A., *773
 Hornbrook, K. R., *1203
 Hoshi, Mitsuru, 827-831
 Howard, Charles F., Jr., 138-142
 Howell, S. L., *328
 Hsia, S. L., *189
 Huber, V., *246
 Hughes, J. R., *838
 Hulse, Mildred, *361
 Humbert, James R., *250
 Hummeler, Klaus, *189
 Hunt, C. E., *1044
 Hunter, P. R., *120-121
 Hutchins, G. M., *1201
 Hutchinson, Donald L., *180
 Huttunen, Jussi K., *314

I

Iber, Frank L., *362, *983
 Idahl, Lars-Ake, 999-1002
 Illiano, Gennaro, *772
 Insel, Paul A., *347
 Irving, William R., *185
 Isenberg, Jon I., *769
 Issekutz, Bela, Jr., *772
 Isselbacher, Kurt J., *316, *769
 Iversen, Johan, *314
 Izumi, Kanji, 827-831
 Izzo, Joseph L., *333
 Izzo, Mary Jane, *333

J

Jackson, James A., *983
 Jackson, Richard L., 235-245
 Jackson, W. P. U., *250
 Jacobi, H. P., *1047
 Jacobson, Mitchell, *773
 Jadzinsky, Mauricio N., *23-30, *359
 Jaffé, Ernst, *773-774
 James, Albert L., *121
 Jansen, F. K., *121
 Jarett, Leonard, *343, *772, *1119
 Jaya Rao, Kamala S., *1119-1120
 Jefferson, L. S., *341
 Jenkins, David W., *56
 Jequier, E., *1119
 Johansen, Klaus, *911
 Johnsen, Ch., *981
 Johnson, D. G., *329
 Johnson, Irving S., 535-537
 Johnson, Leonard R., *250

Johnson, P. R., *316
 Johnson, R. A., *335
 Johnston, H. M., *774
 Jones, Rayford S., *771
 Jonsson, Anders, *180
 Jordan, George L., Jr., *1201
 Jordan, Scott W., *837
 Jorfeldt, Lennart, *776
 Jorgensen, K. H., 649-656
 Joshua, Henry, *57
 Juan, C., *381
 Juliano, Joseph, *376
 Jung, Y., *250, *314
 Junker, K., *1120

K

Kabara, J. J., *837
 Kachra, Zarin, *374-375
 Kagan, Avir, 1-5
 Kahan, Miles, *364
 Kahn, Charles B., 31-37, *365
 Kahn, Ronald, *334-335, 673-677, *1200
 Kajinuma, Hiroshi, *332
 Kalkhoff, Ronald K., *365, *773
 Kallio, Anna-Kaarina, *349-350
 Kalnins, A., *1204
 Kamenetzky, Stephen A., *365-366
 Kan, Dorinne, *773-774
 Kanazawa, Yasunori, *121
 Kansal, Prakash C., *911
 Karabula, C., *182
 Karam, John H., *332-333, *353, *982
 Karasaki, Kenkichi, 203-208
 Karjala, Robert G., 6-12
 Karlberg, Bengt, *1198
 Karlsson, Kirsten, *1201-1202
 Kasperska, Teresa, *121-122
 Kato, Mikio, *314
 Kattamis, C., *182
 Katsoyannis, Panayotis G., *772-773, *981
 Katz, Adrian, *347
 Kaufman, C. F., *314
 Kaufmann, R. L., *361-362, *365, *366, *383
 Kawamori, Ryuzo, 203-208, *382
 Kaye, Gordon I., *835
 Keamy, Donald G., *185
 Kebabian, John W., *773
 Keenan, William J., *1202-1203
 Keller, U., *122
 Kellum, Mike, *179-180
 Kelsey, J., *120-121
 Kemmler, Wolfgang, 572-581
 Kendall, M. J., *773
 Kenny, Frederick M., *60
 Kerly, Margaret, *57

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64	Supplement 1, 321-384	August, 843-922
February, 65-128	Supplement 2, 385-714	September, 923-986
March, 129-192	June, 715-778	October, 987-1050
April, 193-256	July, 779-842	November, 1051-1130
May, 257-320		December, 1131-1210

AUTHOR INDEX 1972

Kerr, Sylvia J., *253
 Kershner, Ann K., *981
 Kessler, Irving L., *1044
 Khan, Farida, *348
 Khurana, Ramesh C., *250, *1118
 Kikkawa, Ryuichi, 827-831
 Kilo, Charles, *254, 881-905
 Kim, Hakjoong, *773
 Kim, Young Jin, *1118-1119, *1202
 Kim Young S., *771
 Kimmelstiel, Paul, *338
 Kimura, H., *773
 King, Katherine C., *250-251
 King, Ronald, *180
 Kipnis, David M., *249, 606-616, 744-753, *1119
 Kitabchi, Abbas E., *122, *355, *356, 935-938, 1027-1034, 1091-1101, *1122
 Kitamura, T., *773
 Kjellmer, Ingemar, *1201-1202
 Kjellstrand, C. M., *322
 Klachko, D. M., 89-100
 Klahr, Saulo, *57
 Klatt, D., *914
 Klayton, R., *250
 Kleeman, Charles R., *774
 Kleinman, Leonard I., *914
 Klimt, Christian R., *57, 1035-1040
 Klitgaard, Howard M., 271-279
 Klöppel, G., *911
 Knatterud, Genell L., *57, 1035-1040
 Knittle, Jerome L., *361, *366, 754-761
 Knochel, Gerald R., *1198-1199
 Knöfler, H., *911
 Knopf, Ralph F., 216-223, *322, *324
 Knopp, Robert H., *366-367
 Knospe, S., *182
 Knowles, Harvey C., Jr., *381
 Knussmann, R., *251
 Koberich, W., *249, *249-250
 Kogut, Maurice D., *981
 Kohler, William C., *355-356
 Komaroff, Anthony L., *367
 Konecz, Lajos, *769
 Konsek, John P., *57
 Korman, M. G., *249
 Korp, W., *913
 Koschinsky, Theodor, *122, *911-912
 Kotler-Brajburg, Janina, *328, *359, 555-569
 Koutras, Phoebus, *1120
 Kovacevic, Nada, *188
 Kozak, G. P., *323
 Krahl, M. E., 695-702
 Krall, L. P., *361-362
 Kranz, Paul, *376
 Kreisberg, Robert A., 157-162, *367, *1202

Kroes, J. F., *1044
 Krouse, H. A., *1200
 Krstic, M. K., *1046
 Kruck, F., *769
 Kryston, Leonard J., *367-368
 Kubli, F., *1045
 Kumar, Dinesh, *368
 Kuo, Peter T., *1201
 Kuroda, Kohei, *60
 Kurup, P. A., 1162-1167
 Kurwa, Aziz, *251
 Kutzner, R., *119
 Kwann, Hau C., 108-113
 Kyner, Joseph L., *1044-1045

L

Lacy, Paul E., *326, *328, 987-998
 Lacy, W. W., *332, *340-341
 Lafrance, Louise, *912
 Lake, Nareen, *1202
 Lambert, André E., *121, *368
 Lan, V. V., *356, *360-361
 Landau, Bernard R., *329-330
 Lande, Saul, *981
 Landey, Stephanie, *120, *1046
 Landgraf, R., *369, 555-569
 Landgraf-Leurs, M., *369
 Lang, C. Max, *338
 Langer, L., *981
 Langworthy, Alice, *324-325, *1203
 Larkins, R. G., *122, *1204
 Larner, Joseph, 428-438
 Larsson-Cohn, V., *316
 Laube, Heiner, 1072-1076
 Laube, Heinrich, *313
 Lauris, V., *70
 Lavine, Lawrence, 257-270
 Lavis, Victor, *336
 Lawecki, January, *121-122
 Lazarow, Arnold, 193-202
 Lazarus, L., *1118
 Lazarus, Norman R., *328-329
 Lazarus, Sydney S., 129-137, *325-326
 Le Dune, Martha A., *181
 Leary, Peter M., *771
 LeBlanc, Jacques, *912
 Lebon, F., *357
 Lebovitz, Harold E., *184, *248, *315-316, *345, *352, 779-788, *1200
 Lecocq, Frank R., 101-107
 LeCompte, Philip M., *365-366, 762-768
 Lee, J. A., *770
 Lee, Thomas C., *378
 Leef, M. R., *254
 Lefebvre, Pierre J., *334, *369
 Leffler, Allan T., III, *181

Lefrak, Edward A., *1201
 Legg, Merle A., 762-768
 Leitner, J. Wayne, *56
 Lemaire, F. R., *366
 Lemieux, Guy, *251
 Lemonnier, D., *182
 Leonard, Ingrid, *1042-1043
 Leonard, R. F., *1042-1043
 Leopold, Newman A., *374, *1121
 Lerner, Roger L., *348, *773
 Lernmark, Ake, *910
 Leslie, E., *1199
 Leveille, G. A., *835
 Levenson, Stanley M., *773-774
 Levey, Gerald S., *912
 Levin, Emanuel, *774
 Levin, Seymour R., *327, 856-862, *982, *1045
 Levine, Rachmiel, *314, *370, 396-402, 454-456
 Levitt, M. D., *350-351
 Lev-Ran, Arye, *57
 Levrat, R., *179
 Levy, Barnet M., *248
 Levy, Leonard J., *369-370
 Levy, Robert I., *1044-1045
 Lewis, A. A. G., *55
 Lewis, S. B., *332, *340-341, 439-446
 Liddle, Grant W., *251, *332
 Lie, T. H., 89-100
 Liebelt, A. G., *774
 Liebelt, R. A., *774
 Light, Irwin J., *914, *1202-1203
 Like, A., *326, *346, 511-534, *1120
 Liljenquist, J. E., *332, *340-341, *347
 Limburg, B., *321
 Lin, Boniface J., *188, *1204
 Lindgren, Soren, *1198
 Lindros, Kai O., *181
 Lindsay, D. B., *57-58
 Lindsey, Al, *331
 Lindsey, J. R., *1044
 Linscheer, G. William, *54
 Linzell, J. L., *57-58
 Lione, A. P., *775
 Lipman, Richard L., 101-107, 175-177
 Lippert, T. H., *1045
 Lipshitz-Wiesner, Rakoma, *253
 Little, Hunter L., *189
 Little, John R., *251
 Londono, J. H., *376
 Longnecker, Daniel S., 71-79
 Lorente, P., *838
 Loreti, L., *344
 Loubatières, A., *912, *1045, *1120
 Louis, Lawrence H., *837
 Love, E. R., *247

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64
 February, 65-128
 March, 129-192
 April, 193-256
 May, 257-320

Supplement 1, 321-384
 Supplement 2, 385-714
 June, 715-778
 July, 779-842

August, 843-922
 September, 923-986
 October, 987-1050
 November, 1051-1130
 December, 1131-1210

AUTHOR INDEX 1972

Love, Tommy, 101-107
 Lovrien, Fred C., *1045
 Lowenstein, J. M., *1203
 Lucke, Christoph, 1-5
 Luft, Rolf, 224-234, *312, *323-324, 685-694, *770
 Lundquist, I., *120, *251-252
 Lussier, Yolande, *251
 Luton, J.-P., *775-776
 Luyckx, Alfred S., *334, *369
 Lynch, Vincent, *1118-1119
 Lyngsoe, Jens, *186-187, *1045
 Lynn, William S., *336-337

M

Macchi, I. A., *370
 McCormick, J. R., *775
 Mackay, Ian R., *914
 Mackay, J. S., *253
 Mackerer, C. R., *981
 Madison, Leonard L., *331
 Mahan, Clare M., *183-184
 Mahler, Richard J., *314-315, *370
 Majid, P. A., *913
 Majno, Guido, *314
 Mako, Mary E., 1013-1026
 Makowski, Edgar L., *187
 Makulu, David R., *58, *982
 Malaisse, Willy J., *119, *326-327, 594-604, *838, *982, *1042
 Malaisse-Lagae, Francine, *119, *982, *1042
 Malathy, K., 1162-1167
 Maler, Mario, *359
 Malherbe, Christian, *982
 Malins, J. M., *186
 Malone, John I., *315
 Manchester, Keith L., 447-452
 Mandel, Emanuel E., *364-365
 Mann, J. I., *58
 Mannheimer, Shoshana, *57
 Manzano, F., *323
 Marble, Alexander, 632-636
 Marco, Jose, *58, 289-294, *837-838
 Marecek, Raymond L., *370-371, *1200
 Maria, J., *838
 Mariani, M. M., *912, *1045, *1120
 Marine, N., *250
 Marinetti, G. V., *1121-1122
 Marliiss, Errol B., *246, 308-310, *346, *368
 Marreiro Rocha, Dalva, *324
 Marshall, Garland R., 506-508
 Martin, David E., *774, *912
 Martin, Donald B., *57, *1042
 Martin, F. I. R., *182, *972-975, *1204

Martin, Pierre, *251
 Martin, R. J., *315
 Martino, Joseph A., *772
 Masazumi, Adachi, *364
 Mashiter, Keith, *346-347, *1047
 Massara, F., *122
 Massi-Benedetti, Ferdinando, *1199-1200
 Masson, Georges M. C., *253
 Matsaniotis, N., *182
 Matschinsky, Franz M., *328, *345, *359, 555-569
 Matty, A. J., *179
 Mauro, Joseph M., III, *1045
 Matute, M. L., *365
 Maughan, G. B., *316
 Maxfield, L. M., *1044
 Mayhew, D. A., *344-345
 McDaniel, H. G., *371
 McGarry, Denis J., *1203
 McGee, J. H., *376
 McGoodwin, Michael M., *1121
 McKeel, Daniel W., *772
 McMahan, Edward M., *252
 McMillan, Donald E., *371, 863-871
 McMurray, J., *352-353
 McNeely, Betty, *1042
 McNeish, A. S., *56
 Meade, Robert C., 271-279
 Mehlman, M. A., *981
 Mehnert, Hellmut, 1102-1108
 Meinert, Curtis L., *57, 1035-1040, 1197-1198
 Meissner, H. P., *769
 Melani, Franco, 661-672
 Mendlinger, Sheldon, *247, 1151-1161
 Meng, H. C., 149-156
 Mennear, Jon H., 80-83, *184
 Menser, Margaret A., *248-249
 Menzel, Ruth, *182
 Mercola, D. A., 492-505
 Merimee, Thomas J., *342-343, *372, *774-775, *1045-1046
 Merin, Saul, *182
 Merkel, F., *355
 Mertz, Walter, *1043
 Meschia, Giacomo, *187
 Messaritakis, J., *182
 Messina, A., *316
 Metz, Robert, *325
 Metzger, Boyd E., *340
 Metzger, Robert P., *372
 Meyer, James H., *252
 Meyer, Richard J., *772-773
 Meyer, Roland K., *774, *912
 Miale, A., Jr., *351
 Michael, Alfred F., 163-174
 Michael R., *182, *909
 Mickelsen, Olaf, *983

Miller, Leona V., *368, *1120
 Miller, Max, *180, 257-270
 Miller, R., *351
 Milliez, P., *776
 Million, Marcia, *361
 Mills, Lewis C., *367-368
 Milner, R. D. G., *182, *1120
 Mintz, Daniel H., 175-177, *180, *912
 Miya, T. S., *184
 Moffitt, Emerson A., *185
 Molinatti, G. M., *122
 Molnar, George D., *185, *324-325, *775, *836, *1203
 Molsted-Pedersen, Lars, *912, *1046
 Moore, Jack D., *182-183
 Moore, T. J., *775
 Moorhouse, John A., *341-342, *1199
 Moorhouse, S. R., *247
 Morgan, C. D., *254
 Morgan, Jean M., *1046
 Morganroth, Joel, *376-377
 Morita, K., *773
 Morris, A. S., *836
 Morrison, Anthony D., *180-181, *330
 Morrison, George R., *58
 Morsches, B., *250
 Moses, Hamilton, III, *1199
 Moss, Gerald S., *982
 Motte, G., *838
 Motulsky, Arno G., *1121
 Moxness, Karen E., *775, *836
 Mueller, Walter A., *183
 Mukherjee, N. R., 1192-1196
 Mullen, Donald C., *1206
 Muller, Walter A., *301-307, *324, *364, *912-913
 Munger, Bryce L., *338
 Murthy, V. K., *982
 Muzzo, Santiago, *1042
 Myers, R. D., *1046

N

Nabarro, J. D. N., *187, *188, *379
 Nafz, Mary Ann, *353
 Najarian, J. S., *322
 Nakao, Komei, *773-774
 Nankin, Howard, *909-910
 Napoli, Elena, 1168-1172
 Narrod, Stuart A., *247
 Nath, M. C., *311
 Nath, N., *311
 Needham, L. B., *337-338
 Nemerson, Yale, *312
 Nestel, Paul J., *835, 923-929
 Neubauer, B., *252
 Neufeld, Arthur H., *180, *1117-1118

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64	Supplement 1, 321-384	August, 843-922
February, 65-128	Supplement 2, 385-714	September, 923-986
March, 129-192	June, 715-778	October, 987-1050
April, 193-256	July, 779-842	November, 1051-1130
May, 257-320		December, 1131-1210

AUTHOR INDEX 1972

Neville, David M., Jr., *334-335, *1200
 Neville, E. D., *836
 New, Maria I., *120, *1046
 Newman, G. B., *188
 Newton, N. E., *1203
 Newton, R. H., *314
 Nielsen, Poul Ebbe, *186-187
 Nijjar, M. S., *183
 Nishikawa, Mitsuo, *60
 Nitzan, M., *315
 Nobis, H., *913
 Noda, Katuhiko, *183
 Noe, Bryan D., *58-59
 Nonaka, K., *313
 Norman, Nils, 814-826, 939-945
 Novak, J., *314
 Novak, Ladislav P., *982-983

O

Oakley, W. G., *321-322, *1199
 Ockner, Robert K., *121
 O'Dell, Boyd L., *59
 Odén, A., *312-313
 Ogilvie, James T., *362-363
 Ogilvie, R. I., *1206
 Ohira, S., *1204
 Ojl, N., *252
 Okada, Akira, 203-208
 Oldendorf, William H., *315
 Olefsky, Jerrold, *372, *380, *1121
 Olsen, Ward A., *252-253
 Olsson, A. G., *980
 Ono, Masayoshi, *1122
 Opperman, W., *321, *373
 Orci, Lelio, *121, *326, *346, *368, 511-534, 594-604, *838, 1060-1071
 O'Reilly, Robert A., *183
 Ornholt, Jorgen, *911
 Oró, L., *980
 Osborne, Robert K., *57
 Oschman, James L., *315
 Osterby, R., *913
 Ostheimer, Gerald W., *118-119
 Ostrowski, K., *909
 O'Sullivan, John B., *183-184
 Ouyang, Ann, *247-248
 Overack, Daniel E., *182-183
 Oweiss, Ibrahim M., *1118
 Owen, Charles A., Jr., *775
 Owen, O., *375
 Owen, W. Crawford, 157-162, *1202

P

Paasikivi, J., *122-123
 Pace, Caroline S., *345

Packer, James T., 715-721, *1043
 Palazzolo, M., *336
 Pallotta, Johanna, *367, *376-377
 Pallotta, M. G., *253
 Pandos, P., *775-776
 Pannbaker, R. G., *838
 Park, B. N., *373
 Park, C. R., *254, *335, 439-446
 Parker, Donal C., *913
 Parks, Gary A., *1046
 Parrilla, Roberto, *341
 Parrish, James E., *980
 Partridge, John W., *1204
 Passa, P., *838
 Passy, Victor, 722-732
 Patel, D., *373
 Patel, Tehmi N., *350, *1205
 Paul, P., *375
 Peabody, Robert R., *189
 Pearson, Donald, *184
 Pearson, Margaret J., *182, *1204
 Pek, Sumer, *55-56, 216-223, *324, *331-332, *1204
 Pekar, A. H., 486-491
 Pekarek, R. S., *316
 Pellizzari, E. D., *313
 Penhos, Juan C., *356, *360-361, *375, *775
 Perez Lloret, A., 23-30
 Perley, Michael J., *837
 Perry, W. F., *183
 Persson, Bengt, *179-180
 Pestana, Angel, *187
 Peterson, Daniel T., *339
 Peterson, James D., 572-581
 Peterson, Kirk L., *980
 Petersson, B., *909
 Petpierre, B., *1120-1121
 Pfeiffer, Ernst F., *313, *369, *913, 1072-1076
 Phillips, Gerald B., *184
 Pilkis, S. J., *335
 Pillay, Veerasamy, K. G., *54
 Pimstone, Bernard L., *58, *771
 Pingel, M., 805-813
 Pinto, J. E. B., *253
 Pirart, J., *123
 Pi-Sunyer, F. X., *373-374
 Pitkin, R. M., *315
 Pitot, Henry C., *187
 Pittman, Robert P., *59
 Plank, C. J., *315
 Plante, Gérald E., *251
 Plavidal, Ferdinand, 733-743
 Pocelinko, R., *313
 Podolsky, Stephen, *374, *1121
 Poffenbarger, Philip L., *1120

Pollock, J., *120-121
 Pond, Wilson G., *835-836
 Porch, James, *338
 Porte, Daniel, Jr., 65-70; *342, *348, *773, *1123
 Posner, Barry I., *374-375
 Potter, Van R., *54
 Potvliege, P. R., *120
 Powell, William John Jr., *118-119
 Pratt, O. E., *247
 Price, Steven, *345
 Prigge, William F., *55
 Prior, R. L., *184
 Proakis, A. G., *184
 Prout, Thaddeus E., 1035-1040
 Pruitt, Kenneth M., 872-880
 Pyke, D. A., *321-322, *1199

Q

Quibrera, Ricardo, *55-56
 Quickel, Kenneth E., Jr., *184, *315-316, 779-788, *1200

R

Rackley, C. E., *367
 Radhakrishnamurthy, B., 733-743
 Ragab, Abdelsalam H., 906-907
 Raghuramulu, N., *1119-1120
 Raheja, Krishan L., *1046
 Rähä, Niels, *250-251
 Raines, P. L., *775
 Raivio, K., *250-251
 Ramey, Estelle R., *375
 Rand, Robert W., *349
 Randle, Philip J., 538-545
 Rao, K. Visweswara, 1192-1196
 Rao, Kamal S. Jaya, 1192-1196
 Rappaport, A. M., *1204
 Raptis, S., *913
 Rasio, Eugenio A., *330
 Raskin, Philip, 101-107
 Rauls, Tyler J., *189
 Reaven, Eve P., *339
 Reaven, Gerald M., *84-88, *339, *372, 794-796, 1109-1115, *1121
 Recant, Lillian, *329, *359-360, *775
 Reddy, W. J., *351-352, *371
 Reddy, Bandaru S., *775
 Redetzki, H. M., *838
 Redetzki, J. E., *838
 Reed, D. W., *838
 Reed, Peter C., *982
 Regen, D. M., *775
 Reichard, G. A., Jr., *375

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64
 February, 65-128
 March, 129-192
 April, 193-256
 May, 257-320

Supplement 1, 321-384
 Supplement 2, 385-714
 June, 715-778
 July, 779-842

August, 843-922
 September, 923-986
 October, 987-1050
 November, 1051-1130
 December, 1131-1210

AUTHOR INDEX 1972

- Reichle, Frederick A., *322-323
 Reiffen, Barney, *367
 Reinke, U., *1204
 Reitano, G., *316
 Renauld, A., *253
 Renner, Rolf, *1122-1123
 Renold, Albert E., *179, *246, *326,
 *368, 510, 619-631, 1060-1071
 Retzlaff, K., *911
 Reuter, Melanie, *772
 Reza, Michael J., *330
 Ribes, G., *912, *1120
 Ricketts, Henry T., 648, 660, 677, 684
 Riemann, J. F., *352
 Rifemberck, David, *247
 Rimoin, D. L., *1045-1046
 Rishi, Surendra, *375-376
 Rivarola, M. A., 23-30
 Rivera-Calimlim, Leonor, *1121
 Robb, Jean R., 967-971
 Robberecht, P., *59
 Roberts, Philip, *251
 Robertson, J. W., *341
 Robertson, R. Paul, *348
 Robitaille, Pierre, *251
 Robollo, O. R., *184
 Rodman, Harvey M., *329-330
 Roe, Thomas F., *981
 Rogala, Henry K., *121-122
 Rogers, Lydia, *252-253
 Rogers, Marsha, *328
 Rogers, Nancy L., 403-413
 Roginski, E. E., *1043
 Roheim, Paul S., *56
 Roldan, A. G., *184-185
 Roncone, Angela, *333
 Root, Mary A., 637-648, 657-660
 Rose, Herbert G., *376
 Rose, Noel R., *253
 Rose, Shelby D., *1043
 Rosen, Ora M., *185
 Rosenberg, I. H., *983
 Rosenberg, Leon E., *248, 414-425
 Rosenbloom, Arlan L., 45-49, *355-356,
 376, *776
 Rosenfeld, Paul S., *378
 Rosenthal, Judith W., *836
 Rosevear, John W., *185, *775, *836
 Rosner, J. M., 23-30
 Ross, Iain S., *186
 Rossi, Livia, *312
 Rossman, Lawrence G., *913
 Rössner, S., *316, *980
 Roth, Jesse, *313, *334-335, 673-677,
 *1200
 Roth, Nathan H., *349
 Rottiers, R., *914
 Rousseau, Suzanne, *912
 Roux, J., *250-251
 Rowe, John W., *376-377
 Rubenstein, Arthur H., *57, *344, *347,
 572-581, 661-662, 1013-1026
 Rubin, Emanuel, *838
 Rudas, B., *121
 Ruderman, Neil B., *341, *343
 Rudo, N. D., *983
 Ruegamer, W. R., *1047
 Ruiz, Harold, 733-743
 Russell, R. O., *367
 Russell, Wilson G., 403-413
 Russo, R. E., *361-362, *366
 Ruttgers, H., *1045
 Ryan, Graeme B., *314
 Ryan, Jerome R., *188
- S**
- Saba, Thomas M., *312
 Sadeghi-Nejad, A., *377
 Safrit, Henry F., *184
 Saito, Tokuko, *1047
 Sakagami, Masanori, 476-484
 Sakai, Tsunesada, *336
 Sakura, Naoki, 476-484
 Salen, Gerald, *1200-1201
 Saliternik, R., *770
 Salvatierra, Cairo, *914
 Sandler, Richard, *185
 Saner, G., *313
 Santeusano, Fausto, *324
 Santti, Risto S., *185
 Saraceni, D., 23-30
 Sau, K., *381
 Saudek, Christopher D., *334
 Sauerherber, Richard D., *372
 Savory, J., *376
 Sax, Daniel S., *374, *1121
 Saxton, C., *913
 Sayers, George, *983
 Schanberg, Saul M., *252
 Schauder, Peter, *377-378
 Schedl, Harold P., *59, *983
 Scheid, C., *370
 Schein, P. S., *59
 Scheynius, A., *123
 Schiff, D., *185
 Schimmel, Richard J., *59-60
 Schlein, Edward M., *1198-1199
 Schlichtkrull, J., 649-656
 Schmidt, William M. I., *912
 Schnatz, J. David, *353-354, *1043
 Schneeloch, B., *187-188
 Schneider, Louis E., *983
 Schnelle, Norbert, *185
 Schnure, Joel J., 101-107
 Schöffling, K., *249, *249-250
 Scholtz, Michael C., *914
 Schreiber, Paul H., *54, *1200-1201
 Schroder, Karl E., 1072-1076
 Schrott, Helmut G., *1121
 Schteingart, David E., *331-332
 Schullinger, John N., *837
 Schwartz, Ernst, *1046
 Schwartz, Robert, *60, *250-251
 Schwarz, F., *1046
 Schwarz, K., *369
 Scorpio, Ralph M., *247
 Scott, David F., *54
 Scow, Robert O., 946-954
 Scriba, P., *369
 Scully, Robert, *1042
 Seelig, Steven, *983
 Segal, Stanton, *315
 Sechlin, Jahove, *56, *181, *771-772
 *837, *910-911
 Seifter, Eli, *773-774
 Seiler, M. W., *60
 Selawry, Helena, *329, *359-360
 Seltzer, Holbrooke S., 955-966, 976-980
 Senior, B., *377
 Serafini, A. N., *351
 Service, F. John, *836
 Setchell, B. P., *57-58
 Sethi, S. S., *373-374
 Shah, Madhukar N., *983
 Shanahan, E. Anne, *118-119
 Shapiro, Stanley H., 129-137, *325-326
 Sharma, Bal K., *54
 Sharma, Opendra K., *253
 Shaw, Ralph A., *367-368
 Shaw, Walter N., viii Supplement 2
 Sheikholislam, Bagher M., *378
 Sheldon, W. H., *1201
 Sheridan, B., *253
 Sherman, Barry M., *313, *1043-1044,
 *1204
 Sherman, Herbert, *367
 Sherwin, Robert S., *347
 Shetty, Kaup R., *378
 Shichiri, Motoaki, 203-208
 Shier, Nathan William, *983
 Shigeta, Yukio, 203-208, 827-831
 Shih, Vivian, *316
 Shima, Kenji, *60
 Shimizu, Taeko, *1047
 Shishiba, Yoshimasa, *1047
 Shizume, Kazuo, *1047
 Shlitz, L., *1121-1122
 Shrader, Ruth E., *1047
 Shreeve, W. W., *252
 Shroyer, Lois A., *382

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64	Supplement 1, 321-384	August, 843-922
February, 65-128	Supplement 2, 385-714	September, 923-986
March, 129-192	June, 715-778	October, 987-1050
April, 193-256	July, 779-842	November, 1051-1130
May, 257-320		December, 1131-1210

AUTHOR INDEX 1972

- Shuangshoti, Samruay, *1122
 Shuman, Charles R., *322-323
 Sidbury, James, *1200
 Siegal, Alan M., 157-162, *1202
 Siegel, Donald C., *982
 Sieracki, J. C., *250
 Siltanen, Irmeli, *349-350
 Silver, Donald, *1206
 Silverman, David A., *253
 Simmons, R. L., *322
 Simon, James D., 930-934
 Simons, N., *770
 Simopoulos, Artemis, *1043-1044
 Sinclair-Smith, B. C., *332, *340-341
 Sirek, Ann M., *378-379
 Sirek, Anna, *378-379
 Sirek, O. V., *378-379
 Sjöström, Lars, *54, *180
 Skyler, J. S., *352
 Slack, Warner V., *367
 Slaunwhite, W. Roy, III, *1204-1205
 Slavinski, R. H., *252
 Sleisenger, Marvin H., *771
 Sloan, J. M., *253
 Slusher, Norman, 843-855
 Smith, Desmond F., *327, 856-862, *1045
 Smith, Leslie F., 457-460
 Smith, Robert M., *343, *1119
 Snarr, J. F., *1123, *1206
 Snider, Joel J., 295-300
 Snodgrass, G. J. A. I., *1047
 Snook, Jean Twombly, *185-186
 Sobel, R. E., *376
 Sode, Jonas, *181
 Soeldner, J. Stuart, *354, *373, *383, 703-712, *769, *775, *1044-1045
 Soifer, David, *60
 Soler, N. G., *186
 Solomon, H. M., *313
 Solomon, Solomon S., *336, *363, 1027-1034
 Song, Sun K., *838
 Sonksen, Peter H., *379, *775
 Soveny, C., *249
 Spalding, J. F., *914
 Spargo, Benjamin H., *338
 Spark, Richard F., *334
 Spathis, C. S., *186
 Spergel, Gabriel, *348
 Sperling, Mark A., *60
 Spingola, Laurence J., *252
 Spitzer, John J., *251
 Sprague, Randall G., 632
 Spruyt, Joy E. L., *57
 Srinivasan, Sathanur R., 733-743
 Srivastava, M. C., *379
 Stacpoole, Peter W., *358
 Stadler, F., *769
 Stanley, A. W., *367
 Starling, Kenneth A., *1119
 Starman, Barbara, *377-378
 Starr, Jerome I., *347, 661-672
 Stauffacher, Werner, *179, *246, *326, 1060-1071
 Stearns, Frank, *247
 Steele, Ann A., *835, *1045
 Steele, Forest A., *835
 Stein, Janet M., *186
 Steinberg, Daniel, 1179-1184
 Steinberg, Terry, 722-732
 Steiner, Alton L., *1119
 Steiner, Donald F., *347, 572-581, 661-672, 1013-1026
 Steiner, George, *982
 Steinke, Jurgen, 143-148, *247, 350, *365, *379, *838, *1198, *1205
 Stenberg, J., *909
 Stephenson, J. B. P., *56
 Sterky, G., *980-981
 Stern, Judith, *316
 Stern, L., *185
 Stern, Michael P., *380
 Stilz, John G., 235-245
 Stimmler, L., *1047
 Stoll, Ralph W., *1047, *1122
 Stone, Daniel B., *1045
 Stoppani, A. O. M., *184-185
 Storvick, Waldemar O., 235-245
 Stout, Clarke, *338
 Stout, Robert W., *186, *380
 Strack, I., *385
 Strandgaard, Svend, *186-187
 Strauch, G., *775-776
 Strickland, Alva L., *1122
 Stroeh, Lowell E., 235-245
 Stromberg, P., *329
 Strong, Leroy E., *382
 Stroud, Robert M., 872-880
 Strul, Anna, *348
 Strumia, E., *122
 Stuhlman, Robert A., 715-721, *1043
 Stukowski, Barbara, *910
 Stunkard, Albert J., *1205
 Sudilovsky, Oscar, *187
 Sulev, J. C., *254
 Sun, A. M., *339
 Sussman, Karl E., *56
 Sussman, Leonard, *336
 Sutherland, James M., *914, *1202-1203
 Suwanwela, Nibha, 108-113, *355
 Suzuki, Fujio, *1122
 Swenson, Donna E., *55
 Swenson, Robert S., 1109-1115
 Sverdluk, R. C., *253
 Sybulski, S., *316
 Szabo, Andrew J., *337, *380-381
 Szabo, Olga, *314-315, *337, *380-381
 Szulman, Aron E., 39-44

T

- Tacus, Leonardo, *359
 Taft, P., 972-975
 Takeda, Yoshiro, *1122
 Talarioc, K. S., *836
 Talbert, O. Rhett, *911
 Täljedal, Inge-Bert, *56, *123, *181, *771-772, *837, *910-911
 Tallman, Carter B., *185
 Tanaka, Kay, *316
 Tanner, J. M., *119-120
 Tarpley, H. L., *775
 Tarui, Sechiro, *60
 Tateishi, Hiroshi, *253
 Tattersall, R. B., *321-322
 Taylor, Andrew L., 175-177
 Taylor, Enid, *187
 Taylor, G. W., *187
 Taylor, J. Bradley, 1109-1115
 Taylor, K. W., *909
 Taylor, L. M., *187
 Taylor, S. H., *913
 Taylor, William F., *324-325, *775, *836, *1203
 Tcherdakoff, P., *776
 Teitelbaum, A., *770
 Tepperman, Jay, *1046
 Teramo, K., *250-251
 Thijssen, J. H. H., *1046
 Thomas, G. B., *313
 Thompson, Clara W., *1204
 Thuy, Le Phuc, *1047
 Tibblin, Elisabeth, *180
 Tibblin, Gösta, *180, *312-313
 Tildon, J. Tyson, *181
 Tobin, R. B., *981
 Toews, C. J., *341
 Tomita, Tatsuo, *326
 Tomkin, Gerald H., *381
 Tompkins, C. V., *379
 Torno, N., *381
 Toseland, P. A., *187
 Tragl, Karl H., 84-88
 Traisman, Howard S., *249
 Trap-Jensen, Jens, *1045
 Treasure, T., *187
 Triebwasser, John, 101-107
 Trimmer, Michael, 39-44
 Trout, David L., *179
 Truswell, A. S., *58
 Tsang, Reginald C., *914, *1043
 Tseng, Chiu H., *338
 Tsoulos, Nicholas G., *187

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64
 February, 65-128
 March, 129-192
 April, 193-256
 May, 257-320

Supplement 1, 321-384
 Supplement 2, 385-714
 June, 715-778
 July, 779-842

August, 843-922
 September, 923-986
 October, 987-1050
 November, 1051-1130
 December, 1131-1210

AUTHOR INDEX 1972

Turner, Paul, *771
 Turner, R. C., *187-188
 Tweel, Harry K., *188
 Tyler, Jean M., *332
 Tyrrell, J. B., *188
 Tyson, R. Robert, *322-323
 Tzagournis, Manuel, *381-382
 Tze, Wah Jun, *327

U

Ullygot, G., *1199
 Underwood, Louis E., *776, *1122
 Unger, Roger H., *58, *60, *183, 301-307, *324, *912-913, *1198-1199

V

Valverde, Isabel, 289-294
 van Assche, F. A., *253-254
 Vance, James E., 570-571, 581-583, *1047, *1122
 Van Herle, Andre J., *335-336
 Van Itallie, T. B., *374
 Van Lan, Vo, *375
 van Marthens, Edith, *189
 van Riet, H. G., *1046
 vanWayjen, R. G. A., *1046
 VanWoert, Maureen, *1119
 Van Wyk, Judson J., *1122
 Vanderlaan, Eileen F., *913
 Varandani, Partab T., *353, *382
 Vasil'eva, I. A., *55
 Vecchio, Luigi Lo, 1168-1172
 Veneziale, Carlo M., *330-331
 Vermeulen, A., *914
 Veros, A. J., 486-491
 Vilar, O., 23-30
 Villanueva, Maria L., 289-294, *837-838
 Villee, Claude A., *185, *1199
 Vinay, Patrick, *251
 Vince, F. P., *119-120
 Vining, Keats K., Jr., *382
 Visek, W. J., *184
 Vogler, Nancy J., *254, 881-905
 Voight, Karl H., *313
 Voigt, K. D., *1204
 Voina, Sandra J., *776, *1122
 Volk, Bruno W., *338-339
 Volund, Aa., 805-813
 Voyles, Nancy, *329
 Vranic, Mladen, *188, *382-383

W

Wade, Angel, *329
 Wahl, Georgia, *772

Wahlberg, F., *122-123
 Wahren, John, *323-324, *770-771, *776
 Wajchenberg, Bernardo L., *363
 Walaas, E., *123
 Walker, G., *379
 Walker, Mary M., 987-998
 Walter, Robert M., *333-334
 Wannemacher, R. W., Jr., *316
 Wapnir, Raul A., *181
 Ward, J. D., 1173-1178
 Ward, Walter F., *836
 Wasserman, R. C., *314
 Watkins, Dudley T., *983
 Waxler, S. H., *254
 Weber, B., *1205
 Weidemann, Eckehart, *1046
 Weinges, K., *769
 Weinstock, Murray, *376
 Weir, B. J., *1205-1206
 Weisinger, Jose, 1109-1115
 Weissman, Peter N., *324
 Weitzel, Gunther, *1122-1123
 Wellmann, Klaus F., *338-339
 Wells, Henry J., *315
 Wells, Lemen J., 193-202
 West, Kelly M., *338
 West, Susan B., *835
 Westall, Janet R., *372
 Westberg, N. Gunnar, 163-174
 Westfall, David N., *776
 Wexler, B. C., *1123
 Whayne, Thomas F., Jr., *188
 White, Priscilla, 31-37, *361-362, *366
 White, Raleigh R., *1120
 Whitehead, Richard, *251
 Whitfield, Margaret, *328
 Whittingham, Senga, *914
 Wichelow, M. J., *980
 Wick, Arne N., *372
 Wieland, Otto, *910
 Wiesner, Wolfgang, *910
 Wildenhoff, K. E., *1205
 Wilder, B. J., *355-356
 Wiley, J. H., *835
 Wilhelmsen, Lars, *180
 Wilke, W., *182
 Wilkinson, J. S., *352-353
 Wille, L., *123
 Williams, R., *1199
 Williams, Robert E., *183-184
 Williams, Robert H., *329, *360, *377-378, *1047, *1122
 Williams, T. F., *254
 Williamson, D. H., *59
 Williamson, Joseph R., *254, 881-905
 Wilmshurst, E. G., *365, *366, *383
 Wilson, Helen D., *59

Wilson, John E., *1205
 Wilson, Penelope, *247
 Winand, J., *119, *182
 Winegrad, Albert I., *180-181, *330
 Winters, Robert W., *837
 Wise, P. H., *1205
 Wissler, R. W., *344
 Witters, Lee, *376-377
 Wittman, James S., III, *188-189
 Wold, John S., 71-79
 Wolf, Richard C., *774, *912
 Wolfe, Walter G., *1206
 Wolff, J. E., *118
 Wolff, M. Kirsch, *56
 Wolff, Peter H., *254
 Wollheim, C. B., *346
 Woods, James S., *254
 Woods, Stephen C., *1123
 Wrenshall, G. A., *382-383
 Wright, Peter H., *58, 605, 617-618
 Wright, R., *189
 Wurtman, R. J., *909

Y

Yakovac, William C., *189
 Yamaguchi, N., *775
 Yamaguchi, K., *250-251
 Yanaihara, Chizuko, 476-484
 Yanaihara, Noboru, 476-484
 Yeung, C. Y., *1123
 York, David A., *838, *1206
 Young, J. D., *1118
 Young, Margaret C., *120
 Younger, Donna, 31-37
 Yudilevich, David L., *180
 Yunis, Eduardo, *60

Z

Zahn, Helmut, 457, 468-475
 Zalut, Clyde, *772-773, *981
 Zamenof, Stephen, *189
 Zandomeneghi, R., *1206
 Zatzman, Marvin L., *182-183
 Zeman, Frances J., *1041, *1047
 Zetterström, Rolf, *179-180
 Ziboh Vincent A., *189
 Ziegler, M., *182, *909, *914
 Zingg, W., *254
 Zinman, B., *1206
 Zivin, J. A., *1123, *1206
 Zor, Uriel, *346-347
 Zucker, Louis M., *316, *1123
 Zuckerman, Leon, 209-215, *1199
 Zweig, S. M., *89
 Zweng, H. Christian, *189

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64	Supplement 1, 321-384	August, 843-922
February, 65-128	Supplement 2, 385-714	September, 923-986
March, 129-192	June, 715-778	October, 987-1050
April, 193-256	July, 779-842	November, 1051-1130
May, 257-320		December, 1131-1210

Opposite Kinetics of L-Leucine and L-Phenylalanine Induced Insulin Release Studied with the Perfused Rat Pancreas

R. LANDGRAF, M. LANDGRAF-LEURS,
P. SCRIBA, and K. SCHWARZ (Introduced by
E. F. PFEIFFER*), Munich, Germany

Little is known about the dynamics of insulin release provoked by amino acids. Therefore isolated pancreases were perfused with saline-dextran buffer, containing leucine or phenylalanine, without recycling. Samples were taken at short intervals and the amount of insulin was measured by an immunoassay. In the absence or presence of substimulatory levels of glucose, 10 and 20 mM leucine caused a biphasic pattern of insulin secretion, comparable to that of 20 mM glucose. When leucine was perfused together with 20 mM glucose no significant additive effect could be observed. However when glucose plus leucine were perfused after an initial stimulatory period with leucine alone, a typical biphasic response was again observed and the additive effect was more pronounced. In contrast, phenylalanine provoked no insulin release in the absence of glucose. In the presence of 2.5 mM glucose, a burst of insulin output occurred after removal of the phenylalanine from the perfusate. When phenylalanine (10 or 20 mM) was added during the second phase of the glucose-induced insulin release, it potentiated the glucose effect after an initial inhibition.

These data suggest the existence of more than one receptor for amino acids for the stimulation of insulin secretion, comparable to, but not necessarily identical with the carbohydrate receptors. Assuming that leucine and phenylalanine use the same transport system (D.L. Oxender, and H. N. Christensen, *J. Biol. Chem.* 238: 3686, 1963) our data indicate that the receptor sites for the stimulation of insulin secretion by amino acids may not be transport sites.